University of Arkansas, Fayetteville ScholarWorks@UARK

Patents Granted

2-28-2017

Delivery of therapeutic agents by a collagen binding protein

Tulasi Ponnapakkam

Sagaya Theresa Leena Philominathan

Joshua Sakon University of Arkansas, Fayetteville

Ranjitha Katikaneni

Takaki Koide

See next page for additional authors

Follow this and additional works at: https://scholarworks.uark.edu/pat

Citation

Ponnapakkam, T., Philominathan, S. T., Sakon, J., Katikaneni, R., Koide, T., Matsushita, O., Gensure, R. C., & Nishi, N. (2017). Delivery of therapeutic agents by a collagen binding protein. *Patents Granted.* Retrieved from https://scholarworks.uark.edu/pat/318

This Patent is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Patents Granted by an authorized administrator of ScholarWorks@UARK. For more information, please contact scholar@uark.edu, uarepos@uark.edu.

Inventors

Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, and Nozomu Nishi



US009579273B2

(12) United States Patent

Ponnapakkam et al.

(54) DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN

- (71) Applicants: The Board of Trustees of the University of Arkansas, Little Rock, AR (US); The Kitasato Institute, Tokyo (JP); MONTEFIORE MEDICAL CENTER, New York, NY (US); NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY, Kagawa (JP)
- (72) Inventors: Tulasi Ponnapakkam, New York, NY (US); Sagaya Theresa Leena Philominathan, Cheshire, CT (US); Joshua Sakon, Fayetteville, AR (US); Ranjitha Katikaneni, New York, NY (US); Takaki Koide, Tokyo (JP); Osamu Matsushita, Kanagawa (JP); Robert C. Gensure, New York, NY (US); Nozomu Nishi, Kagawa (JP)
- (73) Assignees: The Kitasato Institute (JP); National University Corporation Kagawa University (JP); Montefiore Medical Center; The Board of Trustees of the University of Arkansas
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 14/365,226
- (22) PCT Filed: Dec. 14, 2012
- (86) PCT No.: PCT/US2012/069831
 § 371 (c)(1),
 (2) Date: Jun. 13, 2014
- (87) PCT Pub. No.: WO2013/090770PCT Pub. Date: Jun. 20, 2013

(65) **Prior Publication Data**

US 2014/0377215 A1 Dec. 25, 2014

Related U.S. Application Data

- (60) Provisional application No. 61/570,620, filed on Dec. 14, 2011, provisional application No. 61/596,869, filed on Feb. 9, 2012.
- (51) Int. Cl. *A61K 8/65* (2006.01) *A61K 8/99* (2006.01) (Continued)
- (52) **U.S. Cl.**

(10) Patent No.: US 9,579,273 B2

(45) **Date of Patent:** Feb. 28, 2017

- (2013.01); A61K 38/193 (2013.01); A61K 38/29 (2013.01); A61K 38/30 (2013.01); A61K 39/44 (2013.01); A61K 47/48246 (2013.01); A61Q 7/00 (2013.01); A61Q 7/02 (2013.01); A61K 2039/505 (2013.01); A61K 2039/6031 (2013.01); A61K 2800/57 (2013.01)
- (58) Field of Classification Search None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,914,126 A	6/1999	Li et al.							
6,362,163 B1	3/2002	Gardella et al.							
	(Continued)								

FOREIGN PATENT DOCUMENTS

EP	0207751	1/1987
WO	WO 0006195	2/2000
WO	WO 0049159	8/2000
WO	WO 03052091	6/2003
WO	WO 2004071543	8/2004
WO	WO 2005082941	9/2005
WO	2006072623	7/2006
WO	WO 2010087397	8/2010
WO	WO 2010042425	11/2011
WO	WO 2012157339	11/2012

OTHER PUBLICATIONS

Philominathan et al, JBC, Apr. 17, 2009, 284/16:10868-10876.* Locklin, R.M. et al., "Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone," J Cell Biochem. (2003) 89(1):180-90.

(Continued)

Primary Examiner - Nita M Minnifield

(74) Attorney, Agent, or Firm — Andrus Intellectual Property Law, LLP

(57) **ABSTRACT**

Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

12 Claims, 21 Drawing Sheets (15 of 21 Drawing Sheet(s) Filed in Color)

(51) Int. Cl.

A61K 38/29	(2006.01)
C07K 14/635	(2006.01)
A61Q 7/00	(2006.01)
A61K 8/66	(2006.01)
A61K 47/48	(2006.01)
A61K 8/49	(2006.01)
A61K 8/64	(2006.01)
A61K 38/17	(2006.01)
A61K 38/18	(2006.01)
A61K 38/19	(2006.01)
A61K 38/30	(2006.01)
A61K 39/44	(2006.01)
A61Q 7/02	(2006.01)
A61K 39/00	(2006.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

OTHER PUBLICATIONS

Locus BAA06251 (GI 710023), Collagenase precursor from Clostridium histolyticum, Jan. 30, 2003. This amino acid sequence is disclosed in this application as SEQ ID No. 6. The sequence of residues 901-1021 of BAA06251 corresponds to the collagen binding domain included in the fusion protein of SEQ ID No. 1.

Locus EAW68494 (GI 119588900), Parathyroid hormone isoform from *Homo sapiens*, Dec. 18, 2006. Residues 64-147 of EAW68494 correspond to the PTH of SEQ ID No. 7.

Lotinun, S. et al., "Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression," Endocrine. (2002) 17(1),29-36.

Lotinun, S. et al., "Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism," Endocrinology. (2003) 144(5):2000-7.

Lumachi, F. et al, "Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender." Ann N Y Acad Sci. (2007) 1117:362-6. Epub Jul. 26, 2007. Ma,, Y.L. et al., "Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprolegerin and gene-associated bone formation," Endocrinology (2001) 142(9):4047-54.

Machado Do Reis, L. et al., "Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice," Bone (2008) 43(2):264-73, Epub Apr. 13, 2008.

Malluche, H.H. et al., "Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure," Miner. Electrolyte Metab. (1986) 12(2):113-8.

Malluche, H.H. et al., "Osteornalacia and hyperparathyroid bone disease in patients with nephrotic syndrome," J Clin Invest. (1979) 63(3):494-500.

Malluche, H.H. et al., "Influence of the parathyroid glands on bone metabolism," Eur J Clin Invest. (2006) 36(Suppl 2):23-33.

Malluche, H.H. et al., "Effects of long-term infusion of physiologic doses of I-34 PTH on bone" Am J Physiol. (19S2) 242(2):F197-201. Masi, L. et al., "Molecular, biochemical and cellular biology of PTH anabolic action," J Endocrinol Invest. (2005) 28(8 Suppl):37-40.

Mathias, R. et al., "Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital," J Am Soc Nephrol. (1993) 3(12):1938-46.

Matsushita, O. et al., "A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase," J Biological Chem (1998) 273(6):3643-3648.

Matsushita, O. et al., "Gene duplication and multiplicity of C. Histolyticum collagenases," J Bacteriol. (1999) 181:923-933.

Matsushita, O. et al., "Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase," J of Biological Chem (2001) 276(12):8761-8770.

Matsushita, O., "Studies on the Clostridal Collagenases," Nippon Saikingaku Zasshi (1999) 54(4):753-761.

McCauley, L.K. et al., "PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis," J Cell Biochem (1996) 61:638-647.

McCauley, L.K. et al., "Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells," Endocrinology (1997) 138(12):5427-33.

McCauley, L.K. et al., "Parathyroid hormone stimulates fra-2 expression in osteoblastic cells in vitro and in vivo," Endocrinology (2001) 142(5):1975-81.

Minisola, S. et al., "Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover," Bone Miner. (1993) 20(2):113-23. Minisola, S. et al., "Uneven deficits in vertebral bone density in postmenopausal patients with primary hyperparathyroidism as evaluated by posterior-anterior and lateral dual-energy absorptiometry." Osteoporos Int. (2002) 13(8):618-23.

Mitlak, B.H. et al., "Asymptomatic primary hyperparathyroidism," J Bone Miner Res. (1991) 6(Suppl 2):S103-10; discussion S121-4. Miyachi, Y. et al., "Long-term safety and efficacy of high-concentration (20 mug/g) tacalcitol ointment in psoriasis vutgaris," Eur J Dermatol (2002) 12(5):463-468.

Morley, P. et al., "Anabolic effects of parathyroid hormone on bone," Trends Endocrinol. Metab. (1997) 8(6):225-31.

Morley, P. et al., "Parathyroid hormone: an anabolic treatment for osteoporosis," Curr Pharm Des. (2001)7(8):671-87.

Murray, E.J. et al., "E64d, a membrane-permeable cysteine protease inhibitor, attenuates the effects of parathyroid hormone on osteoblasts in vitro," Metabolism (1997) 46(9):1090-4.

Nasu, M. et al., "Stimulatory effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on insulin-like growth factor-binding protein-5 mRNA expression in osteoblastic UMR-106 cells: the difference between transient and continuous treatments." FEBS Lett. (1997) 409(1):63-6.

Neer, R.M. et. al., "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis," N. Engl. J. Med. (2001) 344(19):1434-1441.

Nemeth, E.F., "Pharmacological regulation of paraihyroid hormone secretion," Corr Pharm. Des. (2002) 8(23):2077-87.

Nilsson, P., "Bone disease in renal failure. Clinical and histomorphometric studies," Scand J Urol Nephrol Suppl. (1984) 84:1-68.

Nishi. N. et al, "Collagen-binding growth factors; Production and characterization of functional fusion proteins having as collagenbinding domain," PNAS (1998) 95(12):7018-7023.

OTHER PUBLICATIONS

O'Brien, C.A. et al, "IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice," Am J Physiol Endocrinol Metab. (2005) 289(5):E784-93. Epub Jun. 14, 2005.

Okazaki, R., "Parathyroid hormone—its mechanisms of action and issues on clinical application," Clin Calcium. (2005) 15(5):845-51. Olgaard, K. et al., "Can hyperparathyroid bone disease be arrested or reversed?," Clin J Am Soc Nephrol. (2006) 1-(3):367-73. Epub Mar. 29, 2006.

Onyia, J.E. et al., "Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray," J Cell Biochem. (2005) 95(2):403-18.

Owens, R.J. et al., "Mapping the collagen-binding site of human fibronectin by expression in *Escherichia coli*." The EMBO Journal (1986) 5(11)2825-2830.

Pailiard, M. et al., "Determinants of parathormone secretion in primary hyperparathyroidism," Horm Res. (1989) 32(1-3):89-92.

Parfittk, A.M., "The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism—the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis," Metabolism. (1976) 25(10):1157-88.

Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism" J Clin Endocrinol Metab. (1996) 81(10)3584-8.

Peters, E.M.J. et al., "A new strategy for modulating chemotherapyinduced alopecia, using PTH/PTHrP receptor agonist and antagonist," J Invest Dermatol (2001) 117(2):173-178.

Pettway et al., "Anabolic actions of PTH (1-34): Use of a novel tissue engineering model to investigate temporal effects on bone," Bone (2005) 36(6):959-970.

Phelps, E. et al., "Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3',5'-cyclic adenosine monophosphate signaling in osteoblasts," Calcif Tissue Int. (2005) 77(2):96-103 Epub Aug. 11, 2005.

Philominathan et al., "Unidirectional binding of Clostridial Cotleagenase to Triple Helical Substrates," Journal of Biological Chemistry (2009) 284(16):10868-10876.

Pirih, F.Q. et al., "Parathyroid hormone induces the NR4A family of nuclear orphan receptors in vivo," Biochem Biophys Res Commun. (2005) 332(2) 494-503.

Podbesek, R. et al., "Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds," Endocrinology (1983) 112(3):1000-6.

Poole, K.E. et al., "Parathyroid hormone—a bone anabolic and catabolic agent," Curr Opin Pharmacol. (2005) 5(6):612-7. Epub Sep. 21, 2005.

Watson, P.H. et al., "Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat," Bone (1999) 24(2):89-94.

Weir, E.C. et al., "Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo," Calcif Tissue Int. (1992) 51(1):30-4. Whitfield, J.F., "Taming Psoriatic Keratinocytes-PTHs' uses go up another notch," J. Cell. Biochem. (2004) 93:251-256.

Wilson, J.J. et al., "A bacterial collagen-binding domain with novel calcium-binding motif controls domain orientation," EMBO Journal (2003) 22(8)1743-1752.

Xu, M. et al., "Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice," Bone (2010) 47(2):341-52. Epub May 13, 2010.

Yang, C. et al., "Effects of continuous and pulsatile PTH treatments on rat bone marrow stromal cells," Biochem Biophys Res Commun. (2009) 380(4):791-6. Epub Feb. 3, 2009. Yoshihara, K. et al., "Cloning and nucleotide sequence analysis of the coIH gene from Clostridium histolyticum encoding a collagenase a gelatinase," J Bacteriol (1994) 176:6489-6496.

Younes, N.A. et al., "Laboratory screening for hyperparathyroidism," Clin Chim Acta. (2005) 353(1-2):1-12.

Zang, X.Y. et al, "Effects of parathyroid hormone and estradiol on proliferation and function of human osteoblasts from fetal long bone: An in vitro study," Chin Med J (Engl). (1994) 107(8):600-3. Zaruba, M.M. et al., "Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival," Cardiovasc Res (2008) 77(4):722-731.

Zhou, H. et al., "Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice," Bone (2003) 32(5):513-520.

International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US08/004589 dated Oct. 28, 2008 (17 pages).

Extended European Search Report for Application No. 08742686.2 dated Aug. 4, 2010 (8 pages).

United States Patent Office Action for U.S. Appl. No. 12/594,547 dated Aug. 6, 2012 (12 pages).

International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US12/69831 dated Mar. 14, 2013 (12 pages).

International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US2013/25541 dated Jun. 17, 2013 (16 pages).

Fukayama, S. et al., "New insights into interactions between the human PTH/PTHrP receptor and agonist/antagonist binding," Am. J. Physiol. Endocrinol. Metab. (1998) 274:297-301.

Gao, Y. et al., "T cells potentiate PTH-induced cortical bone loss through CD40L signaling," Cell Metab. (2008) 8(2):132-45.

Gardella, T.J., et al., "Converting Parathyroid Hormone-related Peptide (PTHrP) into a Potent PTH-2 Receptor Agonist," J. of Biological Chemistry, (1996) 271(31):19888-19893.

Gensure, R.C. et al., "Parathyroid hormone and parathyroid hormone-related peptide, and their receptors," Biochem Biophys Res Commun, (2005) 32801:666-78.

Gensure, R.C. et al., "Parathyroid hormone without parathyroid glands," Endocrinology (2005) 146(2):544-546.

Gevers, E.F. et al., "Bone marrow adipocytes: a neglected target tissue for growth hormone," Endocrinology (2002) 143(10):4065-73.

Goltzman, D., "Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone," Arch Biochem Biophys. (2008) 473(2):218-24. Epub Mar. 10, 2008.

Gopalakrishnan, R. et al., "Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization," Cells Tissues Organs (2005) 181(3-4):166-75.

Gosavi, A. et al., "An unusual presentation of parathyroid adenoma—a case report," Indian J Pathol Microbiol. (2005) 48(2):208-10.

Gu, W.X. et al., "Mutual up-regulation of thyroid hormone and parathyroid hormone receptors in rat osteoblastic osteosarcoma 17/2.8 cells," Endocrinology (2001) 142(1);157-64.

Hall, A.K. et al., "The effects of parathyroid hormone on osteoblastlike cells from embryonic chick calvaria," Acta Endocrinol(Copenh). (1985) 108(2):217-23.

Han, B. et al., "Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model," J Orthopaedic Research (2002) 20:747-755.

Headley, C.M., "Hungry bone syndrome following parathyroidectomy," Anna J., (1998) 25(3):283-9; quiz 290-I.

Heath, H., 3rd, "Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology," J Bone Miner Res. (1991) 6(Suppl 2):S63-70: discussion S83-4.

Hoare, S.R. et al., "Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39)," Peptides (2002) 23(5):989-998.

Hock, J.M. et al., "Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats," Endocrinology (1988) 124(6):2899-2904.

OTHER PUBLICATIONS

Hock. J.M. et al., "Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone," J Bone Miner Res. (1992) 7(1):65-72.

Holick, M.F. et al., "Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial," (2003) British J. Dermatology 149:370-376.

Homme, M. et al., "Differential regulation of RGS-2 by constant and oscillating PTH concentrations," Calcif Tissue Int. (2009). 84(4):305-12. Epub Feb. 20, 2009.

Horwitz, M.J. et al., "Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose," J Clin Endocrinol Metab. (2010) 95(3):1279-87.

Horwitz, M.J. et al., "Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D," J Bone Miner Res. (2005) 20(10)1792-803. Epub Jun. 6, 2005.

Hruska, K.A. et al., "Regulation of skeletal remodeling by parathyroid hormone," Contrib Nephrol. (1991) 91:38-42.

Iida-Klein, A. et al., "Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice," J Endocrinol. (2005) 186(3):549-57.

Ishii, H. et al., "Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia," Bone (2000) 26(2):175-82.

Ishikawa, T. et al., "Delivery of a growth factor fusion protein having collagen-binding activity to wound tissues," Artif. Organs (2003) 27(2):147-154.

Ishikawa, T. et al., "Production of a biologically active epidermal growth factor fusion protein with high collagen affinity," J. Biochem. (2001) 129(4)627-433.

Ishizuya, T. et al., "Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteobiastic cells," J Clin Invest. (1997) 99(12)2961-70.

Ito, M., "Parathyroid hormone and bone quality," Clin Calcium. (2005) 15(12):31-7.

Ito, M., "Parathyroid and bone: Effect of parathyroid hormone on bone quality," Clin Calcium. (2007) 17(12):1858-64.

Jeon, E. et al., "Engineering and application of collagen-binding fibroblast growth factor 2 for sustained release," (2013) J. of Biomed. Materials Research: Part A.

Jilka, R.L., "Molecular and cellular mechanisms of the anabolic effect of intermittent PTH," Bone (2007) 40(6):1434-1446, Epub Apr. 6, 2007.

Jilka, R.L. et al., "Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms," J Bone Miner Res. (2010) 25(II):2427-37.

Kaji, H., "Parathyroid and bone: Effects of parathyroid hormone on bone resorption and formation: differences between intermittent and continuous treatment," Clin Calcium., (2007) 17(12):1836-42.

Katikaneni et al., "Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to coolagen binding domain," Int. J. Cancer (2012) 131(5):E813-821. Kaye, M. et al. "Elective total parathyroidectomy without autotransplant in end-stage renal disease," Kidney Int. (1989) 35(6):1390-9.

Khan, A. et al., "Primary hyperparathyroidism: pathophysiology and impact on bone," Cmaj. (2000) 163(2):184-7.

Kido, S. et al., "Mechanism of PTH actions on bone," Clin Calcium. (2003) 13(1):14-8.

Kistler, H., "Primary hyperparathyroidism: An analysis of 152 patients with special references to acute life threatening complications (acute hyperparathyroidism)," Schweiz Med Wochenschr, (1976) 106(Suppl 3): 1-61.

Kitazawa, R. et al., "Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: comparative study by histomorphometry," Bone Miner. (1991) 12(3):157-66. Klempa, I., "Treatment of secondary and tertiary hyperparathyroidism—surgical viewpoints," Chirurg. (1999) 70(10):1089-101.

Koh, A.J. et al., "3', 5'-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro," Endocrinology (1999) 140(7):3154-62.

Komarova. S.V., "Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone," Endocrinology, (2005) 146(8):3589-95, Epub Apr. 28, 2005.

Kousteni, S. et al., "The cell biology of parathyroid hormone in osteoblasts," Curr Osteoporos. Rep. (2008)6(2):72-6.

Kroll, M.H., "Parathyroid hormone temporal effects on bone fonnation and resorption," Bull Math Biol. (2000) 62(1):163-88.

Lemaire, V. et al., "Modeling the interactions between osteoblast and osteoclast activities in bone remodeling," J Theor Biol., (2004) 229(3):293-309.

Li, X. et al., "Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis," J Biol. Chem. (2007) 282(45):33086-97. Epub Aug. 9, 2007.

Li, X. et al., "In vivo parathyroid hormone treatments and RNA isolation and analysis," Methods Mol Biol. (2008) 455:79-87.

Liu, J. et al., "Intermittent PTH administration: a novel therapy method for periodontitis-associated alveolar bone loss." Med Hypotheses. (2009) 72(3):294-6, Epub Nov. 30, 2008.

Potter, L.K. et al., "Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics," Bone (2005) 37(2):159-169.

Potts, J.T., "Parathyroid hormone: past and present," J Endocronology (2005) 187:311-325.

Qin, L. et al., "Parathyroid hormone: a double-edged sword for bone metabolism," Trends Endocrinol Metab. (2004) 15(2):60-5.

Rattanakul, C. et al., "Modelin of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy" Biosystems (2003) 70(1):55-72.

Richardson, M.L. et al., "Bone mineral changes in primary hyperparathyroidism," Skeletal Radiol. (1986) 15(2):85-95.

Rickard, D.J. et al., "Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells," Bone (2006) 39(6):1361-1372. Epub Aug. 10, 2006.

Rixon, R.H. et al., "Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase." J Bone Miner Res. (1994) 9(8):1179-89.

Robinson, J.A. et al., "Identification of a PTH regulated gene selectively induced in vivo during PTH-mediated bone formation," J Cell Biochem. (2006) 98(5):1203-20.

Rosen, C.J., "The cellular and clinical parameters of anabolic therapy for osteoporosis," Crit Rev Eukaryot Gene Expr. (2003) 13(1):25-38.

Rubin, M.R. et al., "The potential of parathyroid hormone as a therapy for osteoporosis," Int J Fertil Womens Med. (2002) 47(3):103-15.

Rubin, M. et al., "The anabolic effects of parathyroid hormone therapy," Osteoporosis International (2002) 13(4):267-277.

Rubin, M.R. et al., "The anabolic effects of parathyroid hormone therapy," Clin Geriatr Med. (2003) 19(2):415-32.

Scaefer, F., "Pulsatile parathyroid hormone secretion in health and disease," Novartis Found Symp. (2000) 227:225-39; discussion 239-43.

Schluter, K.-D. et al., "A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ETA

receptors," British Journal of Pharmacology (2001) 132:427-432. Schmitt, C.P. et al., "Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats," Kidney Int. (2000) 57(4):1484-92.

Schmitt, C.P. et al., "Structural organization and biological relevance of oscillatory parathyroid hormone secretion," Pediatr Nephrol. (2005) 20(3):346-51. Epub Feb. 8, 2005.

Schneider, A. et al., "Skeletal homeostasis in tissue-engineered bone," J Orthop Res. (2003) 21(5):859-64.

OTHER PUBLICATIONS

Seeman, E. et al., "Reconstructing the skeleton with intermittent parathyroid hormone," Trends Endocrinol Metab. (2001) 12(7):281-3.

Shen, V. et al., "Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion," J Bone Miner Res. (2000) 15(4):740-6.

Shinoda, Y. et al., "Mechanisms underlying catabolic and anabolic functions of parathyroid hormone on bone by combination of culture systems of mouse cells," J. of Cellular Biology (2010) 109(4):755-63.

Silver, J. et al., "Harnessing the parathyroids to create stronger bones," Curr Opin Nephrol Hypertens. (2004) 13(4):471-6.

Silverberg, S.J. et al., "Skeletal disease in primary hyperparathydroidism." J Bone Miner Res., (1989) 4(3):283-91.

Skripitz, R. et al., "Parathyroid hormone—a drug for orthopedic surgery?," Acta Orthop Scand. (2004) 75(6):654-62.

Skripitz, R. et al., "Stiumulation of implant fixation by parathyroid hormone (1-34)-A histomorphometric comparison of PMMA cement and stainless steel," J Orthop Res. (2005) 23(6):1266-70. Epub Jun. 16, 2005.

Smajilovic, S. et al., "Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats," Open Cardiovasc. Med, J. (2010) 4:110-6.

Spurney, R.F. et al., "Anabolic effects of G protein-coupled receptor kinase inhibitor expressed in osteoblasts," J Clin Invest. (2002) 109(10):1361-71.

Stewart, A.F., "PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis," Bone (1996) 19(4):303-306.

Stracke, S. et al., "Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism," Nephron Clin Pract. (2009) 111(2):c102-9. Epub Jan. 13, 2009.

Strewler, G.J., "Local and systemic control of the osteoblast," J. of Clin. Invest. (2001) 107:271-272.

Suttamanatwong, S. et al., "Regulation of matrix Gla protein by parathyroid hormone in MC3T3-E1 osteoblast-like cells involves protein kinase A and extracellular signal-regulated kinase pathways," J Cell Biochem. (2007) 102(2):496-505.

Suttamanatwong, S. et al., "Sp proteins and Runx2 mediate regulation of matrix gla protein (MGP) expression by parathyroid hormone," J Cell Biochem. (2009)107(2):284-92.

Suzuki, A. et al., "PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells," J Cell Biochem. (2008) 104(1):304-17. Swarthout, J.T. et al., "Parathyroid hormone-dependent signaling pathways regulating genes in bone cells," Gene (2002) 282(1-2):1-17.

Swarthout, J.T. et al., "Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent" J Biol Chem. (2001) 276(10);7586-92, Epub Dec. 6, 2000.

Takada, H. et al., "Response of parathyroid hormone to anaerobic exercise in adolescent female athletes," Acta Paediatr Jpn. (1998) 40(1):73-7.

Takasu, H. et al., "Dual signaling and ligand selectivity of the human PTH/PTHrP receptor," J Bone Miner Res. (1999) 14(1):11-20.

Talmage, R. V. et al., "Calcium homeostasis.: reassessment of the actions of parathyroid hormone," Gent Comp Endocrinol. (2008) 156(1):1-8. Epub Nov. 12, 2007.

Tam, C.S. et al., "Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration," Endocrinology (1982) 10(2):506-12.

Tawfeek, H. et al., "Disruption of PTH receptor 1 in T cells protects against PTH-induced hone loss," PLoS (2010) 5(8):e12290.

Tokumoto, M. et al., "Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors," Ther Apher Dial. (2005) 9(Suppl. 1.):S27-34.

Tollin. S.R. et al., "Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type lb," J Bone Miner Res. (2000). 15(7):1412-6.

Toyoshima, T. et al., "Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in vitro and in vivo," Connective Tissue Research (2001) 42(4):281-290.

Uzawa, T. et al., "Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone," Bone (1995) 16(4):477-84.

Vanstone. M.B. et al., "Rapid correction of bone mass after parathyroidectomy in an adolescent with primary hyperparathyroidism," J. Clin. Endocrinol. Metab. (2011) 96(2): E347-50. Epub Nov. 24, 2010.

Wan, Q. et al., "Intra-articular injection oiparathyroid hormone in the temporomandibular joint as a novel therapy for mandibular asymmetry," Med Hypotheses (2009) 74(4):685-7.

Wang, C.A. et al., "Natural history of parathyroid carcinoma. Diagnosis, treatment, and results," Am J Surg. (1985) 149(4):522-7. Wang, Y. et al., "A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level," Viol Cell Biomech. (2009) 6(2):101-12.

Wang, Y. et al., "Gender diffences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I," J Endocrinol. (2006) 189(2):279-87.

Abdelhadi, M. et al., "Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism," J Clin Endocrinol Metab. (1998) 83(11):3845-51.

Abe, Y. et al., "Enhancement of graft bone healing by intermittent administration of guman parathyroid hormone (1-34) in a rat spinal arthodesis model," Bone (2007) 41(5):775-785.

Abshirini, H.et al., "Pathologic fractures: a neglected clinical feature of parathyroid adenoma," Case (2010) p. 357029. Epub Nov. 29, 2010.

Akimoto, M. et al., "Effects of CB-VEGF-A injection in rat flap models for improved survival," (2013) Plast. Reconstr. Surg. 131(14):717-725.

Aleksyniene, R. et al, "Parathyroid hormone—possible future drug for orthopedic surgery," Medicina (Kaunas) (2004) 40(9):842-9.

Andrade, M.C., et al., "Bone mineral density and bone histomorphometry in children on long-term dialysis," Pediatr Nephrol. (2007) 22(10):1767-72. Epud Aug. 7, 2007.

Barros, S.P., et al., "Parathyroid hormone protects against periodontitis-associated bone loss," J Dent Res. (2003) 82(10):791-5.

Bauer, R., et al., "Structural comparison of ColH and ColG collagen-binding domains from Clostridium histolyticum," (2013), *Journal of Bacteriology*, 195(2), 318-327.

Bedi, B., et al., "Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss," Ann N Y Acad Sci. (2010) 1192:215-21.

Belinsky, G.S. et al., "Direct measurement of hormone-induced acidification in intact bone," J Bone Miner Res., (2000) 15(3):550-6.

Bellido, T., et al., "Chronic elevation of parathyroid hormone in mice reduces expression of selerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis," Endocrinology (2005) 146(11):4577-83. Epub Aug. 4, 2005.

Bergenstock, M.K. et al., "Parathyroid hormone stimulation of noncanonical Wnt signaling in bone" Ann N Y Acad Sci. (2007) 1116:354-9.

Bergwitz, C. et al., "Rapid desensitization of parathyroid hormone dependent adenylate cyclase in perifused human osteosarcoma cells (SaOS-2)." Biochem Biophys Acta. (1994) 1222(3):447-56.

Bianchi, E.N. et. al., "Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteobtasts" Bone (2009) 45(4):716-25. Epub Jun. 25, 2009.

Bilezikian, J.P., et al., "Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future," J Bone Miner Res. (2002) 17(Suppl 2):N57-67.

OTHER PUBLICATIONS

Bilezikian, ', J.P. et al., "Characterization and evaluation of asymptomatic primary hyperthyroidism, " J Bone Miner Res. (1991) 6(Suppl 2):S85-9; discussion S121-4.

Blachowicz, A. et al., "Serum I-84 and 7-84 parathyroid hormone concentrations and bone in patients with primary hyperparathyroidism," Langenbecks Arch Surg. (2008) 393(5):709-13, Epub Jul. 11, 2008.

Buargub, M.A. et al., "Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients," Saudi J Kidney Dis Transpl. (2006) 17(3):401-7.

Calvi, L.M. et al., "Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone," J. Clin. Invest. (2001)107:277-286.

Calvi, L.M. et al., "Osteoblastic cells regulate the haematopoietic stem cell niche," Nature (2003) 425:841-846.

Canalis, E., "Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariac," Metabolism (1983) 32(1);14-20.

Canalis, E. et al., "Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures," J Clin Invest. (1989) 83(1):60-5.

Carter, P.H. et al., "Selective and Nonselective Inverse Agonists for Constitutively Active Type-1 Parathyroid Hormone Receptors: Evidence for Altered Receptor Conformations," Endocrinology (2001) 142(4):1534-1545.

Chan, H.W. et al., "Prospective study on dialysis patients after total parathyroidectomy without autoimplant," Nephrology (2009) 15(4):441-7.

Chen, B. et al., "Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2," Biomaterials (2007) 28:1027-1035.

Chen, Q. et al., "Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects," J Clin Endocrinol Metab. (2003) 88(10):4655-8.

Cherian, P.P. et al., "Role of gap junction, hemichannels, and connexin 43 in mineralizing in response to intermittent and continuous application of parathyroid hormone," Cell Commun Adhes. (2008) 15(1):43-54.

Chevalley, T. et al., "Bone and hormones, Effects of parathyroid hormone on the bone." Presse Med. (1999) 28(10):547-53.

Cohen, A. et al., "Osteoporosis in adult survivors of adolescent cardiac transplantation may be related to hyperparathyroidism, mild renal insufficiency, and increased bone turnover," J Heart Lung Transplant (2005) 24(6):696-702.

Compston, J.E., "Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure," Bone (2007) 40(6):1447-1452. Cormier, C., "Parathyroid hormone in osteoporosis," Presse Med. (2006) 35(3 Pt 2):495-501.

Corsi, A. et al., "Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations." J Bone Miner Res. (2003) 18(7): 1235-46.

Cosman, F., "Parathyroid hormone treatment for osteoporosis," Current Opinion in Endocrinology, Diabetes & Obesity (2008) 15:495-501.

Cundy, T. et al., "Hyperparathyroid bone disease in chronic renal failure," Ulster Med J. (1985) 54(Suppl):S34-43.

Datta, N.S. et al., "Distinct roles for mitogen-activated protein kinase phosphatase-1 (MJP-1) and ERK-MAPK in PTH I R signaling during osteoblast proliferation and differentiation," Cell (2010) 22(3):457-66, Epub.

Deal, C. "The use of intermittent human parathyroid hormone as a treatment for osteoporosis," Curr Rheumatol Rep. (2004) 6(1): 49-58.

Demiralp, B. et al, "Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos," Endocrinology (2002) 143(10):4038-47.

Dobnig, H. et al., "The effects of programmed administration of human parathyroid honnone fragment (1-34) on bone histomorphometry and serum chemistry in rats," Endocrinology (1997) 138(11):4607-12.

Drake, M.T. et al., "Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells," Endocrinology (1994) 134(4):1733-7.

Endo, K. et al., "1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hyperealecmic rats with continuous parathyroid hormone-related peptide infusion," J Bone Miner Res. (2000) 15(1):175-81.

Etoh, M. et al., "Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone," J Bone Miner Metab. (2010) 28(6):641-649.

Fitzpatrick, L.A. et al., "Acute primary hyperparathyroidism," Am J. Med, (1987) 82(2) 75-82.

Fleming, A. et al., "High-throughput in vivo screening for bone anabolic compounds with zebrafish," J Biomol Screen. (2005)10(8):823-:31. Epub Oct. 18, 2005.


Fouda, M.A., "Primary hyperparathyroidism: King Khalid University Hospital Experience," Ann Saudi Med., (1999) 19(2):110-5.

Fox, J. et al., "Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys," Bone (2007) 41(3):321-330.

Fraher, L.J. et al., "Comparison of the biochemical responses to human parathyroid hormone-(I-31)NH2 and hPTH-(1-34) in healthy humans," J Clin Endocrinol Metab. (1999) 84(8):2739-43. Frolik, C.A. et al., "Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure," Bone (2003) 33(3):372-379.

Fujita, T., "Parathyroid hormone in the treatment of osteoporosis," BioDrugs (2001) 15(11):721-728.


* cited by examiner







н	1000 	-NNCN SLIK	-DNGN SLAIK 1-GDGT ELSVK	I-GDGT ELSVK	I-ENGT TVQVQ	-GTON TVEVK	-GTGN TVEVK	-ETIP KVTAE	ISCTGN TVNLQ	-NKIN KLTIN	-EKVD KESIE	-EKSD RFNIE	ASNIS SINIK	I-QSCA TUNVK	(-SIAN NLKVN -SYMP RINIE	• 02	*
E	990	TPGKYYLYVYKYSC	APGKYYLYVYKYSC Kforyylyvykydy	KPGKYYYYYYYYY	EPGKYYLYVYKFEN	HPGKYYLHVYQYG	KPGKYYLSVXKYG	TPGTYTLSVYNENC KDOEVVILSVYNENC	NECKLICALOEB	KPCRYYILAYK NS S	KPGKYYLVIYKTLG	KPGKYYLVIYKVSC	X-CHHYVELYVEDS	ACTIVISITION-	KPGKYYILV YNHD	• 08	# #
3	980 CNKVSNKVKI	GSTIVGNCHV-	CNTIKGKONV- CNHIEANENA-	CNHIEANINA-	CNNINGKLHA-	CNKLVGSYNA-	CNKLLGNYNA-	CKTLSGEFEA- Ckkittcefea.	CNKLSNTCKL-	CNKIMCSIKVE	GNOLSNTVKIN	ENLIYSTVKID	NNSKVGTEKST	STVLKGERTLE	GAILNGDYNAT GONLSGKEKAD	• 0 • 0	•
Ìu Iu	970 WDR T T Y COVD-	NNY IAY SKL-	NNY IAYOSVS- IONYAAYOOVN-	ONYAST COLD-	ONYASE OEE-	NNYVTYAQTQ-	MNYVTXATKRD	NNYLAYPKUS- Ktyveaypktus-	-OKNAYONYA	NNY IGY PTKKE	SNYMAFUNKEL	SNY I TY PNKEL	ONHIASCIDK-	MNYVLYATGNE	NNYVAYPTIS- NNAVSYATDD-	٠ô	* È
¥	90 90 970 980 990 1000	TGUTWTUYKESDLNNYIAYGSKL-GSTIVGNCHV-TPGKYYLYVYKYSG-NNGN SLIIK	LGLAWNLYKESDLNNYIAYGSVS-GNTIKGKONV-APGKYYLYVYKYSG-DNGN/SLAIK IGMTWVLHHESDMONYAAYGOVN-GNHIEANFNA-KPGKYYLYVYKYDN-GDGT/ELSVK	I CATWULAHESDMONYAAYOOAN-CNHIEANFNA-KPCKYYLYVYKYDN-GDGT/ELSVK ICATWULTHESDSONYASFOOED-CMAINGKWNA-KPCKYYLYVYKFEN-ENGT/TVHVO	ICATWVLYHESDSQNYASTCQEE-CNMINGKLHA-EPCKYYLYVYKFEN-ENGT TVQVQ ICATWVLYHESDSQNYASTCQEE-CNMINGKLHA-EPCKYYLYVYKFEN-ENGT TVQVQ	IGVNWVLY SAADLNNYVTYAQTQ-GNKLVGSYNA-HPGKYYLHVYQYGG-GTGN TVEVK	Tolinwvlysesdinnyvytkedonklijonyna-kpokyvlsvykygg-gton tvevk	TGINWVVHHEDDLNNYLAYEKTS-CKTLSGEFEA-TPGTYYLSVYNFNG-ETIP/KVTAE EGINSVVHHEDDLNNYLAYERYES-CKTLSGEFEA-FPGTYYLVVHNNNFKTP/K2TV	IKONWILYSADDLSNYVDYANAD-ONKISNYCKI-NPGKYYLCVYQFENSGTON TVNLQ	NSTIFNWLA'S SDNTNNY I GY PTKKE GNKLMGSFK VPK PGRYYILAYKNSS-NKIN KLTIN SSNE NWELAYS SDNTNNY I GY ATKREGNKITGNEKUDK PGRYYIVAYKTSS-NKIN KLINIK	DKSEFNWILLFSDEDKSNYMAFFNKELGNOLSNTVKINKPGKYYLVIYKTLG-EKVD/KFSIE	DKSEFSWLLESEEDKSNYITYPNKELENLFYSTVKIDKPGKYYLVVYFVVGCSUJW NEFUW Dcymei JeknydjenytbystrestinkinckinjKu/fvv/jev/jev/gcs-sujw Nefum		VGITWILYKEGDLMNYVLYATGNEGTVLKGEKTLE-PGRYYLSVYTYDN-QSGA TVNVK	KOISWOLFHESDINNYVAYPTTS-CALINGDYNATKPCKYYILVYNHDK-SIAN NLKVN CGATWVVYDENNNAVSYATDD-OONLSGKEKADKPCRYYIHLYNENG-SYMP'RINLE	• 02 6	* 1
	tr Sola with	Csporogenes C	CbotulinumA3C Bcereus AH603	Banthracis BB14905 B	Lsphaericus B Crernec0842	Bmycoides		Bbrevis A abrevis A		Csporogenes B Chofulinuma3a	Csporogenes A	CbotulinumA3A Ceordel145 B		¥3	Csordellii A ColM #3		

U.S. Patent








1

Å 0.01 0.001 0.0001 0.01 8.1 В 8 183 6 183 4 18° 2 18° Ç, 28 60 80 100 ŝ 40








Fig. 6C








Fig. 7A

Fig. 7B





Fig. 7C












Fig. 10


























Injection

Grey Scale Analysis at Injection Site







- \$**8**53



Colorada (Anna Maria and Anna

No Chemotherapy






Chemotherapy


Prophylaxis





Therapy











15

DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/US2012/ 069831, filed Dec. 14, 2012, which claims the benefit of priority of United States Provisional Patent Application No. 10 61/570,620, filed Dec. 14, 2011 and of United States Provisional Patent Application No. 61/596,869, filed Feb. 9, 2012, all of which are incorporated herein by reference in their entireties.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with United States government support awarded by the National Institutes of Health grant 20 number NCRR COBRE 8P30GM103450 and INBRE GM103429. The United States may have certain rights in this invention.

SEQUENCE LISTING

A Sequence Listing accompanies this application and is incorporated herein by reference in its entirety. The Sequence Listing was filed with the application as a text file on Dec. 14, 2012.

INTRODUCTION

Delivery of therapeutic agents to sites within the body of a subject where a particular therapeutic agent is needed in 35 order to be effective is a developing area. Such delivery systems will allow more efficient use of therapeutic agents while reducing toxicity caused by some therapeutic agents. Use of targeted liposomes or polypeptides, such as antibodies, to target therapeutic agents to particular sites within the 40 currently no cure and few treatments for OI. body has proved successful, but additional delivery agents are needed.

Alopecia (hair loss) is a psychologically and emotionally distressing event with multiple causes. Alopecia occurs most commonly in male-pattern baldness, affecting approxi- 45 agents by administering compositions including a bacterial mately two thirds of males by age 35; a similar pattern of hair loss can be observed in females with polycystic ovarian syndrome. In both of these disorders, the hair loss is androgen mediated. Alopecia can also occur as an autoimmune disease, termed alopecia areata; a disorder which affects 50 1.7% of the population. It can occur as a side-effect of medical treatments, particularly in chemotherapy, with 65-85% of chemotherapy patients experiencing some degree of alopecia. Psychological consequences of hair loss have been well studied in the chemotherapy setting. Chemo- 55 collagenopathy, such as osteogenesis imperfecta, by admintherapy-induced alopecia (CIA) can result in anxiety, depression, a negative body image, lowered self-esteem and a reduced sense of well-being. In fact, 47-58% of female cancer patients consider hair loss to be the most traumatic aspect of chemotherapy, and 8% would decline treatment for 60 fear of hair loss. In addition to these studies in chemotherapy patients, evidence exists in other forms of alopecia to support therapy to reduce psychological consequences of hair loss. Thus a new treatment to stop hair loss or speed hair regrowth would be beneficial.

While drugs with mild anti-androgenic effects (i.e. spironolactone) had been used with limited success as therapy for alopecia, the first effective medication for alopecia was minoxidil (Rogaine). This antihypertensive has an observed side-effect of causing hair growth, and is now used as topical therapy for many forms of alopecia. However, responses are incomplete, with some subjects showing only slowing of hair loss rather than actual regrowth. Finasteride (Propecia) is a newer agent that blocks conversion of testosterone to dihydrotestosterone, resulting in improvements in androgenic alopecia at the expense of partial systemic androgen blockade. However, response rates with long-term (10 years) therapy are only around 50%. Overall, despite considerable research in this area, there is still no adequate therapy for hair loss.

In addition, unwanted hair growth is a cosmetic issue many people deal with on a regular basis. Unwanted hair growth on the face, legs, arms, chest or back is a growing cosmetic problem. Many people use laser therapy, waxing or other therapies to remove unwanted hair. There are currently no topical pharmaceuticals to limit hair growth.

Collagenopathies represent a large number of diseases in which collagen structure or formation is not normal. This group of diseases results in a broad spectrum of symptoms including bone defects, vascular defects, and skin defects. ²⁵ Many of these diseases have no or only ineffective treatments available.

For example, osteogenesis imperfecta (OI), also known as brittle bone disease, is caused by an inborn mutation of type I collagen. Approximately 25,000 to 50,000 Americans are affected and the effects of the disease range from mild, in which many individuals are unaware of the disease, to severe in which individuals cannot live a normal life due to recurrent broken bones. Most OI patients carry a mutation which causes an amino acid change in collagen changing a glycine to a bulkier amino acid which results in disruption of the triple helix structure of the collagen and undertwisting. The body may respond by hydrolyzing the collagen and this may result in a reduction in bone strength. There is

SUMMARY

Provided herein are methods of delivering therapeutic collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF) and the bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen.

In another aspect, methods of treating a subject with a istering a composition comprising a bacterial collagenbinding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject in an amount effective to treat the collagenopathy are provided. The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen.

In yet another aspect, methods of treating hyperparathyroidism by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject are provided.

In still a further aspect, methods of slowing hair growth or regrowth after removal by administering a composition 10

55

comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor antagonist to a subject are provided.

In a still further aspect, methods of increasing hair growth or the speed of hair re-growth after removal or loss by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject are provided.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the office upon request and payment of the necessary fee.

FIG. 1 is a sequence alignment showing the alignment of several M9B bacterial collagenases from the Bacillus and Clostridium families. The residues shown in blue are important for collagen binding activity, those shown in green are important for maintaining the architecture or protein folding. 20 Both of these are also underlined for the top and bottom sequences. Residues shown in red are critical for Ca²⁺ binding and those in orange are critical for positioning the Ca^{2+} binding residues.

FIG. 2 is a set of drawings showing the chemical struc- 25 tures of synthesized peptides.

FIG. 3A is a graph showing the circular dichroism spectra of the collagenous peptides measured at 4° C.

FIG. 3B is a graph showing the thermal denaturation profile of the various collagenous peptides. The temperature 30 was increased at the rate of 0.3° C./min.

FIG. 4A is a graph showing the scattering profile with the intensity I(Q) plotted against the scattering vector Q.

FIG. 4B is a graph showing the pair-distance distribution function P(r) in the real space obtained using GNOM for 35 [PROXYL-(POG)₃POA(POG)₆]₃:CBD complex (Red), [PROXYL-(POG)₄POA(POG)₅]₃:CBD complex (Blue), [PROXYL-(POG)₅ POA(POG)₄]₃:CBD complex (Green), [PROXYL-(POG)₆POA(POG)₃]₃:CBD complex (Orange) and [11PROXYL-(POG)₃PCG(POG)₄]₃:CBD complex 40 (Cyan).

FIG. 5 is a set of plots showing HSQC NMR data obtained using the collagen binding domain (CBD)-collagenous peptide interactions. FIG. 5A shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spec- 45 trum of [(POG)₁₀]₃:CBD complex (green) at 1:1 ratio. Amide resonance of V973, G975 and S979 are present during this titration. FIG. **5**B shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [PROXYL-(POG)₆POA(POG)₃]₃:CBD complex 50 (red) at 1:1 ratio. Amide resonances of V973, G975 and S979 disappeared because of their proximity to the spinlabeled group. FIG. 5C is a cartoon showing the structure of CBD and the CBD residues that are line broadened upon titration with [PROXYL-(POG)₆POA(POG)₃]₃.

FIG. 6 is a set of plots showing HSQC NMR data obtained using the CBD-collagenous peptide interactions. FIG. 6A shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₁₀]₃:CBD complex (green) at 1:1 ratio. Amide resonances of Q972, 60 V973, G975 and S979 are present during this titration. FIG. **6**B shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [PROXYL-(POG)₅POA(POG)₄]₃:CBD complex (red) at ratio 1:1. Amide resonances of Q972, V973, G975 and S979 are line 65 broadened due to the PROXYL moiety. FIG. 6C is a cartoon of the structure of CBD showing the CBD residues that are

4

uniquely line broadened upon titration with [PROXYL- $(POG)_5POA(POG)_4]_3$. FIG. 6D shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₁₀]₃:CBD complex (green) at 1:1 ratio. Amide resonances of L946, Q972, V973, G975 and S979 are present during this titration. FIG. 6E shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [PROXYL-(POG)₄POA(POG)₅]₃:CBD complex (red) at 1:1 ratio. Amide resonances of L946, Q972, V973, G975 and S979 disappeared because of the spin-label. FIG. 6F shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₄POA (POG)₅]₃:CBD (cyan) at ratio 1:1. In the absence of spin label, amide resonances of L946, Q972, V973, G975 and S979 are not line broadened. FIG. 6G shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of $[(POG)_{10}]_3$:CBD complex (green) at 1:1 ratio. Amide resonances of L946, G953, Q972, V973, D974, G975, N976, V978, S979 are present during this titration. FIG. 6H shows an overlay of ¹H-¹⁵N HSOC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [PROXYL-(POG)₃POA(POG)₆]₃:CBD complex (red) at ratio 1:1. Amide resonances of L946, G953, Q972, V973, D974, G975, N976, V978, S979 are line broadened due to the PROXYL moiety. FIG. 6I is a cartoon of the structure of CBD showing the CBD residues that are line broadened by the spin label of [PROXYL-(POG)₃POA(POG)₆]₃.

FIG. 7 is a set of graphs showing the intensity drop of (A) Q972, (B) G975, (C) S979 and (D) L924 on CBD as a function of increasing concentrations of mini-collagen i.e. [(POG)₁₀]₃ (black), [PROXYL-(POG)₆POA(POG)₃]₃(red), [PROXYL-(POG)₅POA(POG)₄]₃(blue), IPROXYL-(POG)₄POA(POG)₅]₃(green), and [PROXYL-(POG)₃POA $(POG)_6]_3(cyan).$

FIG. 8 is a set of plots showing HSQC NMR data obtained using the CBD-collagenous peptide interactions. FIG. 8A shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₁₀]₃:CBD complex (green) at 1:1 ratio. Amide resonances of S906, S997 and G998 are present during this titration. FIG. 8B shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₄POA(POG) ₅C-PROXYL]₃:CBD complex (red) at ratio 1:1. Amide resonances of S906, S997 and G998 are line broadened due to the PROXYL moiety. FIG. 8C shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₄POA(POG)₅C-carbamidomethyl]₃: CBD (cyan) at 1:1 ratio. In the absence of spin label, amide resonances of S906, S997 and G998 are not line broadened. FIG. 8D is a cartoon of the structure of CBD showing the CBD residues that are line broadened due to the spin label of [(POG)₄POA(POG)₅C-PROXYL]₃. Amide resonances of S906, S997 and G998 (red) disappeared upon titration with [(POG)₄POA(POG)₅-PROXYL]₃. FIG. 8E shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₁₀]₃:CBD complex (green) at 1:1 ratio. Amide resonances of S906, Q972, V973, G975, S979, S997 and G998 are present during this titration. FIG. 8F shows an overlay of 1H-15N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [11PROXYL-(POG)₃PCG(POG)₄]₃:CBD complex (red) at 1:1 ratio. Amide resonances of S906, Q972, V973, G975, S979, S997 and G998 disappeared because of the spin-label. FIG. 8G shows an overlay of ¹H-¹⁵N HSQC spectrum of CBD (black) and ¹H-¹⁵N HSQC spectrum of [(POG)₃PCG (POG)₄]₃:CBD (cyan) at ratio of 1:1. Resonances of S906, Q972, V973, G975, S979, S997 and G998 are intact in the absence of the spin label. FIG. **8**H is a cartoon of the structure of CBD showing the residues that are line broadened upon titration with $[11PROXYL-(POG)_3PCG (POG)_4]_3$. Only amide resonances of S906, R929, S997, and G998 (red) disappeared at 0.2:1 ratio. When the peptide ratio was raised to 0.3:1, additional resonances of V973, G975, S979 (blue) disappeared.

FIG. **9** is a set of structure drawings derived from SAXS scattering profiles using ab initio simulated annealing calculations for (A) [PROXYL-(POG)₃POA(POG)₆]₃:CBD ¹⁰ complex, (B) [PROXYL-(POG)₄POA(POG)₅]₃:CBD complex, (C) [PROXYL-(POG)₅POA(POG)₄]₃:CBD complex and (D) [PROXYL-(POG)₆POA(POG)₃]₃:CBD complex, (E) [(POG)₄POA(POG)₅C-PROXYL]₃:CBD complex, (F) [(POG)₄POA(POG)₅C-carbamidomethyl]₃:CBD. The Gly→Ala mutation sites are highlighted. FIGS. **9**G and **9**H show two probable binding modes of [11PROXYL-(POG)₃PCG(POG)₄]₃:CBD complex.

FIG. 10 is a set of plots showing HSQC NMR data 20 obtained using the CBD-collagenous peptide interactions. FIG. 10A is an overlay of ¹H-¹⁵N HSQC spectrum of [POGPO-¹⁵N-G-(POG)₈]₃ (black) with ¹H-¹⁵N HSQC spectrum of [POGPO-¹⁵N-G-(POG)₈]₃:CBD complex (red) at 1:1 ratio. FIG. 10B shows an overlay of ¹H-¹⁵N HSQC ²⁵ of [POGPO-¹⁵N-G-(POG)₂-POA-(POG)₅]₃ spectrum (black) with ¹H-¹⁵N HSQC spectrum of [POGPO-¹⁵N-G-(POG)₂POA-(POG)₅]₃:CBD complex (red) at 1:1 ratio. FIG. 10C shows an overlay of ¹H-¹⁵N HSQC spectrum of 30 $[(POG)_8$ -PO-¹⁵N-G-POG]₃ (black) with ¹H-¹⁵N HSQC spectrum of $[(POG)_8$ -PO-¹⁵N-G-POG]₃:CBD complex (red) at 1:1 ratio. FIG. 10D shows an overlay of ¹H-¹⁵N HSQC spectrum of [(POG)₄-POA-PO-¹⁵N-G-POG]₃ (black) with ¹H-¹⁵N HSQC spectrum of [(POG)₄-POA-PO-¹⁵N-G-POG]₃:CBD complex (red) at 1:1 ratio.

FIG. 11 shows the tissue distribution of S^{35} -PTH-CBD 1 hour and 12 hours after subcutaneous injection. Note the skin outline.

FIG. 12 is a set of photographs documenting the hair $_{40}$ growth on the back of mice at day 36 after depilation, treatment groups as indicated (Antagonist=PTH(7-33)-CBD, Agonist=PTH-CBD).

FIG. **13** is a set of photographs showing the histology at Day 36 after the indicated treatment. Skin samples were 45 taken from the dorsal region and processed for Hematoxylin and Eosin (H&E) staining. Representative sections are shown from each treatment group as indicated. (Antagonist=PTH(7-33)-CBD, Agonist=PTH-CBD).

FIG. 14 is a graph showing the hair follicle counts per 50 high powered field. Anagen VI hair follicles were counted by two independent observers in a blinded fashion. Results are expressed as mean+/-standard deviation. **=p<0.01 vs. no chemo ANOVA followed by Dunnett's test. (Antagonist=PTH(7-33)-CBD, Agonist=PTH-CBD). 55

FIG. **15** is a set of photographs showing the hair growth on the back of the mice after each of the indicated treatments and a graph showing the results of a grey scale analysis of the hair at the injection site over time after the injection.

FIG. **16** is a set of photographs showing the hair on the 60 back of mice after the indicated treatment without prior depilation.

FIG. **17** is a set of photographs and a graph showing the grey scale analysis of hair growth on the backs of mice comparing the indicated treatments with the PTH-CBD 65 being administered prior to the chemotherapy as opposed to after chemotherapy began.

FIG. **18** is a photograph of three mice 13 days after waxing to remove hair and treatment with PTH-CBD, PTH antagonist-CBD or vehicle alone.

FIG. **19** is a set of photographs of mice showing hair regrowth in a model of alopecia areata after treatment with a control or with PTH-CBD.

FIG. **20** is a graph showing the endogenous parathyroid hormone levels in ovarectomized aged rats injected with a single dose of human PTH-CBD 6 months prior to sacrifice.

DETAILED DESCRIPTION

Methods of delivering a therapeutic agent by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a therapeutic agent to a subject in need of treatment with the therapeutic agent are provided herein. In this embodiment, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist and is not a bFGF or EGF polypeptide. The bacterial collagen-binding polypeptide segment delivers the therapeutic agent to sites of partially untwisted or under-twisted collagen.

In addition, methods of treating collagenopathies, such as osteogenesis imperfecta (OI), by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject in need of treatment for a collagenopathy are provided. Collagenopathies include but are not limited to osteogenesis imperfecta, Stickler's syndrome, Ehlers-Danlos syndrome, Alport's syndrome, Caffey's disease, and localized collagen or cartilage damage. Many of these diseases are caused by genetic defects that result in the collagen in certain tissues being under twisted or partially untwisted.

For example, individuals with OI carry a mutation which causes an amino acid change in collagen changing a glycine to a bulkier amino acid which results in disruption of the triple helix structure of the collagen and under-twisting of the collagen. In the Examples, we demonstrate that the bacterial collagen-binding polypeptides described herein target and bind to these areas of under-twisted collagen. Thus, use of the collagen-binding polypeptides described herein to deliver a therapeutic agent capable of treating OI to the sites of under-twisted collagen may allow more effective treatment.

The collagen-binding polypeptide segment and the therapeutic agent may be chemically cross-linked to each other or may be polypeptide portions of a fusion protein. The terms "fusion protein" and "fusion polypeptide" may be used to refer to a single polypeptide comprising two functional segments, e.g., a collagen-binding polypeptide segment and a polypeptide based therapeutic agent, such as PTH/PTHrP receptor agonist polypeptide segment. The fusion proteins may be any size, and the single polypeptide of the fusion protein may exist in a multimeric form in its functional state, e.g., by cysteine disulfide connection of two monomers of 55 the single polypeptide. A polypeptide segment may be a synthetic polypeptide or a naturally occurring polypeptide. Such polypeptides may be a portion of a polypeptide or may comprise one or more mutations. The two polypeptide segments of the fusion proteins can be linked directly or indirectly. For instance, the two segments may be linked directly through, e.g., a peptide bond or chemical crosslinking, or indirectly, through, e.g., a linker segment or linker polypeptide. The peptide linker may be any length and may include traditional or non-traditional amino acids. For example, the peptide linker may be 1-100 amino acids long, suitably it is 5, 10, 15, 20, 25 or more amino acids long such that the collagen binding portion of the fusion polypeptide

can mediate collagen binding and the therapeutic agent can have its therapeutic effect. Peptide linkers may include but are not limited to a PKD (polycystic kidney disease) domain from a collagenase or other protein such as in SEQ ID NO: 2, a GST or His-tag, or a Ser or Gly linker.

The collagen-binding polypeptide segment is a polypeptide that binds collagen and may be part of a larger fusion protein, bioactive agent, or pharmaceutical agent. Determination of whether a composition, polypeptide segment, fusion protein, or pharmaceutical or bioactive agent binds 10 collagen can be made as described in U.S. Patent Publication No. 2010/0129341, which is incorporated herein by reference in its entirety. Briefly, it is incubated with collagen in binding buffer, and the mixture is then filtered through a filter that would otherwise allow it to pass through but that 15 blocks the collagen and therefore holds back materials that bind to the collagen. The filtrate is then assayed for the presence of the composition, polypeptide segment, fusion protein, or pharmaceutical or bioactive agent. Suitably, at least 80%, 85%, 90%, 95%, 98% or more suitably at least 20 99% of the collagen-binding composition, polypeptide segment, fusion protein, or pharmaceutical or bioactive agent is retained by the filter in this assay, as compared to when the filtration is performed without collagen.

The collagen-binding polypeptide segment may be a 25 bacterial collagen-binding polypeptide segment. It may be a *Clostridium* collagen-binding polypeptide segment. The collagen-binding polypeptide segment may be a segment of a collagenase, or a bacterial collagenase, or a Clostridium collagenase. Suitably the polypeptide segment is only a 30 portion of the collagenase and the collagen-binding polypeptide segment does not have collagenase activity. The collagen-binding polypeptide may be a bacterial M9B (including those derived from Bacillus spp. and Clostridium spp.) or M9A (including those derived from Vibrio spp.) 35 collagen-binding protein or a collagen-binding peptide derived from such a protein. By "derived from" we mean that the peptide is a fragment of the full-length protein, a peptide that has amino acid changes relative to the wild-type protein or a combination thereof. The key is that the peptide 40 retains the ability to bind collagen. For example, a peptide may be derived from a protein by selecting a region of the protein capable of binding to collagen. Compositions including a bacterial collagenase as a collagen binding peptide are described in US Patent Publication No. 2010/0129341, 45 which is hereby incorporated herein by reference in its entirety.

FIG. 1 shows a sequence alignment of the collagenbinding region of several M9B bacterial collagen-binding proteins included as SEQ ID NOs: 13-34. As can be seen 50 from the sequence alignment, these proteins have a relatively small amount of sequence identity (about 30%), but they all bind to collagen in a similar fashion and are believed to have similar conformation as discussed in the Examples. Thus any of the peptides shown in FIG. 1 or collagen- 55 binding fragments thereof can be used in the compositions and methods described herein. In FIG. 1, the amino acid residues critical for the conformation of the peptide and for the collagen-binding activity are underlined and shown in green and blue respectively. The key amino acid residues for 60 collagen-binding are a tyrosine or phenylalanine at position 970 of ColG, position 977 of the ColH sequence of SEQ ID NO:1 (position 937 in FIG. 1) or a similar position of one of the sequences shown in FIG. 1; a tyrosine at position 994 of ColG, position 1000 of the ColH sequence of SEQ ID NO:1 65 (position 962 in FIG. 1) or a similar position of one of the sequences shown in FIG. 1; a tyrosine, phenylalanine or

8

histidine at position 996 of ColG, position 1002 of the ColH sequence of SEQ ID NO:1 (position 964 in FIG. 1) or a similar position of one of the sequences shown in FIG. 1. Thus a peptide with relatively low sequence identity, sharing the structure and function of the ColG protein may also be used as a collagen binding domain (CBD) herein.

In one embodiment, the collagenase is ColH, SEQ ID NO: 6. The collagen-binding polypeptide segment may be or may include residues 901-1021 of SEQ ID NO:6 (residues 34-158 of SEO ID NO:1), or a fragment of residues 34-158 of SEQ ID NO:1 at least 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 amino acid residues in length. The collagen-binding polypeptide segment is at least 50%, 60%, 70%, 80%, or at least 85%, at least 90%, at least 95%, at least 96%, at least 98%, or at least 99% identical to residues 34-158 of SEQ ID NO: 1. The collagen-binding polypeptide segment may be or may include residues 807-1021 of SEQ ID NO:6 (residues 37-251 of SEQ ID NO:2), or a fragment of residues 807-1021 of SEQ ID NO:6 at least 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 amino acid residues in length. Residues 807-901 comprise the polycystic kidney disease (PKD) domain of the collagen-binding protein. Those of skill in the art will appreciate that other linkers could be used to link the collagen-binding peptide to a therapeutic agent as outlined above. The collagen-binding polypeptide segment may be or may comprise a fragment of residues 901-1021 of SEQ ID NO:6, e.g., a fragment of at least 8, at least 10, at least 20, at least 30 at least 40, or at least 50 consecutive amino acid residues of residues 901-1021 of SEQ ID NO:6. Suitably the collagen-binding polypeptide consists of residues 894-1008, 894-1021, 901-1021, or 901-1008 of SEQ ID NO: 6 or a homolog thereof as shown by the sequence alignment in FIG. 9.

Among other proteins the collagen-binding segment can be derived from are ColG (Matsushita et al., (1999) J. Bacteriol. 181:923-933), a class I collagenase from *Clostridium histolyticum*. ColH is a class II collagenase (Yoshihara et al., (1994) J. Bacteriol. 176: 6489-6496). The collagen-binding polypeptide segment may also be a polypeptide segment from any one of the protein sequences provided in FIG. **1** which aligns collagen-binding peptides from members of *Clostridium* and *Bacillus*. Those of skill in the art will appreciate that other members of this collagenbinding protein family may be useful in the methods described herein.

The therapeutic agents linked to the collagen-binding polypeptide may be any suitable pharmaceutical or other active agent, including but not limited to, osteogenic promoters, antimicrobials, anti-inflammatory agents, polypeptides such as recombinant proteins, cytokines or antibodies, small molecule chemicals or any combination thereof. Suitably the therapeutic agents are capable of promoting bone growth, decreasing inflammation, promoting collagen stability. Suitably, the therapeutic agent is one whose therapeutic effect is in the region of collagen or damaged collagen. The therapeutic agent may include, but is not limited to, bone morphogenic protein (BMP), G-CSF, FGF, BMP-2, BMP-3, FGF-2, FGF-4, anti-sclerostin antibody, growth hormone, IGF-1, VEGF, TGF-B, KGF, FGF-10, TGF-a, TGF-\u03b31, TGF-\u03b3 receptor, CT, GH, GM-CSF, EGF, PDGF, celiprolol, activins and connective tissue growth factors. In alternative embodiments, the active agent may be a PTH/ PTHrP receptor agonist or antagonist.

Bone loss due to a collagenopathy such as osteogenesis imperfecta, Stickler's syndrome or others which put an individual at higher risk for a bone fracture due to a collagen 25

defect could be treated by administration of a bone anabolic peptide. The CBD may target the bone anabolic agents to sites where the collagen is malformed and thus may prevent fracture.

Vascular fragility due to defects such as Ehlers-Danlos 5 syndrome type IV, Alport's syndrome or other diseases where blood vessel rupture is more likely due to a defect in collagen formation may be administered peptides that stimulate vascular growth or repair. The CBD will target the peptide to the areas having collagen damage and these areas 10 are likely to have damaged vessels. The therapeutic agents will stimulate growth and repair at the site of damage and prevent vessel rupture.

Skin fragility due to disorders such as Ehlers-Danlos syndrome, Caffey's disease or other diseases where weak-15 ening of the skin due to a collagen defect leads to hyperelasticity, easy bruising or poor wound healing. Dermal and epidermal growth factors may serve as therapeutic agents which when linked to CBD and delivered to areas of damaged collagen will stimulate growth and repair of the 20 skin, preventin striae and improving healing.

Collagen defects may also lead to cartilage malformation or insufficiency. Cartilage growth factors could be delivered locally to sites of damaged cartilage to aid in repair and restore function.

The PTH/PTHrP receptor agonist polypeptide segment may be a synthetic polypeptide or a naturally occurring polypeptide. Such polypeptides may be a portion of a polypeptide or may comprise one or more mutations. The mutations may make the PTH/PTHrP receptor agonist a 30 better or worse agonist as compared to the wild-type PTH/ PTHrP. Agonist activity with the PTH/PTHrP receptor can be assayed as described in Example 3 below by a cAMP stimulation assay. An agonist will stimulate cAMP synthesis in the assay described. Suitably, an agonist can activate 35 receptor activity at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or even 110% or 120% as much as wild-type PTH(1-34).

The PTH/PTHrP receptor agonist polypeptide segment is a PTH or PTHrP polypeptide segment. One human isoform 40 of PTH is SEQ ID NO:7. One human isoform of PTHrP is SEQ ID NO:8. While the human isoforms are provided, those of skill in the art will appreciate that other non-humanderived isoforms may be used as well. Such non-humanderived isoforms may be able to interact with human PTH/ 45 PTHrP receptor and vice versa. The PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-33 of SEQ ID NO:1 (residues 1-33 of PTH (SEQ ID NO:7)). The PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-34 of PTH (SEQ ID 50 NO:7). In other embodiments, it is a fragment of residues 1-34 of PTH (SEQ ID NO:7). In other embodiments, the PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-84 of PTH (SEQ ID NO:7). In other embodiments, the PTH/PTHrP receptor agonist poly- 55 peptide segment may be or may include residues 1-14 of PTH (SEQ ID NO:7). In still other embodiments, the PTH/PTHrP receptor agonist is a PTH or PTHrP polypeptide segment for any other species.


The PTH/PTHrP receptor antagonist can include in one 60 embodiment PTH(7-34), i.e., residues 7-34 of PTH (SEQ ID NO:7). In another embodiment, it is or includes residues 7-33 of PTH (SEQ ID NO:7). In other embodiments, it is a fragment of residues 7-34 of SEQ ID NO: 8. In another embodiment, the PTH/PTHrP receptor antagonist includes 65 PTH(7-14), i.e., residues 7-14 of PTH (SEQ ID NO:7). In another embodiment, the PTH/PTHrP receptor antagonists

include ((-1)-33) of PTH/PTHrP. In another embodiment, the PTH/PTHrP receptor antagonists include residues 1-14 of PTH with an N-terminal extension. Adding an N-terminal extension to PTH or active N-terminal fragments of PTH converts the PTH peptides to antagonists. The N-terminal extension can be 1, 2, 3, 4, 5, or more amino acids in length. The identity of the amino acids in the N-terminal extension is typically not important. In one embodiment, the PTH/ PTHrP receptor antagonist includes residues 1-33 of PTH with a Gly-Ser extension at the N-terminus (SEO ID NO:11). In another embodiment, the PTH/PTHrP receptor antagonist includes PTHrP(7-34), i.e., residues 7-34 of SEQ ID NO:8, or a fragment of residues 7-34 of SEQ ID NO:8. In another embodiment, the PTH/PTHrP receptor antagonist includes mouse TIP(7-39) (See Hoare S R, Usdin T B. 2002. Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39). Peptides 23:989-98.). Other PTH/PTHrP receptor antagonists that may be used in the fusion proteins are also disclosed in Hoare et al. The PTH/PTHrP receptor antagonist may be a fragment of at least 8, 10, 12 or more amino acids from residues 1-34 of SEQ ID NO:7. In other embodiments the PTH/PTHrP receptor antagonist may be PTH/PTHrP receptor antagonist polypeptide from another species.

In one embodiment, the therapeutic agent or PTH/PTHrP receptor agonist or antagonist polypeptide segment is N terminal to the collagen-binding polypeptide segment in the fusion protein. That is, the two polypeptide segments each have an N-terminal and a C-terminal, and the N-terminal of the collagen-binding polypeptide segment is linked directly or indirectly, e.g., through a linker polypeptide segment (such as PKD, a Glycine or Serine linker) to the C-terminal of the therapeutic agent or PTH/PTHrP agonist or antagonist polypeptide segment.

The fusion proteins described above comprising (a) a collagen-binding polypeptide segment linked to (b) a therapeutic agent or a PTH/PTHrP receptor agonist or antagonist polypeptide segment can be replaced by pharmaceutical agents comprising (a) a collagen-binding polypeptide segment linked to (b) a therapeutic agent or PTH/PTHrP receptor agonist or a non-peptidyl PTH/PTHrP receptor agonist. An example of a non-peptidyl PTH/PTHrP receptor agonist is compound AH3960 (Rickard et al., (2007) Bone 39:1361-1372).

AH3960



AH3960 contains two amino groups. Amino groups in small chemical molecules such as AH3960 can be used to cross-link the therapeutic agent to amino groups on the collagen-binding polypeptide segment through a crosslinker such as DSG (disuccinimidyl glutarate) or through the combination of SANH (succinimidyl-4-hydrazinonicotinate acetone hydrazone) and SFB (succinimidyl-4-formyl benzoate). Therapeutic agents can be cross-linked through their amino group to a carboxyl group of the collagen-binding polypeptide segment by EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) or vice versa. These cross-linking products are available from Pierce (piercenet. com, Thermo Fisher Scientific Inc., Rockford, Ill.). Protocols and reaction conditions are also available in the product 5 literature from Pierce (piercenet.com).

In another embodiment of the pharmaceutical agents comprising (a) a collagen-binding polypeptide segment; linked to (b) a polypeptide therapeutic agent or a PTH/ PTHrP receptor agonist or antagonist polypeptide segment, 10 segment (a) and segment (b) are separate polypeptides, and the two polypeptides are linked by chemical cross-linking. The two polypeptides can be cross-linked through amino groups by reagents including DSG (disuccinimidyl glutarate) or glutaraldehyde. They can also be cross-linked 15 through amino groups by derivatizing one polypeptide with SANH (succinimidyl-4-hydrazinonicotinate acetone hydrazone) and the other with SFB (succinimidyl-4-formyl benzoate), and then mixing the two derivatized polypeptides to cross-link. The two polypeptides can be cross-linked 20 between an amino group of one polypeptide and a carboxyl of the other by reaction with EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride). The polypeptides can also be cross-linked (e.g., covalently coupled) by any other suitable method known to a person of ordinary 25 skill in the art. These cross-linking reagents are available from Pierce (piercenet.com, Thermo Fisher Scientific Inc., Rockford, Ill.). Protocols and reaction conditions are also available in the product literature from Pierce (piercenet-.com). These and other applicable cross-linking methods are 30 described in U.S. published patent applications 2006/ 0258569 and 2007/0224119.

Also provided herein are methods of treating hyperparathyroidism by administering PTH-CBD to a subject in need of treatment for hyperparathyroidism. In one embodiment 35 the PTH administered to the subject may be a PTH from a different species. As shown in the Examples a single administration of CBD-PTH to ovarectomized aged rats was able to reduce the amount of endogenous PTH produced by the animal. Thus, administration of PTH-CBD to individuals 40 suffering from hyperparathyroidism may experience a decrease in symptoms associated with hyperparathyroidism and have decreased levels of PTH after administration of PTH-CBD.

The effects of PTH agonists and antagonists on hair 45 growth have been studied for over almost 15 years. PTH has a common receptor with PTH-related peptide (PTHrP), which is normally produced by dermal fibroblasts. PTHrP affects keratinocyte proliferation/differentiation and modulates the hair cycle. Most of the testing on hair growth effects 50 has been performed with PTH antagonists, as indications from initial testing were that these were the most effective agents. Both injected and topical formulations have been tested in animal models of chemotherapy-induced alopecia and in the SKH-1 hairless mouse. Part of the effect of PTH 55 antagonists on hair growth is to transition the hair follicles into a dystrophic catagen stage, which protects them from chemotherapeutic damage. However, clinical trials of topical PTH antagonists for chemotherapy-induced alopecia by IGI Pharmaceuticals were discontinued in phase 2 because 60 of limited efficacy. Thus new compositions for treating alopecia are needed.

The problems of delivery and retention of PTH to the skin can be overcome by using collagen-targeted PTH analogs. To accomplish this, we synthesized several fusion proteins 65 of different PTH agonists and antagonists linked to a collagen binding domain derived from the ColH1 collagenase of

Clostridium histolyticum. In the studies described in the Examples, we found that the agonist compound PTH-CBD promotes transition of hair follicles to the anagen phase and has potent effects on hair growth. The antagonist compound PTH(7-33)-CBD had little effect on hair growth in chemotherapy models and had a deleterious effect on hair regrowth after depilation. Compounds such as PTH-CBD, which promote anagen phase transition of hair follicles, have been sought after due to their potential to treat a large variety of disorders of hair loss. PTH-CBD appears to have a similar mechanism of action to cyclosporine, which also promotes transition of hair follicles to anagen phase, although the mechanism is less likely to be the result of direct effects on WNT signaling. While clinical use of cyclosporine for this purpose is limited by systemic toxicity, PTH-CBD has not shown toxic effects, even with systemic administration.

Thus in another aspect, methods of increasing hair growth are provided herein. The methods include administering a CBD linked to a PTH/PTHrP receptor agonist to a subject in need of treatment to induce hair growth or stop hair loss. The method is applicable to individuals with alopecia, including chemotherapy induced alopecia, but also alopecia areata, alopecia caused by male pattern baldness, polycystic ovarian syndrome or other hair loss. The compositions may be administered locally or topically to treat hair loss.

In another aspect, methods of slowing hair growth or regrowth after a hair removal procedure by administering a CBD linked to a PTH/PTHrP receptor antagonist to a subject are provided. In one embodiment, the PTH antagonist composition is applied locally, topically. The PTH antagonist may be applied after a hair removal procedure to prevent or slow hair regrowth. As described in the Examples, we have demonstrated that hair regrowth is slowed after waxing in animals treated with CBD-PTH antagonist as compared to control animals treated with PTH-CBD or vehicle alone. The compositions may be administered locally or topically to block hair growth.

The compositions described herein may be administered by any means known to those skilled in the art, including, but not limited to, oral, topical, intranasal, intraperitoneal, parenteral, intravenous, intramuscular, intradermal or subcutaneous. Thus the compositions may be formulated as an ingestable, injectable, topical or suppository formulation. The composition may be formulated for administration by injection to result in systemic administration or local administration. The compositions may also be delivered with in a liposomal or time-release vehicle. The compositions may also be delivered in a site-directed delivery vehicle, such as but not limited to, a targeted liposome or an absorbable collagen sponge carrier or other implant.

The inventors have found that when administering compositions including a CBD subcutaneously it binds locally at the site of injection if the composition is dissolved in neutral pH buffer. But if the composition is dissolved in a low pH buffer, for example a buffer having pH 5.0 or pH 4.5 or below, the collagen-binding domain does not bind collagen, and the composition has time to disperse systemically before it binds collagen elsewhere in the body at neutral pH. Thus systemic administration of the compositions involves administering the composition dissolved in buffer or aqueous solution at a pH lower than about 5.0 or at pH 4.5 or below. In another embodiment, systemic administration of the compositions involves administering the fusion proteins dissolved in aqueous solution at pH lower than about 6.0. Alternatively, if the skin condition is localized, the compositions described herein may be administered in a buffer with

a pH of 6.0, 6.5, 7.0, 7.5 or above in order to allow for localized delivery of the compositions to the affected area of the skin.

Pharmaceutical compositions for topical administration may also be formulated using methods and compositions 5 such as those available to those skilled in the art. For example, gels, creams or liposome preparations may be suitable for topical delivery. These delivery vehicles may be formulated to mediate delivery to the lower layers of the skin or to allow for extended release of the pharmaceutical at the 10 site of application.

The compositions can be administered as a single dose or as divided doses. For example, the composition may be administered two or more times separated by 4 hours, 6 hours, 8 hours, 12 hours, a day, two days, three days, four 15 days, one week, two weeks, or by three or more weeks. Optionally, such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. The composition is expected to be more effective than a comparable or control composition comprising the therapeutic agent or a PTH/PTHrP receptor agonist that is not linked to a collagen-binding protein. In one embodiment, a smaller amount of the composition may be used or the composition may be administered less frequently than a comparable composition comprising the therapeutic agent or 25a PTH/PTHrP receptor agonist which is not linked to a collagen-binding protein.

The dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The individual 30 doses of pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a therapeutic agent may be approximately the same on a molar basis as doses used for the therapeutic agent alone. It is expected that the pharmaceutical agents comprising a collagen-binding poly-35 compositions used, the type of disease being treated, the peptide segment linked to a therapeutic agent may be administered less frequently, because linking the agent to the collagen-binding polypeptide segment gives it much more prolonged activity in vivo.

Administration of the compositions to a subject in accordance with the invention appears to exhibit beneficial effects in a dose-dependent manner. Thus, within broad limits, administration of larger quantities of the compositions is expected to achieve increased beneficial biological effects than administration of a smaller amount. Moreover, efficacy is also contemplated at dosages below the level at which 45 toxicity is seen.

It will be appreciated that the specific dosage administered in any given case will be adjusted in accordance with the compositions being administered, the disease to be treated or inhibited, the condition of the subject, and other 50 relevant medical factors that may modify the activity of the agent or the response of the subject, as is well known by those skilled in the art. For example, the specific dose for a particular subject depends on age, body weight, general state of health, diet, the timing and mode of administration, the 55 rate of excretion, medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given patient can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the compositions of the 60 invention and of the therapeutic agent administered alone, such as by means of an appropriate conventional pharmacological or prophylactic protocol.

The maximal dosage for a subject is the highest dosage that does not cause undesirable or intolerable side effects. The number of variables in regard to an individual prophy-65 lactic or treatment regimen is large, and a considerable range of doses is expected. The route of administration will also

impact the dosage requirements. It is anticipated that dosages of the compositions will reduce symptoms of the condition being treated by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to pretreatment symptoms or symptoms is left untreated. It is specifically contemplated that pharmaceutical preparations and compositions may palliate or alleviate symptoms of the disease without providing a cure, or, in some embodiments, may be used to cure the disease or disorder.

Suitable effective dosage amounts for administering the compositions may be determined by those of skill in the art, but typically range from about 1 microgram to about 10,000 micrograms per kilogram of body weight weekly, although they are typically about 1,000 micrograms or less per kilogram of body weight weekly. In some embodiments, the effective dosage amount ranges from about 10 to about 10,000 micrograms per kilogram of body weight weekly. In another embodiment, the effective dosage amount ranges from about 50 to about 5,000 micrograms per kilogram of body weight weekly. In another embodiment, the effective dosage amount ranges from about 75 to about 1.000 micrograms per kilogram of body weight weekly. The effective dosage amounts described herein refer to total amounts administered, that is, if more than one compound is administered, the effective dosage amounts correspond to the total amount administered.

The effectiveness of the compositions described herein may be enhanced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to a control treated with the therapeutic agent alone. It will be appreciated that the effectiveness of the treatment in any given case will be enhanced variably in accordance with the specific condition of the subject, the specific formulations of the compounds and other relevant medical factors that may modify the activity of the compositions or the responses of the subject as is appreciated by those of skill in the art.

The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention or of the appended claims. All references cited herein are hereby incorporated by reference in their entireties.

EXAMPLES

Example 1

CBD Targets Partially Untwisted or Undertwisted Regions of Collagen

Clostridium histolyticum collagenase causes extensive degradation of collagen in the connective tissue resulting in gas gangrene. The C-terminal collagen-binding domain (CBD) of these enzymes is the minimal segment required to bind to the collagen fibril. CBD binds unidirectionally to the partially untwisted C-terminus of triple helical collagen. Whether CBD could also target under-twisted regions even in the middle of the collagen triple helix was examined. Partially untwisted collageneous peptides were synthesized by introducing a Gly→Ala substitutions into the collagen $([(POG)_xPOA(POG)_y]_3$ where x+y=9 and x>3). ¹H-¹⁵N heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR) titration studies with ¹⁵N-labeled CBD demonstrated that the untwisted mini-collagen binds to a 10 Å wide 25 Å long cleft. Six untwisted collagenous peptides each labeled with a nitroxide radical were then titrated with ¹⁵N-labeled CBD. The paramagnetic nuclear spin relaxation effects showed that CBD binds close to either the Gly \rightarrow Ala substitution site or to the C-terminus of each mini-collagen. Small angle X-ray scattering (SAXS) measurements revealed that CBD prefers to bind the Gly \rightarrow Ala site rather than the C-terminus. The HSQC NMR spectra of ¹⁵N- 5 labeled mini-collagen and untwisted mini-collagen were unaffected by the titration of unlabeled CBD. The results imply that CBD binds to the partially unwound region of the mini-collagen but does not actively unwind the triple helix. Materials and Methods:

¹⁵N-Labeled Protein Production: The sib (Gly893-Lys1008) peptide derived from *Clostridium histolyticum* class I collagenase (ColG) was expressed as a glutathione S-transferase (GST)-fusion protein. The GST-tag was cleaved off by thrombin, and CBD was purified as described previously. Matsushita, et al., (2001) *J Biol Chem* 276, 8761-8770. Uniform ¹⁵N isotope labeling was achieved using Tanaka minimal medium containing 40 mM ¹⁵NH₄Cl. The labeling efficiency was estimated to be 99.6% by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS).

Peptides: (POG)₁₀ (SEQ ID NO: 35) was purchased from Peptide Institute, Inc. (Osaka, Japan). Other peptides were constructed by a standard N-(9-fluorenyl) methoxycarbonyl (Fmoc)-based strategy on Rink-amide resins (Novabiochem, Darmstadt, Germany). N-terminal spin-labeling was per-²⁵ formed on the resin by the treatment with 5 equivalents of 3-carboxy-PROXYL (Aldrich), 1-hydroxybenzotriazole, diisopropylcarbodiimide in N,N-dimethylformamide at room temperature for 2 hours. Peptide cleavage and deprotection steps were performed by a treatment with a 30 standard trifluoroacetic acid (TFA) scavenger cocktail (TFA: m-cresol:thioanisole:water:triisopropylsilane=82.5:5:5:5: 2.5, v/v). The spin-labeling at Cys residues was performed using 3-(2-iodoacetamido)-PROXYL (IPSL, Sigma-Aldrich). Briefly, 10 molar excess of IPSL dissolved in ethanol 35 was added to the same volume of 10 mg/ml peptide in 0.1 M Tris-HCl (pH 8.8), 5 mM ethylenediaminetetraacetic acid. After reacting at room temperature for 1 hr, the reaction was quenched by adding excess dithiothreitol. All peptides were purified by reverse-phase HPLC using a Cosmosil 40 5C18 AR-II column (Nacalai Tesque, Kyoto, Japan) and characterized by MALDI-TOF-MS. All the measured masses agreed with the expected values. The chemical structures of synthesized peptides are shown in FIG. 2.

Circular Dichroism Spectroscopy: The triple helical conformation and the stability of the collagenous peptides were ⁴⁵ verified using CD spectroscopy (See FIGS. **3** and **4**). CD spectra were recorded with a J-820 CD spectropolarimeter (JASCO Co., Hachioji, Japan) equipped with a Peltier thermo controller, using a 0.5-mm quartz cuvette and connected to a data station for signal averaging. All peptide ₅₀ samples were dissolved in water (1 mg/ml), and stored at 4° C. for 24 h. The spectra are reported in terms of ellipticity units per mole of peptide residues $[\theta]_{mrw}$. Thermostability of the triple helix was monitored by the $[\theta]_{225}$ values of each peptide with increasing temperature at the rate of 0.3° C./min.

NMR Spectroscopy: NMR experiments were performed on a Bruker 700 MHz spectrometer equipped with CryoprobeTM. All the NMR titration experiments were carried out at 16±0.5° C. The working temperature is lower than the melting temperatures (T_M) of all the paramagnetic spinlabeled collagenous peptides (Table 1) used. The concentration of the protein was 0.1 mM in 50 mM Tris-HCl (pH 7.5) containing 100 mM NaCl and 20 mM CaCl₂. The dilution effect on the course of titration was minimized by the titration of a highly concentrated (4 mM) peptide stock. ⁶⁵ Aliquots of collagenous peptide were added to the protein and equilibrated for 5 min before acquiring ¹H-¹⁵N HSQC

spectra. The pH of the NMR samples monitored during the titration exhibited no significant shift in the pH (within ± 0.2 units).

TABLE 1

Melting temperatures (T_m) of various mini-collagen peptides
that were used in NMR titration and the experiments described herein.

	Peptides	Tm (° C.)	SEQ ID NO:
0	(POG) ₄ POA(POG) ₅	29	38
	PROXYL-(POG) ₄ POA(POG) ₅	29	38
	PROXYL-(POG)3POA(POG)6	28	39
	PROXYL-(POG)5POA(POG)4	28	37
	PROXYL-(POG)6POA(POG)3	27	36
-	(POG) ₄ POA(POG) ₅ C-PROXYL	30	41
.>	¹¹ PROXYL-(POG) ₃ PCG(POG) ₄	28	40

Dynamic Light Scattering Experiments: The dynamic light scattering (DLS) data were collected using DynaPro-E ₂₀ equipped with a temperature controlled microsampler on the samples of CBD, collagenous peptides and CBD:minicollagen complexes in 10 mM Tris-HCl (pH 7.5) containing 100 mM sodium chloride and 20 mM CaCl₂. The protein samples were spun at 10,000 rpm for 10 min and were filtered through 0.02 µm Whatman syringe directly into a 50-µL quartz cuvette. For each experiment, 20 measurements were made. The mean hydrodynamic radius (R_H) , standard deviation, polydispersity, and percent of peak area were analyzed using Dynamics V6 (Protein Solutions). The hydrodynamic radius and molecular weight estimations were calculated from time dependent fluctuations induced by Brownian motion as described. Proteau, et al. (2010) Curr Protoc Protein Sci Chapter 17, Unit 17 10.

Small Angle X-Ray Solution Scattering Experiments: The small angle X-ray solution scattering (SAXS) data were collected on solutions of CBD, collagenous peptides and CBD-mini-collagen complexes in 10 mM Tris-HCl (pH 7.5), 100 mM NaCl and 20 mM CaCl, at SAXS/WAXS setup located at the 5-ID-D beamline of the DND-CAT synchrotron research center, Advanced Photon Source, Argonne National Laboratory (Argonne, Ill.). The main advantage of X-ray scattering is that it can be carried out in solution in near physiological conditions. Petoukhov et al., (2007) Curr Opin Struct Biol 17, 562-571. 1.2398 Å (10 keV) radiation was selected from the APS Undulator A insertion device using a Si-111 monochromator, with 1:1 horizontal focusing and higher harmonic rejection from a Rh coated mirror, and beam defining slits set at 0.3 mm vertical by 0.25 mm horizontal. A 1.6 mm diameter capillary flowcell with a flow rate of 4 µl/sec was used to collect four frames with 10 second exposure time. The SAXS detector used was a Mar165 scintillator fiber-optic coupled CCD detector and covered the momentum transfer range 0.005 < q < 0.198 Å⁻¹, where q=4 $\pi \sin \theta/\lambda$ (2 θ is the scattering angle). The WAXS detector was a custom Roper scintillator fiber-optic coupled CCD detector and covered 0.191<q<1.8 Å⁻¹ S. Weigand, et al. (2009) Advances in X-ray Analysis 52, 58-68.

All scattering data were acquired at sample temperature of 10° C. The four scattering patterns from each detector were averaged and merged with the rejection of outlying scans. For further analysis the program IGOR Pro 5.5 A (WaveMetrics) was used. The scattering profiles of the protein, peptide and their complexes were obtained after subtracting the buffer profiles. The reduced scattering data were plotted as scattering intensity I(Q) vs. Q (FIG. 4A). The radius of gyration, R_g , was obtained from the Guinier approximation by linear least squares fitting in the QR_g<1 region, where the forward scattering intensity I(0) is proportional to the

molecular weight of the protein complex. An indirect Fourier transformation of I(Q) data using GNOM provided the particle distribution function P(r) in the real space (FIG. 4B). Svergun, D. (1992) J Appl Crystallogr 25, 495-503. Where P(r) intersects with x-axis represents the maximum diameter D_{max} averaged in all orientations. The molecular envelopes were constructed for all the samples based on the SAXS data after ab initio calculation with the program GASBOR. Svergun, et al. (2001) Biophys J 80, 2946-2953. Simulated annealing minimization of randomly distributed dummy atoms converged to the protein structure after being tested for the best fit to the I(Q) scattering data. No symmetry restraints were applied to any of the shape reconstructions. For each of the complexes, ten ab initio models were calculated with GASBOR and averaged using DAMAVER. Svergun, D. (2003) J Appl Crystallog 36. The atomic models represented as a compact interconnected configuration of beads with diameter D_{max} were adjusted to fit the experimental data $I_{exp}(s)$ to minimize error. Atomic models were docked into ab initio envelopes with the program SUB-COMB. Kozin, M. B., and Svergun, D. (2000) J Appl 20 Crystallogr 33, 775-777.

Docking Model: The CBD-collagenous peptide complex is generated from Protein Data Bank entries of ColG s3b (1NQD) and partially untwisted collagenous peptide 1CAG (Ala mutation in 15^{th} position). Other untwisted mini collagen molecules were generated by modifying 1CAG using fragments derived from [(POG)₁₀]₃ structure (1K6F). To obtain the complex, the soft docking algorithm BiGGER was used. Palma, et al. (2000) *Proteins* 39, 372-384. Solutions were filtered using NMR titration data and the highest scoring model that satisfied NMR and SAXS results was chosen. The manual adjustments were aided by the use of MIFit. McRee. (1999) *J Struct Biol* 125, 156-165. Results and Discussion:

¹H-¹⁵N HSQC NMR Titration-CBD Targeting the Under-Twisted Sites in Collagen: The untwisted collagenous pep-³⁵ tide [(POG)₆POA(POG)₃]₃ (SEQ ID NO: 36) that has Ala in the 21st position from the N-terminus was synthesized. This peptide was further modified to accommodate a paramagnetic spin label at the N-terminus. ¹H-¹⁵N HSQC NMR titrations were performed with [PROXYL-(POG)₆POA 40 (POG)₃]₃ (SEQ ID NO: 36) and ¹⁵N-labeled CBD at ratios ranging from 0.02:1 to 1.5:1. As demonstrated earlier, a total of eleven residues on the collagen binding interface (S928, W956, G971, K995, Y996, L924, T957, Q972, D974, L991 and V993) either disappeared from the HSQC spectrum or $_{45}$ exhibited significant chemical shift perturbation from their original position on the course of titration. Philominathan, et al. (2009) J Biol Chem 284, 10868-10876. The PROXYL group on the N-terminus of the collagenous peptides can cause a distance-dependent line broadening of the NMR

signals of CBD during the course of titration. In addition to the eleven residues, three more residues, V973, G975 and S979 exhibited appreciable line broadening and these residues eventually disappeared from the $^{1}H^{-15}N$ HSQC spectrum of CBD (FIGS. 5A and 5B). When the [PROXYL-(POG)₆POA(POG)₃]₃ (SEQ ID NO: 36):CBD complex was reduced with ascorbic acid those three residues reappeared in the ¹H..¹⁵N HSQC spectrum. The disappearance of these three residues was consistent with the titration of [PROXYL-G(POG)₇]₃ (SEQ ID NO: 42) (C-terminus is at 22^{nd} position from the N-terminal PROXYL) in our earlier publication. The comparison of the two titration results demonstrates that CBD is targeting the Gly \rightarrow Ala substituted site. If CBD had only bound to the C-terminus of [PROXYL-(POG)₆POA(POG)₃]₃ (SEQ ID NO: 36) (C-terminus is at 30^{th} position from the N-terminal PROXYL), we would expect to observe the disappearance of only one residue (V973) at the most, as in the published titration of [PROXYL-G(POG)₇(PRG)]₃ (SEQ ID NO: 43). The disappearance of the residues (V973, G975 and S979) located at distal side from the Ca^{2+} binding site (FIG. 5C) confirmed that CBD binds unidirectionally to untwisted collagen as well. The collagen binding surface in CBD is a 10-Å-wide and 25-Å-long cleft. The width of the binding cleft in CBD matches the diameter of the triple helix and its length could accommodate [(POG)₃]₃ (SEQ ID NO: 44). NMR results imply that CBD is binding to the under-twisted [(POG)₂ POA]₃ (SEQ ID NO: 45) region of the collagen.

As paramagnetic relaxation enhancement is a distance dependent phenomenon, Gly-Ala substitution made at closer to the N-terminal PROXYL group should result in the disappearance of more residues on CBD. PROXYL containing collagenous peptides, [PROXYL-(POG)₅POA(POG)₄]₃ (SEQ ID NO: 37) (Ala at 18^{th} position from the N-terminal PROXYL), [PROXYL-(POG)₄POA(POG)₅]₃ (SEQ ID NO: 38) (Ala at the 15^{th} position from the PROXYL) and [PROXYL-(POG)₃POA(POG)₆]₃ (SEQ ID NO: 39) (Ala at the 12th position from the PROXYL) were synthesized. Just as in the previous titrations, the line broadening effects on the residues of CBD were analyzed from the changes in the ¹H-¹⁵N HSQC spectrum. The shorter the distance between Gly→Ala substitution site and the N-terminal PROXYL, more residues in CBD disappeared (FIG. 6 and Table 2). The magnitude of intensity drop for four amide resonances (Q972, G975, S979 and L924) of four different minicollagen molecules was also the function of the distance (FIG. 7). The NMR results are consistent with CBD binding to the [(POG)₂POA]₃ (SEQ ID NO: 45) region in each of the four under-twisted mini-collagen. The binding constants obtained from all the NMR titrations were <100 µM indicating a moderate binding affinity between CBD and undertwisted mini-collagen.

TABLE 2

Residues that disappear due to the presence of PROXYL either at the Nterminus, C- terminus or in the middle of the collagenous peptide sequence Alanine Residues disappeared due to PROXYL Peptides position No. Blank [(POG)10]3 (SEQ ID NO: 35) 1 PROXYL at N-terminus [PROXYL-(POG)6POA(POG)3]3 21 V973, G975, 5979 2 (SEQ ID NO: 36)

TABLE 2-continued

20

Residues that disappear due to the presence of PROXYL either at the Nterminus, C- terminus or in the middle of the collagenous peptide sequence

No.	Peptides		Residues disappeared due to PROXYL									
3	[PROXYL-(POG)5POA(POG)4]3 (SEQ ID NO: 37)	18	Q972, V973, G975, 5979									
4	[PROXYL-(POG)4POA(POG)5]3 (SEQ ID NO: 38)	15	L946, Q972, V973, G975, S979									
5	[PROXYL-(POG)3POA(POG)6]3 (SEQ ID NO: 39)	12	L946, G953, Q972, V973, D974, G975, N976, V978, S979									
	PROXYL at C-terminus	_										
6	[(POG)4POA(POG)5-PROXYL]3 (SEQ ID NO: 41)	15	S906, R929, S997, G998									
	PROXYL in the middle											
7	[11PROXYL-(POG)3PCG(POG)4]3 (SEQ ID NO: 40)		V973, G975, 5979 and 5906, R929, S997, G998									

The helical conformation in both the [(POG)₂POA]₃²⁵ helical confirmation of both the (POG)₂POA (SEQ ID NO: (SEQ ID NO: 45) and the C-terminal [(POG)₃]₃ (SEQ ID NO: 44) are similarly under-wound. The degree of rotation about the screw axis symmetry that describes the internal triple helical twist is defined as the helical twist value κ . The κ -value oscillates around an average value of -103° for [(POG)₁₀]₃ (SEQ ID NO: 35). Bella (2010) J Struct Biol 170, 377-391. The C-terminus of a mini-collagen is undertwisted (κ value shifts from -103° to -110°) but the N-terminus is usually over-twisted. Collagen peptides with 35 Gly→Ala substitution in the center of the peptide sequence still form triple helices, but with an abrupt under-twisting (κ value shifts from -103° to -115°) at the substitution site followed over-twisting to the norm. Because the $[(POG)_{2}]_{40}$ POA]₃ (SEQ ID NO: 45) region is somewhat more undertwisted than C-terminal [(POG)₃]₃ (SEQ ID NO: 44), the former could be preferentially targeted by CBD than the latter. However, CBD could still bind to the C-terminus.

CBD Also Targets the C-Terminus of the Under-Twisted 45 Mini-Collagen: To demonstrate that CBD binds to the C-terminal (POG)₃ (SEQ ID NO: 44) as well, a collagenous peptide [(POG)₄POA(POG)₅-PROXYL]₃ (SEQ ID NO: 38) was synthesized. [(POG)₄POA(POG)₅C-PROXYL]₃ (SEQ ID NO: 41) was titrated with ¹⁵N-labeled CBD at ratios 50 0.02:1 to 1.5:1 with increments of 0.02, and the changes in the HSQC spectrum of CBD were monitored. When the mini-collagen was bound to the cleft, a total of eleven residues on the collagen binding interface either line broadened or showed significant chemical shift perturbation as 55 described earlier. Philominathan, et al. (2009) J Biol Chem 284, 10868-10876. Four additional residues S906, R929, S997 and G998 disappeared from the HSQC spectrum due to PROXYL (FIGS. 6 A, B and D). These peaks reappeared upon addition of ascorbic acid. This phenomenon is identical 60 to our previous titration of [GPRG(POG)₇C-PROXYL]₃ (SEQ ID NO: 46) when CBD bound the C-terminus. If CBD were to bind only to the partially unwound Ala site, we would have observed the disappearance of fewer residues. Thus in addition to targeting the (POG)₂POA (SEQ ID NO: 65 45) region of the collagenous peptide, CBD also binds to the C-terminal (POA)₃ (SEQ ID NO: 44). As described, the

45) region and the C-terminal (POG) $_3$ (SEQ ID NO: 44) are similarly under-twisted compared to the norm. Bella. (2010) J Struct Biol 170, 377-391. Our current explanation for why CBD is targeting the under-twisted regions is that the partial unwinding positions main-chain carbonyl groups to favor hydrogen-bonding interactions with the hydroxyl group of Tyr994. Tyr994 mutation to Phe resulted in 12-fold reduction in binding to mini-collagen, and the mutation to Ala lost binding capability. Wilson, et al. (2003) EMBO J 22, 1743-1752.

To demonstrate CBD's ability to target both the (POG), POA (SEQ ID NO: 45) region and the C-terminal (POG)₃ (SEQ ID NO: 44) region, a collagenous peptide [11PROXYL-(POG)₃PCG(POG)₄]₃ (SEQ ID NO: 40) modified to accommodate PROXYL group in the middle (11th position) was synthesized. PROXYL group is covalently joined to the cysteine residue. Due to the presence of the bulky PROXYL group, this peptide is expected to be partially untwisted. The precise degree of under-twisting is not known for the peptide, but mini-collagen with GPX repeats exhibits a moderate under-twisting (κ =-105°). Bella. (2010) J Struct Biol 170, 377-391. The bulky PROXYL group will likely induce greater untwisting than κ =-105°. In addition to the eleven amide resonances either line-broaden or shifted, 1H-15N HSQC NMR titrations revealed two distinct phenomena. At lower ratio (0.2:1) amide resonances corresponding to S906, R929, S997, and G998 disappeared from the HSQC spectrum of CBD (FIGS. **8**E, F and H). Then at higher ratio (0.3:1), additional amide resonances corresponding to V973, G975 and S979 disappeared from the HSQC spectrum of CBD (FIGS. 8E, F and H). In order to cause the disappearance of four residues (S906, R929, S997 and G998), CBD must initially bind to the N-terminal (POG)₃ (SEQ ID NO: 44). The disappearance of resonances V973, G975 and S979 can be explained if CBD binds to the C-terminal (POG)₃ (SEQ ID NO: 44) of the mini-collagen. However the initial phenomenon signifies that CBD binds preferentially to the under-twisted midsection to C-terminus.

To demonstrate that PROXYL caused the line broadening and Ala or Cys residues did not, three more control peptides, $[(POG)_4POA(POG)_5]_3$ (SEQ ID NO: 38), $[(POG)_4POA$ $(POG)_5C$ -carbamidomethyl]_3 (SEQ ID NO: 41), and $[(POG)_3PCG(POG)_4]_3$ (SEQ ID NO: 40) that lack the 5 PROXYL groups were synthesized, and NMR titrations were repeated (FIGS. 6F, 8C and 8G, respectively). The titration results were nearly identical with those of $[(POG)_{10}]_3$ (SEQ ID NO: 35). Only the eleven amide resonances were either line broadened or shifted even at 1:1 10 (mini-collagen:CBD) ratio. These control peptides bound to the same cleft, and PROXYL caused the additional residues to line broaden.

To illustrate if CBD binds only to the partially untwisted site in the middle of the collagen peptide and/or to the 15 C-terminus of mini-collagen, dynamic light scattering experiments (DLS) were performed. DLS experiments provided the stoichiometries of collagen:CBD complexes. The hydrodynamic radius of $[(POG)_4POA(POG)_5-PROXYL]_3$ (SEQ ID NO: 38):CBD and $[11PROXYL-(POG)_3PCG 20$ $(POG)_4]_3$ (SEQ ID NO: 40):CBD was 3 nm and the apparent molecular weight of the complex was 42 ± 1 kDa, which is similar to those observed for $[(POG)_{10}]_3$ (SEQ ID NO: 35):CBD complex (Table 3). Other complexes also exhibited similar values. Thus far, all the mini-collagen and CBD 25 always formed 1:1 complex. CBD binds to either one of the available sites in mini-collagen but does not occupy both sites to form a 1:2 complex.

Small Angle X-Ray Scattering Experiments (SAXS): The three dimensional molecular shapes of the CBD-collagenous peptide complexes were constructed using SAXS measurements. The main advantage of SAXS measurements is that the experiments are performed in solution under near physiological conditions. In our previous work, these three dimensional molecular envelopes were used to demonstrate asymmetric binding of CBD to the C-terminal (POG)₃ (SEQ ID NO: 44) of mini-collagen. The molecular shapes were constructed for complexes of CBD and six different untwisted mini-collagen molecules. In all cases CBD bound to (POG)₂POA (SEQ ID NO: 45) region preferentially to C-terminal (POG)₃ (SEQ ID NO: 44) (FIGS. 9A-F). For example the docking model for CBD:[(POG)₄POA(POG)₅]₃ (SEQ ID NO: 38) constructed using the crystal structure of CBD (pdb accession code 1NQD) interacting with (POG), POA (SEQ ID NO: 45) region of the untwisted collagen (pdb accession code 1CAG) fit the envelope well (FIG. 9B). Although NMR results demonstrated that CBD also binds to the C-terminal (POG)₂ (SEO ID NO: 44) of [(POG)₄POA (POG)₅-PROXYL]₃ (SEQ ID NO: 38), CBD predominantly binds to the (POG)₂POA (SEQ ID NO: 45) region of the peptide (FIGS. 9E and 9F).

Structures derived from SAXS profiles using simulated annealing calculations for [11PROXYL-(POG)₃PCG (POG)₄]₃ (SEQ ID NO: 40) (FIGS. 9G and 9H) indicated an additional density that could be attributed to the PROXYL group. The SAXS derived three-dimensional shape of

TABLE 3

Hydrodynamic radius (RH), apparent molecular weight (Mw), Radius of gyration

(Rg) and Maximum particle diameter (Dmax) computed from Dynamic light scattering (DLS) and small angle X-ray scattering (SAXS) for various CBD:collagenous peptides

complexes.

			ic Light ing (DLS)	Small Angl	e X-ray
		Hydro-	Apparent	Scattering	(SAXS)
No	Complexes	dynamic Radius (RH)	Molecular Weight (Mw)	Radius of Gyration (Rg)	Max Diameter (Dmax)
1	CBD:[(POG)10]3 (SEQ ID NO: 35)	3	43	22.62 ± 0.04	93
2	CBD:[PROXYL-(POG)6POA(POG)3]3 (SEQ ID NO: 36)	3	44	24.67 ± 0.09	87
3	CBD:[PROXYL-(POG)5POA(POG)4]3 (SEQ ID NO: 37)	3	42	21.08 ± 0.02	90
4	CBD:[PROXYL-(POG)4POA(POG)5]3 (SEQ ID NO: 38)	3	43	25.48 ± 0.08	92
	CBD:[(POG)4POA(POG)5]3 (SEQ ID NO: 38)	3	43	124.45 ± 0.14	85
5	CBD:[PROXYL-(POG)3POA(POG)6]3 (SEQ ID NO: 39)	3	42	21.97 ± 0.14	94
6	CBD:[(POG)4POA(POG)5C-PROXYL]3 (SEQ ID NO: 41)	3	44	24.09 ± 0.16	85
	CBD:[(POG)4POA(POG)5]3 (SEQ ID NO: 38)	3	42	24.67 ± 0.1	84
7	CBD:[11PROXYL-(POG)3PCG(POG)4]3 (SEQ ID NO: 40)	3	42		96
	CBD:[(POG)3PCG(POG)4]3 (SEQ ID NO: 40)	3	43	23.59 ± 0.05	90

[11PROXYL-(POG)₃PCG(POG)₄]₃ (SEQ ID NO: 40):CBD complex superimposes well with either NMR derived complexes i.e., CBD binding to the N-terminal (POG)₃ (SEQ ID NO: 44) or to the C-terminal (POG)₃ (SEQ ID NO: 44) (FIGS. **9**G and **9**H).

Little Structural Change of ¹⁵N-Minicollagen Upon CBD Binding: The studies thus far suggest that CBD scans the collagen fibril for under-twisted regions. Upon binding to the less structured regions, does it actively unwind collagen? Active unwinding by CBD would facilitate collagenolysis.¹⁰ To investigate two collagenous peptides selectively labeled with ¹⁵N near N- or near C-terminus of [(POG)₁₀]₃ (SEQ ID NO: 35) were synthesized (Table 4, peptides A, B), and the structural changes due to the binding of unlabeled CBD 15 were monitored using ¹H-¹⁵N HSQC titration.¹⁰

TABLE 4

¹⁵ N-	Labeled Mini-collagen	SEQ ID NO:
A	POGPOG*POGPOGPOGPOGPOGPOGPOG	35
в	POGPOGPOGPOGPOGPOGPOGPOGPOG*POG	35
С	POGPOG*POGPOGPO <u>A</u> POGPOGPOGPOGPOG	38
D	POGPOGPOGPOGPO <u>A</u> POGPOGPOGPOG*POG	38

*indicates the $^{15}\mathrm{N}\text{-}\mathrm{labeled}$ Glycine; <u>A</u> indicates Gly \rightarrow Ala substitution.

The ¹⁵N-Gly labeled peptides exhibited two distinct cross peaks in the ¹H-¹⁵N HSQC spectrum (FIGS. **10**A and **10**B). Those cross peaks corresponded to unwound monomer and triple helical conformations assigned in earlier NMR studies. Liu, et al. (1996) Biochemistry 35, 4306-4313 and Li, et al. (1993) Biochemistry 32, 7377-7387. The Gly residue 35 closer to the terminal triplets exhibits both monomer and trimer peaks in the HSQC spectrum, whereas the Gly residue in the middle of the triple helix exhibits a strong trimer cross peak. If CBD is to bend or to cause any unwinding of the triple helix upon binding, we expected the cross peak $_{40}$ corresponding to the triple helix to line broaden and disappear on the course of titration, and the cross peak corresponding to the single chain to intensify. However during the course of the titration, CBD did not instigate any changes on the ${}^{1}\text{H}{}^{-15}\text{N}$ HSQC spectra of the collagenous peptides. Thus ${}_{45}$ CBD bound to C-terminal (POG)₃ (SEQ ID NO: 35) imposed little structural changes to the triple helix.

Untwisted mini-collagen molecule selectively labeled with ¹⁵N-Gly either at near the N- or C-termini (Table 4C and D) was titrated with unlabeled CBD. Cross peaks ⁵⁰ corresponding to monomer and triple-helix were identified on the HSQC spectra (FIGS. **10**C and **10**D). The titration of unlabeled CBD induced little change in the intensity of either monomer or trimer cross peak. Even upon binding to the partially unwound mini-collagen, CBD does not initiate ⁵⁵ any further unwinding.

CBD unidirectionally binds to the under-twisted site in the triple helical collagen. CBD may help disband the collagen fibril, but does not unwind the triple helix. Targeting under-twisted regions of tropocollagen may circumvent ⁶⁰ the energy barrier required for unwinding the triple helices. When CBD is used as a drug delivery molecule, the injected molecule distributes prominently to the end plates of vertebral discs, near the growth plates of tibia and fibula, and also to skin. It could be unloading its payload to the most blood ⁶⁵ accessible collagen that is undergoing remodeling, thus rich in under-twisted regions.

Example 2

Structural Comparison of ColH and ColG Collagen-Binding Domains

The C-terminal collagen-binding domain (CBD) of collagenase is required for insoluble collagen fibril binding and for subsequent collagenolysis. The high resolution crystal structures of ColG-CBD (s3b) and ColH-CBD (s3) the molecules resemble one another closely (r.m.s.d. $C_{\alpha}=1.5$ Å), despite sharing only 30% sequence identity. Five out of six residues chelating Ca²⁺ are conserved. The dual Ca²⁺ binding sites in s3 are completed by a functionally equivalent aspartate. The three most critical residues for collagen interaction in s3b are conserved in s3. The general shape of the binding pocket is retained by altered loop structures and side-chain positions. Small angle X-ray scattering data revealed that s3 also binds asymmetrically to mini-collagen. 20 Besides the calcium-binding sites and the collagen-binding pocket, architecturally important hydrophobic residues and hydrogen-bonding network around the cis-peptide bond are well-conserved in metallopeptidase subfamily M9B.

Common structural features described above and in Bauer
²⁵ et al. (2012) J Bacteriol November 9 (which is incorporated herein by reference in its entirety), enabled us to update the sequence alignment of the CBD in the M9B subfamily (FIG. 1). Conserved residues are important for one of four reasons: calcium chelation (red), cis-trans isomerization of the linker
³⁰ (yellow), collagen-binding (blue) or protein folding (green). FIG. 1 also indicates the strands of the structure along the top of the figure.

The dual calcium-binding site is formed by four chelating residues (Glu899, Glu901, Asn903, and Asp904) within the N-terminal linker, two chelating residues (Asp927 and Asp930) from the β -strand C and invariant Tyr1002 hydrogen-bonds and orients Asp930. Residue numbers used in this paragraph are of s3b. Likewise other supporting cast such as Glv921 is conserved in the middle of β -strand strategically placed to make room for Glu899. The dual calcium chelation site is fashioned sometimes by functionally equivalent residues. As mentioned, Asp897 of s3 acts equivalently to Asp927 of s3b. Asp897 equivalents are tentatively identified in B. brevis s3a and s3b, C. botulinum A3 s3a and C. histolyticum ColG s3a. Tridentate and divalent Asp and Glu residues are conserved with only C. sordellii s3a as the exception. The monodentate Asp904 residue is sometimes substituted by Asn. For those substituted, the net charge of the dual calcium site is neutral rather than -1.

The peptide between residues 901-902 has cis conformation in the holo state for both s3b and s3. The position 902 in other CBD molecules is Pro, Asp or Asn. Pro frequently succeeds the peptide bond to ease trans-cis isomerization. The s3 molecule has Pro. In s3b, OD of Asn902 hydrogenbonds with the main-chain N of Asp904. The hydrogen-bond is critical for the peptide isomerization. Spiriti and van der Vaart. (2010) Biochemistry 49:5314-5320, which is incorporated herein by reference in its entirety. For the remainder of CBD molecules with Asp at the position, OD of Asp could play the same role as that of Asn902. Other hydrogen-bonds identified by simulation studies important in stabilizing the transition states are well conserved. These donor-acceptor pairs in s3 and s3b are tabulated (Table 5). Calcium ions could catalyze the isomerization in all the CBD molecules and their transition states and catalytic mechanism may look very similar.

	TABLE	5
--	-------	---

2 6 1	trans-cis peptide isomerization counterparts in s3.
Important H-bonds in s3b for transition state formation	Corresponding H-bonds in s3
T910_OG1 N903_NH2 T910_OG1 N900_N E899_OE1 N903_ND2 E899_OE2 S922_N N902_OD1 D904_N D930_OD2 Y1002_OH Y1002_OH Y932_OH	S879_OG1 N872_ND2 S879_OG1 K86_N E868_OE1 N872_ND2 E868_OE2 T891_N NA (N902 replaced with P871) D939_OD2 Y97_OH NA (Y932 replaced with F901)

Non-functional residues that are important in either fold-15 ing or architectural stability are conserved. Hydrophobic residues packed between the β -sheets are better conserved if they are located in the vicinity of functionally critical residues. For example, invariant Trp956 of strand E is packed between the β -sheets. The residues flanking (Thr955 20 & Thr957) interact with mini-collagen. Tyr932 is packed between the sheets and helps positioning Tyr1002. Residues at tight turns are conserved as well. Gly975 is well conserved to allow a type II' turn in s3b. Gly942 (Gly975 equivalent) in s3 allows Asp941 side-chain to stabilize the 25 in the presence of physiological Ca²⁺. Thus, the enzyme reverse turn. A highly conserved six-residue stretch, between residues 986 and 991, adopts a tight turn and precedes the functionally important strand H. The region is well ordered in the crystal structures with low B-factors, and is the least dynamic based on NMR and limited proteolysis MALDI- 30 TOF MS (25). Philominathan, et al. (2009) J Biol Chem 284:10868-10876 and Sides et al. J Am Soc Mass Spectrom. (2012) 23(3):505-19 both of which are incorporated herein by reference in their entireties. The main-chain carbonyl and amino groups of Arg985 hydrogen-bond with OH of Tyr989 35 to stabilize the turn. Only Gly987 can make room for the bulky Tyr989 side chain. Tyr990 packs against the invariant Ala909 and conserved 3_{10} helix. Ala909 is at the base of the linker that undergoes α -helix- $\rightarrow\beta$ -strand transformation. The tight turn may ensure that collagen interacting Leu992, 40 Tyr994, and Tyr996 would be correctly positioned. Tyr994 is the most critical residue in interacting with collagenous peptides. Wilson, et al. (2003) EMBO J 22:1743-1752. The strands adjacent to strand H, i.e. strands C and E, are very well conserved. The three antiparallel strands mold the 45 collagen-binding pocket. Strand F staples the β -sheets by interacting with both sheets. The β -strand first interacts in an antiparallel orientation with strand E then breaks its direction at Gly971 to interact with strand G. In place of Gly971, Ala or Pro is found at the location where the strand switches 50 its allegiance. The dual interaction of the strand helps positioning Tyr970 to interact with mini-collagen.

Three residues shown to interact strongly with minicollagen are conserved. The invariant Tyr994 and well conserved Tyr970 and Tyr996 constitute the "hot spot". 55 Y994A mutation lost binding capability. Since Y994F resulted in 12-fold reduction in binding to mini-collagen, the hydroxyl group of Tyr994 may interact with collagen through a hydrogen-bond. Tyr996, which is a critical residue in binding mini-collagen, is not so well conserved. Y996A 60 caused 40-fold reduction in binding to the mini-collagen. Y996 is s3b is replaced with Phe in s3, though both side chains have identical orientation. In other CBD molecules, an aromatic residue, such as Phe or His, is sometimes found at the site. Y970A results in 12-fold reduction in binding to 65 mini-collagen. Thr957 was found to interact with minicollagen by $^{15}\mbox{N-HSQC-NMR}$ titration. The $\beta\mbox{-branched}$

amino acid residues or Leu are found at the positions equivalent to Thr957 in most of the CBDs. Six other residues were identified by ¹⁵N-HSQC-NMR titration to interact with mini-collagen are not very well conserved. Since divergent CBDs (s3 and s3b) adopted a similar saddle-shaped binding pocket, other CBDs may also adopt similar collagen-binding strategy.

Divergent CBD could target different collagen sequences and could possibly target different collagen types; however, 10 this structural study suggest otherwise. Rather, all the CBD domains may bind similarly to an under-twisted region such as the C-terminus of a collagen fibril. The C-terminus of type I collagen is exposed in the fibril surface based on X-ray fiber diffraction experiments, and it is the most accessible site for the bacterial collagenase to initiate assaults. However CBD binding only at the C-terminal region of tropocollagen is unfounded. Gold particle-labeled tandem ColG-CBD (s3a-s3b) labeled with gold particle bound to type I collagen fibrils exhibited no periodicity. In the collagen fibrils, the molecules are staggered from each other by about 67 nm. Therefore CBD could target partially under-twisted regions in the middle of a tropocollagen that are also vulnerable for assaults.

Much like s3b, s3 is both compact, and extremely stable could degrade extracellular matrix for prolonged time. The linker that induced structural transformation is a common feature found in M9B collagenase. It could act as Ca²⁺ sensor to trigger domain rearrangement as means of enzyme activation. Ca²⁺ concentration in extracellular matrix is higher than that inside a bacterium. Both s3 and s3b bind similarly to a mini-collagen, thus M9B collagenase molecules could initiate collagenolysis from analogous structural features in various collagen fibril. Fusion protein of any CBD derived from M9B collagenase and a growth factor should result in comparable clinical outcome.

Example 3

CBD-PTH Agonist Spurs Hair Growth and CBD-PTH Antagonist Inhibits Hair Growth

In-Vitro Characterization of CBD-Linked PTH Compounds: Collagen binding of each peptide was verified in flow-through collagen binding assays as previously described in U.S. Patent Publication No. 2010/0129341, which is incorporated herein by reference in its entirety. PTH-CBD, consisting of the first 33 amino acids of PTH linked directly to the collagen binding domain (SEQ ID NO: 1), was the most potent agonist, having a similar effect to that of PTH(1-34) (SEQ ID NO: 7) on cAMP accumulation. Ponnapakkam et al. (2011) Calcif 88:511-520. Epub 2011 April 2022. Among the antagonists, PTH(7-33)-CBD (SEQ ID NO: 10) had the best combination of low intrinsic activity and high receptor blockade (not shown), similar to those seen in other PTH antagonists, including those used in hair growth studies. Peters, et al. (2001) J Invest Dermatol 117:173-178.

In-Vivo Distribution of PTH-CBD: Tissue distribution was assessed by administering ³⁵S-labelled PTH-CBD via subcutaneous injection, followed by whole mount frozen and whole-body autoradiography. PTH-CBD with a phosphorylation site between PTH(1-33) and the CBD was purified, activated and labeled with [gamma-35] ATP as described previously. Tamai et al. (2003) Infect Immun. 71:5371-5375. Approximately 10.8 mcg of ³⁵S-PTH-CBD (122 kcm/mcg) was injected subcutaneously in 7 week-old

mice (32-35 g). Mice were sacrificed at 1 hour or 12 hours post-injection, and then frozen in dry ice-acetone. Frozen sections ($50 \mu m$) were prepared with an autocryotome, dried at -20° C., and exposed to an image plate for 4 weeks. There appeared to be an initial distribution of ³⁵S-PTH-CBD to a broad area of skin around the site of injection, followed by a rapid redistribution to the skin of the entire animal, as well as to several other tissues (i.e. bone, intestine, bladder) (FIG. **11**). PTH-CBD thus showed the desired properties of distribution and retention to skin with subcutaneous administration.

PTH-CBD Reverses Hair Loss in Chemotherapy-Induced Alopecia in Mice:

We compared efficacy of CBD linked PTH agonists and antagonists in chemotherapy-induced alopecia, utilizing an experimental design published by Peters, et al., for non-CBD linked PTH compounds. Peters, et al. (2001) J Invest Dermatol 117:173-178. C57BL/6J mice (Jackson Laboratories, Bar Harbor, Me.) were depilated to synchronize the hair 20 follicles, and cyclophosphamide (CYP, 150 mg/kg) was administered on day 9 to maximize the chemotherapyinduced damage. The agonist (PTH-CBD) and the antagonist (PTH(7-33)-CBD) were administered 2 days prior to chemotherapy, and given the long-term retention of the 25 compounds in the skin, we administered only a single dose to cover the timing of the multiple injections of PTH agonist and antagonist in the study by Peters, et. al. The administered dose of CBD-linked compounds (320 mcg/kg) is well tolerated in mice. Ponnapakkam et al. (2011) Calcif 88:511- 30 520. Epub 2011 April 2022.

The results of the photodocumentation record indicate that the agonist, PTH-CBD, was far more effective at stimulating hair growth than was the antagonist (FIG. 12). Histological examination revealed morphological changes 35 in the hair follicles after CYP therapy, which were more superficially located and exhibited clumped melanocytes around the bulb, characteristics of the dystrophic anagen and catagen phase (FIG. 13). While the antagonist PTH(7-33)-CBD had no beneficial effect, treatment with the agonist 40 PTH-CBD led to deeper rooting and reduced melanocyte clumping, thus reversing the dystrophic changes. Counts of anagen VI hair follicles per high-powered field (HPF) were compared between groups; animals treated with PTH-CBD had a higher number of hair follicles, approaching those of 45 animals which did not receive chemotherapy (FIG. 14), while the antagonist PTH(7-33)-CBD had no beneficial effect.

Importantly, we saw no evidence of adverse effects from PTH-CBD administration. While PTH injections are known 50 to elevate blood calcium and can cause kidney stones, PTH-CBD had no effect on serum calcium. In addition, there was no evidence of excess hair length on the body or of excess hair growth on the ears and tail, where a full coat is normally not present. The effects of PTH-CBD on hair 55 growth have been confirmed in models of chemotherapyinduced alopecia without depilation, which more closely mimic clinical protocols.

Quantification of Effects of PTH-CBD in Chemotherapy-Induced Alopecia: We followed these studies by comparing 60 the effects of different doses of PTH-CBD in chemotherapyinduced alopecia. In these studies, we applied the injections more distally on the back and applied a gray-scale analysis to quantify the amount of hair growth. Injecting more distally in the back allows us to compare regrowth of hair 65 after PTH-CBD treatment with less interference from the normal hair regrowth, which normally proceeds from head

to tail in mice. The results are shown in FIG. **15**, indicating a dose-dependent effect on hair regrowth both qualitatively and quantitatively.

Chemotherapy-Induced Alopecia without Depilation: While the depilated model of chemotherapy-induced alopecia provides a uniform model for comparison of drug effects, the depilation process is known to cause hair follicle injury, and may alter the response of the animals to the PTH-CBD administration. We therefore tested the effects of PTH-CBD in another model of chemotherapy-induced alopecia, where the animals were given 3 courses of cyclophosphamide therapy (50 mg/kg/wk), similar to the usual manner in which cancer patients might be treated. In this model, it takes much longer (4-6 months) for alopecia to develop. Animals that received a single dose of PTH-CBD (320 mcg/kg subcutaneous) prior to the first cycle did not develop hair loss as shown in FIG. **16**.

In a second study, we compared the effects of PTH-CBD when given prophylactically, at the time of the first cycle of chemotherapy, vs. therapeutically, after the hair loss had developed. While PTH-CBD was effective in both instances, the effects were more prominent when given prophylactically. This is evident both visually and quantitatively in FIG. **17**, using the same grey scale analysis used in our dose-response study.

Depilation Alopecia: The agonist PTH-CBD appears to increase hair growth by increasing the number of anagen phase hair follicles. As such, there is no reason to believe that hair growth effects should be limited to the chemotherapy model. We therefore tested both PTH-CBD and antagonist compound, PTH(7-33)-CBD, after removing hair from C57/BL6J mice by waxing (FIG. 18). The results were quite interesting; agonist (PTH-CBD) treated animals had earlier anagen eruption (day 7 vs. day 9 for vehicle controls), and exhibited more complete regrowth of hair by the end of the study (day 18). Antagonist (PTH(7-33)-CBD) treated animals also had an early anagen eruption, but the hair growth which followed was markedly curtailed, and the hair cycle was arrested after this point, resulting no further observed regrowth of hair. Thus, it appears that agonist therapy is acting to promote more rapid regrowth of hair by promoting more rapid transition to the anagen phase, while the antagonist inhibited hair regrowth by blocking this transition.

PTH-CBD is a fusion protein of the first 33 amino acids of parathyroid hormone (PTH) and a bacterial collagen binding domain. The collagen binding activity causes PTH-CBD to be retained at its site of action in the dermal collagen, maximizing efficacy and reducing systemic sideeffects. PTH-CBD stimulates hair growth by causing hair follicles to enter an anagen VI or growth phase, presumably by activating WNT signaling and increasing production of beta-catenin. We therefore plan to conduct the following additional studies to confirm this mechanism of action and to determine the effect of PTH-CBD in two distinct genetic mouse models with WNT signaling inhibition. These data will be used in formulating clinical trials for PTH-CBD as a therapy for alopecia.

Alopecia Areata: Alopecia Areata is a disease of patchy hair loss due to autoimmune destruction of the hair follicles. We tested the efficacy of PTH-CBD in promoting regrowth of hair in an animal model of alopecia areata, the engrafted C3H/Hej mouse. In this model, hair loss develops variably over the first 2 months of life. Shown in FIG. **19** is the results of a single dose of PTH-CBD (**320** mcg/kg subcutaneous) administered into the engrafted site, the center of the back, where there was maximal hair loss. Compared to vehicle

control animals, which continued to lose hair at this site, animals receiving PTH-CBD began to show regrowth of hair within the next 1-4 days. Importantly, the response was found to be sustained during the 2 month course of the experiment.

Example 4

CBD-PTH can Prevent or Treat Hyperparathyroidism

In this experiment, rats had their ovaries surgically removed at age 3 months. At age 9 months, rats were injected with either a single dose of PTH-CBD (320 mcg/kg)

SEQUENCE LISTING

30

or vehicle control. Animals were sacrificed 6 months after therapy (age 15 months). Human intact PTH levels were measured to assess serum levels of PTH-CBD, and were found to be undetectable in both groups. Serum calcium was measured and there were no differences between groups (Vehicle: 13.5+/-1.1 vs. PTH-CBD: 14.3+/-1.1 mg/dl, NS). Rat intact PTH levels were measured to assess endogenous PTH production, and PTH-CBD suppressed the normal increase in endogenous PTH levels seen in aged, ovarectomized rats. These findings indicate that a single injection of 10 PTH-CBD can provide long-term suppression of endogenous PTH production, preventing the normal rise seen with age in the ovarectomized rat model, and thus may serve as a therapy for hyperparathyroidism.

<160> NUMBER OF SEQ ID NOS: 47 <210> SEQ ID NO 1 <211> LENGTH: 158 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic fusion protein containing parathyroid hormone segment and collagen-binding domain <400> SEQUENCE: 1 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 5 10 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 Asn Gly Ile Asn Ser Pro Val Tyr Pro Ile Gly Thr Glu Lys Glu Pro 35 40 45 Asn Asn Ser Lys Glu Thr Ala Ser Gly Pro Ile Val Pro Gly Ile Pro 50 55 60 Val Ser Gly Thr Ile Glu Asn Thr Ser Asp Gln Asp Tyr Phe Tyr Phe 65 70 75 Asp Val Ile Thr Pro Gly Glu Val Lys Ile Asp Ile Asn Lys Leu Gly 85 90 Tyr Gly Gly Ala Thr Trp Val Val Tyr Asp Glu Asn Asn Asn Ala Val 100 105 110 Ser Tyr Ala Thr Asp Asp Gly Gln Asn Leu Ser Gly Lys Phe Lys Ala 120 115 Asp Lys Pro Gly Arg Tyr Tyr Ile His Leu Tyr Met Phe Asn Gly Ser 130 135 140 Tyr Met Pro Tyr Arg Ile Asn Ile Glu Gly Ser Val Gly Arg 145 150 155 <210> SEQ ID NO 2 <211> LENGTH: 251 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic fusion protein containing parathyroid hormone fragment and collagen-binding domain and polycystic kidney disease domain of ColH. <400> SEQUENCE: 2 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His

25

30

20

											_	COII		ueu					
Asn	Gly	Ile 35	Pro	Glu	Ile	ГЛа	Asp 40	Leu	Ser	Glu	Asn	Lys 45	Leu	Pro	Val			 	
Ile	Tyr 50	Met	His	Val	Pro	Lys 55	Ser	Gly	Ala	Leu	Asn 60	Gln	Lys	Val	Val				
Phe 65	Tyr	Gly	Lys	Gly	Thr 70	Tyr	Asp	Pro	Asp	Gly 75	Ser	Ile	Ala	Gly	Tyr 80				
	Trp	Asp	Phe	-		Gly	Ser	Asp			Ser	Glu	Gln						
Ser	His	Val	Tyr	85 Thr	Гла	Гуз	Gly	Glu	90 Tyr	Thr	Val	Thr	Leu	95 Arg	Val				
Met.	Asp	Ser	100 Ser	Glv	Gln	Met.	Ser	105 Glu	Lvs	Thr	Met	Lvs	110 Ile	Lvs	Ile				
	-	115		-			120		-			125		-					
Thr	Asp 130	Pro	Val	Tyr	Pro	11e 135	GIY	Thr	GIu	ГЛЗ	Glu 140	Pro	Asn	Asn	Ser				
Lys 145	Glu	Thr	Ala	Ser	Gly 150	Pro	Ile	Val	Pro	Gly 155	Ile	Pro	Val	Ser	Gly 160				
Thr	Ile	Glu	Asn	Thr 165	Ser	Asp	Gln	Asp	Tyr 170	Phe	Tyr	Phe	Asp	Val 175	Ile				
Thr	Pro	Gly	Glu 180	Val	ГЛа	Ile	Asp	Ile 185	Asn	Lys	Leu	Gly	Tyr 190	Gly	Gly				
Ala	Thr	Trp 195	Val	Val	Tyr	Asp	Glu 200	Asn	Asn	Asn	Ala	Val 205	Ser	Tyr	Ala				
Thr	-		Gly	Gln	Asn			Gly	Lys	Phe	Lys 220		Asp	Lys	Pro				
	210 Arg	Tyr	Tyr	Ile	His	215 Leu	Tyr	Met	Phe	Asn	Gly	Ser	Tyr	Met	Pro				
225 Tyr	Arg	Ile	Asn	Ile	230 Glu	Gly	Ser	Val	Gly	235 Arg					240				
<21: <21: <22:	0> F1	YPE : RGANI EATUI	DNA ISM: RE:	Art					expro	essi	on v	ecto:	r						
	0> SI																		
															getgtg seeegt				
															atgagc	18	0		
tgt	tgaca	aat 1	taat	catc	gg ci	tcgt	ataat	c gtę	gtgga	aatt	gtg.	agcg	gat .	aacaa	atttca	24	0		
caca	agga	aac a	agta	ttca	tg t	ccct	tatad	c taq	ggtta	attg	gaa	aatt	aag g	ggcci	tgtgc	30	0		
aac	ccact	tcg a	actt	cttti	tg g	aata	tcttç	g aaq	gaaa	aata	tga.	agag	cat '	ttgta	atgagc	36	0		
															ccaatc	42			
															gttata	48			
															caatgc	54			
															aagact	60			
															cgaag	66			
															ccatgt	72 78			
																84			
aal	Layu	LUYI		uaddi	ua Co	guali	uyaaq	9 UL8	acee	Laud	adl	cyati	uay	Latt	igaaat	84	5		

US 9,579,273 B2

33

-continued

				-contir	nued			
ccagcaagta	tatagcatgg	cctttgcagg	gctggcaagc	cacgtttggt	ggtggcgacc	900		
atcctccaaa	atcggatctg	atcgaaggtc	gttctgtgag	tgaaatacag	cttatgcata	960		
acctgggaaa	acatctgaac	tcgatggaga	gagtagaatg	gctgcgtaag	aagctgcagg	1020		
atgtgcacaa	tggaattaat	tccccggtat	atccaatagg	cactgaaaaa	gaaccaaata	1080		
acagtaaaga	aactgcaagt	ggtccaatag	taccaggtat	acctgttagt	ggaaccatag	1140		
aaaatacaag	tgatcaagat	tatttctatt	ttgatgttat	aacaccagga	gaagtaaaaa	1200		
tagatataaa	taaattaggg	tacggaggag	ctacttgggt	agtatatgat	gaaaataata	1260		
atgcagtatc	ttatgccact	gatgatgggc	aaaatttaag	tggaaagttt	aaggcagata	1320		
aaccaggtag	atattacatc	catctttaca	tgtttaatgg	tagttatatg	ccatatagaa	1380		
ttaatataga	aggttcagta	ggaagataat	attttattag	ttgaggtaac	tccactcgaa	1440		
ttggtcgact	cgagcggccg	catcgtgact	gactgacgat	ctgcctcgcg	cgtttcggtg	1500		
atgacggtga	aaacctctga	cacatgcagc	tcccggagac	ggtcacagct	tgtctgtaag	1560		
cggatgccgg	gagcagacaa	gcccgtcagg	gcgcgtcagc	gggtgttggc	gggtgtcggg	1620		
gcgcagccat	gacccagtca	cgtagcgata	gcggagtgta	taattcttga	agacgaaagg	1680		
gcctcgtgat	acgcctattt	ttataggtta	atgtcatgat	aataatggtt	tcttagacgt	1740		
caggtggcac	ttttcgggga	aatgtgcgcg	gaacccctat	ttgtttattt	ttctaaatac	1800		
attcaaatat	gtatccgctc	atgagacaat	aaccctgata	aatgcttcaa	taatattgaa	1860		
aaaggaagag	tatgagtatt	caacatttcc	gtgtcgccct	tattcccttt	tttgcggcat	1920		
tttgccttcc	tgtttttgct	cacccagaaa	cgctggtgaa	agtaaaagat	gctgaagatc	1980		
agttgggtgc	acgagtgggt	tacatcgaac	tggatctcaa	cagcggtaag	atccttgaga	2040		
gttttcgccc	cgaagaacgt	tttccaatga	tgagcacttt	taaagttctg	ctatgtggcg	2100		
cggtattatc	ccgtgttgac	gccgggcaag	agcaactcgg	tcgccgcata	cactattctc	2160		
agaatgactt	ggttgagtac	tcaccagtca	cagaaaagca	tcttacggat	ggcatgacag	2220		
taagagaatt	atgcagtgct	gccataacca	tgagtgataa	cactgcggcc	aacttacttc	2280		
tgacaacgat	cggaggaccg	aaggagctaa	ccgcttttt	gcacaacatg	ggggatcatg	2340		
taactcgcct	tgatcgttgg	gaaccggagc	tgaatgaagc	cataccaaac	gacgagcgtg	2400		
acaccacgat	gcctgcagca	atggcaacaa	cgttgcgcaa	actattaact	ggcgaactac	2460		
ttactctagc	ttcccggcaa	caattaatag	actggatgga	ggcggataaa	gttgcaggac	2520		
cacttctgcg	ctcggccctt	ccggctggct	ggtttattgc	tgataaatct	ggagccggtg	2580		
agcgtgggtc	tcgcggtatc	attgcagcac	tggggccaga	tggtaagccc	tcccgtatcg	2640		
tagttatcta	cacgacgggg	agtcaggcaa	ctatggatga	acgaaataga	cagatcgctg	2700		
agataggtgc	ctcactgatt	aagcattggt	aactgtcaga	ccaagtttac	tcatatatac	2760		
tttagattga	tttaaaactt	catttttaat	ttaaaaggat	ctaggtgaag	atcctttttg	2820		
ataatctcat	gaccaaaatc	ccttaacgtg	agttttcgtt	ccactgagcg	tcagaccccg	2880		
tagaaaagat	caaaggatct	tcttgagatc	cttttttct	gcgcgtaatc	tgctgcttgc	2940		
aaacaaaaaa	accaccgcta	ccagcggtgg	tttgtttgcc	ggatcaagag	ctaccaactc	3000		
tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	cttctagtgt	3060		
agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	gcctacatac	ctcgctctgc	3120		
taatcctgtt	accagtggct	gctgccagtg	gcgataagtc	gtgtcttacc	gggttggact	3180		
				aacggggggt		3240		
5 - 5	5 - 55 40	55 530	55 555-*5	5555555	5 5			

34

US 9,579,273 B2

35

-continued

				-contir	nued	
ageccagett	ggagcgaacg	acctacaccg	aactgagata	cctacagcgt	gagctatgag	3300
aaagcgccac	gcttcccgaa	gggagaaagg	cggacaggta	tccggtaagc	ggcagggtcg	3360
gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	ctggtatctt	tatagtcctg	3420
tcgggtttcg	ccacctctga	cttgagcgtc	gatttttgtg	atgctcgtca	gggggggcgga	3480
gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	cctggccttt	tgctggcctt	3540
ttgctcacat	gttctttcct	gcgttatccc	ctgattctgt	ggataaccgt	attaccgcct	3600
ttgagtgagc	tgataccgct	cgccgcagcc	gaacgaccga	gcgcagcgag	tcagtgagcg	3660
aggaagcgga	agagcgcctg	atgcggtatt	ttctccttac	gcatctgtgc	ggtatttcac	3720
accgcataaa	ttccgacacc	atcgaatggt	gcaaaacctt	tcgcggtatg	gcatgatagc	3780
gcccggaaga	gagtcaattc	agggtggtga	atgtgaaacc	agtaacgtta	tacgatgtcg	3840
cagagtatgc	cggtgtctct	tatcagaccg	tttcccgcgt	ggtgaaccag	gccagccacg	3900
tttctgcgaa	aacgcgggaa	aaagtggaag	cggcgatggc	ggagctgaat	tacattccca	3960
accgcgtggc	acaacaactg	gcgggcaaac	agtcgttgct	gattggcgtt	gccacctcca	4020
gtetggeeet	gcacgcgccg	tcgcaaattg	tcgcggcgat	taaatctcgc	gccgatcaac	4080
tgggtgccag	cgtggtggtg	tcgatggtag	aacgaagcgg	cgtcgaagcc	tgtaaagcgg	4140
cggtgcacaa	tcttctcgcg	caacgcgtca	gtgggctgat	cattaactat	ccgctggatg	4200
accaggatgc	cattgctgtg	gaagctgcct	gcactaatgt	tccggcgtta	tttcttgatg	4260
tctctgacca	gacacccatc	aacagtatta	ttttctccca	tgaagacggt	acgcgactgg	4320
gcgtggagca	tctggtcgca	ttgggtcacc	agcaaatcgc	gctgttagcg	ggcccattaa	4380
gttctgtctc	ggcgcgtctg	cgtctggctg	gctggcataa	atatctcact	cgcaatcaaa	4440
ttcagccgat	agcggaacgg	gaaggcgact	ggagtgccat	gtccggtttt	caacaaacca	4500
tgcaaatgct	gaatgagggc	atcgttccca	ctgcgatgct	ggttgccaac	gatcagatgg	4560
cgctgggcgc	aatgcgcgcc	attaccgagt	ccgggctgcg	cgttggtgcg	gatatctcgg	4620
tagtgggata	cgacgatacc	gaagacagct	catgttatat	cccgccgtta	accaccatca	4680
aacaggattt	tcgcctgctg	gggcaaacca	gcgtggaccg	cttgctgcaa	ctctctcagg	4740
gccaggcggt	gaagggcaat	cagctgttgc	ccgtctcact	ggtgaaaaga	aaaaccaccc	4800
tggcgcccaa	tacgcaaacc	gcctctcccc	gcgcgttggc	cgattcatta	atgcagctgg	4860
cacgacaggt	ttcccgactg	gaaagcgggc	agtgagcgca	acgcaattaa	tgtgagttag	4920
ctcactcatt	aggcacccca	ggctttacac	tttatgcttc	cggctcgtat	gttgtgtgga	4980
attgtgagcg	gataacaatt	tcacacagga	aacagctatg	accatgatta	cggattcact	5040
ggccgtcgtt	ttacaacgtc	gtgactggga	aaaccctggc	gttacccaac	ttaatcgcct	5100
tgcagcacat	ccccctttcg	ccagetggeg	taatagcgaa	gaggcccgca	ccgatcgccc	5160
ttcccaacag	ttgcgcagcc	tgaatggcga	atggcgcttt	gcctggtttc	cggcaccaga	5220
agcggtgccg	gaaagetgge	tggagtgcga	tcttcctgag	gccgatactg	tcgtcgtccc	5280
ctcaaactgg	cagatgcacg	gttacgatgc	gcccatctac	accaacgtaa	cctatcccat	5340
tacggtcaat	ccgccgtttg	ttcccacgga	gaatccgacg	ggttgttact	cgctcacatt	5400
taatgttgat	gaaagctggc	tacaggaagg	ccagacgcga	attattttg	atggcgttgg	5460

36

5464

aatt

<210> SEQ ID NO 4 <211> LENGTH: 383
<pre><212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>
<223> OTHER INFORMATION: Synthetic GST-PTH-CBD fusion protein
~ Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro 1 5 10 15
Thr Arg Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 20 25 30
Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 35 40 45
Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 50 55 60
Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn 65 70 75 80
Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu 85 90 95
Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 100 105 110
Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 115 120 125
Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 130 135 140
Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp145150155160
Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165 170 175
Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 180 185 190
Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 195 200 205
Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Ile Glu Gly210215220
Arg Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu225230235240
Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val 245 250 255
His Asn Gly Ile Asn Ser Pro Val Tyr Pro Ile Gly Thr Glu Lys Glu 260 265 270
Pro Asn Asn Ser Lys Glu Thr Ala Ser Gly Pro Ile Val Pro Gly Ile 275 280 285
Pro Val Ser Gly Thr Ile Glu Asn Thr Ser Asp Gln Asp Tyr Phe Tyr 290 295 300
Phe Asp Val Ile Thr Pro Gly Glu Val Lys Ile Asp Ile Asn Lys Leu305310315320
Gly Tyr Gly Gly Ala Thr Trp Val Val Tyr Asp Glu Asn Asn Asn Ala 325 330 335
Val Ser Tyr Ala Thr Asp Asp Gly Gln Asn Leu Ser Gly Lys Phe Lys 340 345 350

Ala Asp Lys Pro Gly Arg Tyr Tyr Ile His Leu Tyr Met Phe Asn Gly

-continued

Ser Tyr Met Pro Tyr Arg Ile Asn Ile Glu Gly Ser Val Gly Arg <210> SEQ ID NO 5 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide: Factor Xa recognition sequence <400> SEQUENCE: 5 Ile Glu Gly Arg <210> SEQ ID NO 6 <211> LENGTH: 1021 <212> TYPE: PRT <213> ORGANISM: Clostridium histolyticum <400> SEOUENCE: 6 Met Lys Arg Lys Cys Leu Ser Lys Arg Leu Met Leu Ala Ile Thr Met Ala Thr Ile Phe Thr Val Asn Ser Thr Leu Pro Ile Tyr Ala Ala Val Asp Lys Asn Asn Ala Thr Ala Ala Val Gln Asn Glu Ser Lys Arg Tyr Thr Val Ser Tyr Leu Lys Thr Leu Asn Tyr Tyr Asp Leu Val Asp Leu Leu Val Lys Thr Glu Ile Glu Asn Leu Pro Asp Leu Phe Gln Tyr Ser Ser Asp Ala Lys Glu Phe Tyr Gly Asn Lys Thr Arg Met Ser Phe Ile Met Asp Glu Ile Gly Arg Arg Ala Pro Gln Tyr Thr Glu Ile Asp His Lys Gly Ile Pro Thr Leu Val Glu Val Val Arg Ala Gly Phe Tyr Leu Gly Phe His Asn Lys Glu Leu Asn Glu Ile Asn Lys Arg Ser Phe Lys Glu Arg Val Ile Pro Ser Ile Leu Ala Ile Gln Lys Asn Pro Asn Phe Lys Leu Gly Thr Glu Val Gln Asp Lys Ile Val Ser Ala Thr Gly Leu Leu Ala Gly Asn Glu Thr Ala Pro Pro Glu Val Val Asn Asn Phe Thr Pro Ile Leu Gln Asp Cys Ile Lys Asn Ile Asp Arg Tyr Ala Leu Asp Asp Leu Lys Ser Lys Ala Leu Phe Asn Val Leu Ala Ala Pro Thr Tyr Asp Ile Thr Glu Tyr Leu Arg Ala Thr Lys Glu Lys Pro Glu Asn Thr Pro Trp Tyr Gly Lys Ile Asp Gly Phe Ile Asn Glu Leu Lys Lys Leu Ala Leu Tyr Gly Lys Ile Asn Asp Asn Asn Ser Trp Ile Ile Asp Asn

-continued

42

Gly	Ile	Tyr 275	His	Ile	Ala	Pro	Leu 280	Gly	ГЛа	Leu	His	Ser 285	Asn	Asn	Lys
Ile	Gly 290	Ile	Glu	Thr	Leu	Thr 295	Glu	Val	Met	Lys	Val 300	Tyr	Pro	Tyr	Leu
Ser 305	Met	Gln	His	Leu	Gln 310	Ser	Ala	Asp	Gln	Ile 315	ГЛа	Arg	His	Tyr	Asp 320
Ser	Lys	Asp	Ala	Glu 325	Gly	Asn	Lys	Ile	Pro 330	Leu	Asp	ГЛа	Phe	Lys 335	Lys
Glu	Gly	Lys	Glu 340	Lys	Tyr	Суз	Pro	Lys 345	Thr	Tyr	Thr	Phe	Asp 350	Asb	Gly
Lys	Val	Ile 355	Ile	Lys	Ala	Gly	Ala 360	Arg	Val	Glu	Glu	Glu 365	Lys	Val	Lys
Arg	Leu 370	Tyr	Trp	Ala	Ser	Lys 375	Glu	Val	Asn	Ser	Gln 380	Phe	Phe	Arg	Val
Tyr 385	Gly	Ile	Asp	ГЛа	Pro 390	Leu	Glu	Glu	Gly	Asn 395	Pro	Asp	Asp	Ile	Leu 400
Thr	Met	Val	Ile	Tyr 405	Asn	Ser	Pro	Glu	Glu 410	Tyr	ГЛа	Leu	Asn	Ser 415	Val
Leu	Tyr	Gly	Tyr 420	Asp	Thr	Asn	Asn	Gly 425	Gly	Met	Tyr	Ile	Glu 430	Pro	Glu
Gly	Thr	Phe 435	Phe	Thr	Tyr	Glu	Arg 440	Glu	Ala	Gln	Glu	Ser 445	Thr	Tyr	Thr
Leu	Glu 450	Glu	Leu	Phe	Arg	His 455	Glu	Tyr	Thr	His	Tyr 460	Leu	Gln	Gly	Arg
Tyr 465		Val	Pro	Gly	Gln 470		Gly	Arg	Thr	Lys 475		Tyr	Asp	Asn	Asp 480
	Leu	Thr	Trp	Tyr 485	Glu	Glu	Gly	Gly	Ala 490		Leu	Phe	Ala	Gly 495	
Thr	Arg	Thr			Ile	Leu	Pro	-		Ser	Ile	Val			Ile
His	Asn		500 Thr	Arg	Asn	Asn	-	505 Tyr	Lys	Leu	Ser	-	510 Thr	Val	His
Ser	Lys	515 Tyr	Gly	Ala	Ser	Phe	520 Glu	Phe	Tyr	Asn	Tyr	525 Ala	Суз	Met	Phe
	530	-	-		Asn	535			_		540		-		
545					550					555					560
-			-	565	Asn	-		_	570	-	_		-	575	-
Asp	Leu	Ser	Ser 580	Asn	Tyr	Ala	Leu	Asn 585	Asp	Lys	Tyr	Gln	Asp 590	His	Met
Gln	Glu	Arg 595	Ile	Asp	Asn	Tyr	Glu 600	Asn	Leu	Thr	Val	Pro 605	Phe	Val	Ala
Asp	Asp 610	Tyr	Leu	Val	Arg	His 615	Ala	Tyr	Lys	Asn	Pro 620	Asn	Glu	Ile	Tyr
Ser 625	Glu	Ile	Ser	Glu	Val 630	Ala	Lys	Leu	Lys	Asp 635	Ala	ГЛа	Ser	Glu	Val 640
Lys	Lys	Ser	Gln	Tyr 645	Phe	Ser	Thr	Phe	Thr 650	Leu	Arg	Gly	Ser	Tyr 655	Thr
Gly	Gly	Ala	Ser 660	Lys	Gly	Lys	Leu	Glu 665	Asp	Gln	Lys	Ala	Met 670	Asn	Lys
Phe	Ile	Asp 675	Asp	Ser	Leu	Lys	Lys 680	Leu	Asp	Thr	Tyr	Ser 685	Trp	Ser	Gly

Tyr	Lys 690	Thr	Leu	Thr	Ala	Tyr 695	Phe	Thr	Asn	Tyr	Lys 700	Val	Asp	Ser	Ser
Asn 705	Arg	Val	Thr	Tyr	Asp 710	Val	Val	Phe	His	Gly 715	Tyr	Leu	Pro	Asn	Glu 720
Gly	Asp	Ser	Lys	Asn 725	Ser	Leu	Pro	Tyr	Gly 730	Lys	Ile	Asn	Gly	Thr 735	Tyr
Lys	Gly	Thr	Glu 740	Lys	Glu	Lys	Ile	Lys 745	Phe	Ser	Ser	Glu	Gly 750	Ser	Phe
Asp	Pro	Asp 755	Gly	Lys	Ile	Val	Ser 760	Tyr	Glu	Trp	Asp	Phe 765	Gly	Asp	Gly
Asn	Lys 770	Ser	Asn	Glu	Glu	Asn 775	Pro	Glu	His	Ser	Tyr 780	Asp	Lys	Val	Gly
Thr 785	Tyr	Thr	Val	ГЛа	Leu 790	Lys	Val	Thr	Asp	Asp 795	ГЛа	Gly	Glu	Ser	Ser 800
Val	Ser	Thr	Thr	Thr 805	Ala	Glu	Ile	ГЛа	Asp 810	Leu	Ser	Glu	Asn	Lys 815	Leu
Pro	Val	Ile	Tyr 820	Met	His	Val	Pro	Lys 825	Ser	Gly	Ala	Leu	Asn 830	Gln	Гла
Val	Val	Phe 835	Tyr	Gly	LYa	Gly	Thr 840	Tyr	Asp	Pro	Asp	Gly 845	Ser	Ile	Ala
Gly	Tyr 850	Gln	Trp	Aab	Phe	Gly 855	Asp	Gly	Ser	Asp	Phe 860	Ser	Ser	Glu	Gln
Asn 865	Pro	Ser	His	Val	Tyr 870	Thr	Lys	Гла	Gly	Glu 875	Tyr	Thr	Val	Thr	Leu 880
Arg	Val	Met	Asp	Ser 885	Ser	Gly	Gln	Met	Ser 890	Glu	ГЛа	Thr	Met	Lys 895	Ile
ГЛа	Ile	Thr	Asp 900	Pro	Val	Tyr	Pro	Ile 905	Gly	Thr	Glu	ГЛа	Glu 910	Pro	Asn
Asn	Ser	Lys 915	Glu	Thr	Ala	Ser	Gly 920	Pro	Ile	Val	Pro	Gly 925	Ile	Pro	Val
Ser	Gly 930	Thr	Ile	Glu	Asn	Thr 935	Ser	Asp	Gln	Asp	Tyr 940	Phe	Tyr	Phe	Asp
Val 945	Ile	Thr	Pro	Gly	Glu 950	Val	Lys	Ile	Asp	Ile 955	Asn	ГЛа	Leu	Gly	Tyr 960
Gly	Gly	Ala	Thr	Trp 965	Val	Val	Tyr	Asp	Glu 970	Asn	Asn	Asn	Ala	Val 975	Ser
Tyr	Ala	Thr	Asp 980	Aap	Gly	Gln	Asn	Leu 985	Ser	Gly	ГЛа	Phe	Lys 990	Ala	Aap
Lys	Pro	Gly 995	Arg	Tyr	Tyr	Ile	His 1000		а Туг	r Mei	t Phe	e Ası 100		ly Se	er Tyr
Met Pro Tyr Arg Ile Asn Ile Glu Gly Ser Val Gly Arg 1010 1015 1020															
<210> SEQ ID NO 7 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Homo sapiens															
					່ sa]	prens	5								
)> SI				a 1	Ŧ	M -			Ŧ	<i>c</i> .	Ŧ		Ŧ	
1				5					10		Gly	-		15	
Ser	Met	Glu	Arg 20	Val	Glu	Trp	Leu	Arg 25	ГЛа	ГÀа	Leu	Gln	Asp 30	Val	His
Asn	Phe	Val 35	Ala	Leu	Gly	Ala	Pro 40	Leu	Ala	Pro	Arg	Asp 45	Ala	Gly	Ser

-continued

Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln <210> SEQ ID NO 8 <211> LENGTH: 141 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg His <210> SEQ ID NO 9 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Gly-Ser-PTH(1-33)-CBD fusion protein <400> SEQUENCE: 9 Gly Ser Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp - 30 Val His Asn Gly Ile Asn Ser Pro Val Tyr Pro Ile Gly Thr Glu Lys Glu Pro Asn Asn Ser Lys Glu Thr Ala Ser Gly Pro Ile Val Pro Gly Ile Pro Val Ser Gly Thr Ile Glu Asn Thr Ser Asp Gln Asp Tyr Phe Tyr Phe Asp Val Ile Thr Pro Gly Glu Val Lys Ile Asp Ile Asn Lys Leu Gly Tyr Gly Gly Ala Thr Trp Val Val Tyr Asp Glu Asn Asn Asn Ala Val Ser Tyr Ala Thr Asp Asp Gly Gln Asn Leu Ser Gly Lys Phe

-continued

Lys Ala Asp Lys Pro Gly Arg Tyr Tyr Ile His Leu Tyr Met Phe Asn 130 135 140 Gly Ser Tyr Met Pro Tyr Arg Ile Asn Ile Glu Gly Ser Val Gly Arg 145 150 155 160 <210> SEQ ID NO 10 <211> LENGTH: 152 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic PTH(7-33)-CBD fusion protein <400> SEQUENCE: 10 Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu 1 5 10 Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Gly Ile Asn Ser Pro $_{20}$ Val Tyr Pro Ile Gly Thr Glu Lys Glu Pro Asn Asn Ser Lys Glu Thr 40 35 45 Ala Ser Gly Pro Ile Val Pro Gly Ile Pro Val Ser Gly Thr Ile Glu 55 50 60 Asn Thr Ser Asp Gln Asp Tyr Phe Tyr Phe Asp Val Ile Thr Pro Gly 65 70 75 80 Glu Val Lys Ile As
p Ile Asn Lys Leu Gly Tyr Gly Gly Ala Thr \mbox{Trp} 85 90 95 Val Val Tyr Asp Glu Asn Asn Asn Ala Val Ser Tyr Ala Thr Asp Asp 105 100 110 Gly Gln Asn Leu Ser Gly Lys Phe Lys Ala Asp Lys Pro Gly Arg Tyr 115 120 125 Tyr Ile His Leu Tyr Met Phe Asn Gly Ser Tyr Met Pro Tyr Arg Ile 130 135 140 Asn Ile Glu Gly Ser Val Gly Arg 145 150 <210> SEQ ID NO 11 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic PTH(1-33) with Gly-Ser amino terminal extension <400> SEOUENCE: 11 Gly Ser Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His 1 5 10 15 Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp 20 25 30 Val His Asn 35 <210> SEQ ID NO 12 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic thrombin cleavage sequence <400> SEQUENCE: 12 Leu Val Pro Arg Gly Ser 1 5

<210> SEQ ID NO 13 <211> LENGTH: 111 <212> TYPE: PRT											
<213> ORGANISM: Clostr:	dium histoly.	ticum									
<400> SEQUENCE: 13											
Leu Lys Glu Lys Glu Ası	ı Asn Asp Ser	Ser Asp Lys Ala	Thr Val Ile								
1 5		10	15								
Pro Asn Phe Asn Thr Th	Met Gln Gly	Ser Leu Leu Gly	Asp Asp Ser								
20	25		30								
Arg Asp Tyr Tyr Ser Phe	e Glu Val Lys	Glu Glu Gly Glu	Val Asn Ile								
35	40	45									
Glu Leu Asp Lys Lys Asp	Glu Phe Gly	Val Thr Trp Thr	Leu His Pro								
50	55	60									
Glu Ser Asn Ile Asn Asp	Arg Ile Thr	Tyr Gly Gln Val	Asp Gly Asn								
65 70		75	80								
Lys Val Ser Asn Lys Val	. Lys Leu Arg	Pro Gly Lys Tyr	Tyr Leu Leu								
85		90	95								
Val Tyr Lys Tyr Ser Gly	V Ser Gly Asn	Tyr Glu Leu Arg	Val Asn								
100	105		110								
210. CEO TE NO 14											
<210> SEQ ID NO 14 <211> LENGTH: 111 <212> TYPE: PRT											
<213> ORGANISM: C. spor	rogenes										
<400> SEQUENCE: 14											
Ile His Glu Lys Glu Ası	ı Asn Asp Ser	Phe Glu Ser Ala	Asn Lys Ile								
1 5		10	15								
Val Leu Asn Ala Pro Ile	e Leu Gly Ser	Leu Asn Gly Glu	Asp Leu Arg								
20	25		30								
Asp Ile Tyr Ser Phe Glu	ı Ile Lys Glu	Thr Lys Asp Leu	Asn Ile Lys								
35	40	45									
Leu Thr Asn Leu Asn Ası	n Leu Gly Leu	Thr Trp Thr Leu	. Tyr Lys Glu								
50	55	60									
Ser Asp Leu Asn Asn Tyr	r Ile Ala Tyr	Gly Ser Lys Leu	Gly Ser Thr								
65 70		75	80								
Ile Val Gly Asn Cys His	8 Val Thr Pro	Gly Lys Tyr Tyr	Leu Tyr Val								
85		90	95								
Tyr Lys Tyr Ser Gly Ast	n Asn Gly Asn		Ile Lys								
100	105		110								
<210> SEQ ID NO 15											
<pre><211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. botu</pre>	, mulai ו										
<400> SEQUENCE: 15											
Ile Tyr Glu Lys Glu As	ı Asn Asp Ser	Phe Glu Thr Ala	Asn Lys Ile								
1 5		10	15								
Met Leu Asn Thr Thr Va		Leu Asn Gly Lys	Asp Val Arg								
20	25	Ala Lys Asp Leu	30								
Asp Ile Tyr Ser Phe Asp) Ile Lys Glu		Asp Ile Lys								
35 Leu Asn Asn Leu Asn Asr	40	45									
50	55	60									
Ser Asp Leu Asn Asn Tyn	r Ile Ala Tyr	Gly Ser Val Ser	Gly Asn Thr								
65 70		75	80								

50

-continued

Ile Lys Gly Lys Cys Asn Val Ala Pro Gly Lys Tyr Tyr Leu Tyr Val 85 90 Tyr Lys Tyr Ser Gly Asp Asn Gly Asn Tyr Ser Leu Ala Ile Lys 100 105 110 <210> SEQ ID NO 16 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: B. cereus <400> SEQUENCE: 16 Leu Thr Glu Ser Glu Pro Asn Asn Arg Pro Glu Glu Ala Asn Arg Ile 5 10 1 Gly Leu Asn Thr Thr Ile Lys Gly Ser Leu Ile Gly Gly Asp His Thr20 25 30Asp Val Tyr Thr Phe Asn Val Ala Ser Ala Lys Asn Ile Asn Ile Ser 40 35 45 Val Leu Asn Glu Tyr Gly Ile Gly Met Thr Trp Val Leu His His Glu 50 55 60 Ser Asp Met Gln Asn Tyr Ala Ala Tyr Gly Gln Val Asn Gly Asn His 65 70 75 80 Ile Glu Ala Asn Phe Asn Ala Lys Pro Gly Lys Tyr Tyr Leu Tyr Val 85 90 Tyr Lys Tyr Asp Asn Gly Asp Gly Thr Tyr Glu Leu Ser Val Lys 100 105 110 <210> SEQ ID NO 17 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: B. anthracis <400> SEQUENCE: 17 Leu Thr Glu Ser Glu Pro Asn Asn Arg Pro Glu Glu Ala Asn Arg Ile 1 5 10 15 Gly Leu Asn Thr Thr Ile Lys Gly Ser Leu Ile Gly Gly Asp His Thr 25 20 30 Asp Val Tyr Thr Phe Asn Val Ala Ser Ala Lys Asn Ile Asp Ile Ser 35 40 45 Val Leu Asn Glu Tyr Gly Ile Gly Met Thr Trp Val Leu His His Glu 50 55 60 Ser Asp Met Gln Asn Tyr Ala Ala Tyr Gly Gln Ala Asn Gly Asn His 70 75 65 80 Ile Glu Ala Asn Phe Asn Ala Lys Pro Gly Lys Tyr Tyr Leu Tyr Val 85 90 95 Tyr Lys Tyr Asp Asn Gly Asp Gly Thr Tyr Glu Leu Ser Val Lys 100 105 110 <210> SEQ ID NO 18 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: Bacillus sp. <400> SEQUENCE: 18 Lys Thr Glu Ile Glu Pro Asn Asn Arg Pro Glu Glu Ala Thr Met Leu 1 5 10 15 Pro Phe Asn Thr Pro Leu Ser Gly Ser Leu Met Glu Asp Asp His Thr 20 25 30

-continued

Asp Val Tyr Glu Phe Asn Val Thr Ser Pro Lys Glu Ile Asp Ile St 40 Val Leu Asn Glu Asn Gln Ile Gly Met Thr Trp Val Leu Tyr His G 50 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Asp Gly Asn M 65 70 70 81 11e Asn Gly Lys Trp Asn Ala Lys Pro Gly Lys Tyr Tyr Leu Tyr V. 95 70 7
50 55 60 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Asp Gly Asp Me G1 G1 Asp Gly Lys Trp Asn Ala Lys Pro Gly Lys Tyr Tyr Leu Tyr V 1le Asn Gly Lys Trp Asn Ala Lys Pro Gly Lys Tyr Tyr Leu Tyr V 85 Fri Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Tyr Tyr V Fri Tyr V $<210>$ SEQ ID NO 19 $<211>$ LENGTH: 111 $<212>$ TYPE: PRT $<213>$ ORGANISM: L. sphaericus $<<<$
65 70 75 84 Ile Asn Gly Lys Rrp Asn Ala Lys Pro 90 90 Gly Lys Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Tyr Tyr Lys Phe Glu Asn Glu Asn Gly Thr 105 Tyr Tyr Tyr Lys Phe Glu Asn Glu Asn Asn Asn Arg Pro 100 Glu Ala Thr 116 Tyr Lys Ala Glu Ile Glu Pro Asn Asn Arg Pro 100 Glu Ala Thr 115 Thr 115 Thr 115 200 SEQUENCE: 19 10 Glu Asn Thr Pro Leu Lys Gly Arg Leu Met Asn Asn Ang Asn
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
100 105 110 <210 SEQ ID NO 19 <211 LENGTH: 111 <2122 TYPE: PRT <213 ORGANISM: L. sphaericus <400 SEQUENCE: 19 Lys Ala Glu Ile Glu Pro Asn Asn Arg Pro Glu Glu Ala Thr Ile La 1 5 10 10 10 10 11 15 10 10 10 10 11 15 10 10 10 10 11 15 10 10 10 10 10 11 15 10 10 10 10 10 11 15 10 10 10 10 10 10 10 10 10 10 10 10 10
<pre><211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: L. sphaericus <400> SEQUENCE: 19 Lys Ala Glu Ile Glu Pro Asn Asn Arg Pro Glu Glu Ala Thr Ile La 1 5 10 Pro Phe Asn Thr Pro Leu Lys Gly Arg Leu Met Asp Asp Asp His TI 20 Asp Val Tyr Glu Phe Asn Val Thr Ser Pro Lys Glu Leu Asp Ile Sa 35 Val Leu Asn Glu Asn Arg Ile Gly Met Thr Trp Val Leu Tyr His G 50 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Glu Gly Asn Ma 65 Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 100 <210> SEQ ID NO 20 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus</pre>
<pre><400> SEQUENCE: 19 Lys Ala Glu Ile Glu Pro Asn Asn Arg Pro Glu Glu Ala Thr Ile La 1 S 10 Glu Asn Thr Pro Leu Lys Gly Arg Leu Met Asp Asp Asp His Th 20 Pro Phe Asn Thr Pro Leu Lys Gly Arg Leu Met Asp Asp Asp His Th 30 Asp Val Tyr Glu Phe Asn Val Thr Ser Pro Lys Glu Leu Asp Ile Sa 40 Ser Asp Glu Asn Glu Asn Arg Ile Gly Met Thr Trp Val Leu Tyr His Gl 50 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Glu Gly Asn Ma 65 Asp Cal Lys Leu His Ala Glu Pro Gly Lys Tyr Tyr Leu Tyr Va 85 Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 100 Sec ID NO 20 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus</pre>
Lys Ala Glu Ile Glu Pro Asn Asn Arg Pro Glu Glu Ala Thr Ile Lorent 1 1 Pro Phe Asn Thr Pro Leu Lys Gly Arg Leu Met Asp Asp Asp Asp His The 20 Pro Leu Lys Gly Arg Leu Met Asp Asp Asp Asp His The 30 Asp Val Tyr Glu Phe Asn Val Thr Ser Pro Lys Glu Leu Asp Ile Set 35 Val Leu Asn Glu Asn Arg Ile Gly Met Thr Trp Val Leu Tyr His G 50 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Glu Glu Gly Asn Me 65 Asp Ser Gln Asn Tyr Ala Ser Phe Gly Lys Tyr Tyr Leu Tyr Val 11e Asn Gly Lys Leu His Ala Glu Pro Gly Lys Tyr Tyr Leu Tyr Va 50 Set Ile Asn Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 51 Constant 110 52 Set ID NO 20 52 Set ID NO 20 52 Set ID NO 20 52 Set ID NO 20 53 Set ID NO 20 54 Set II LeuGTH: 111 55 Set ID NO 20 55 Set ID NO 20
1 5 10 15 Pro Phe Asn Thr Pro Leu Lys Gly Arg Leu Asp Asp Asp Asp Mas Mis T Asp Val Tyr Glu Phe Asn Val Thr Ser Pro Leu Asp Asp Asp His T Val Leu Asp Glu Phe Asn Val Thr Ser Pro Lys Glu Leu Asp Ile Ile Asp Ile Asp Ile Asp Ile
202530Asp Val Tyr Glu Phe Asn Val Thr Ser Pro Lys Glu Leu Asp Ile So35Val Leu Asn Glu Asn Arg Ile Gly Met Thr Trp Val Leu Tyr His G5055Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Glu Glu Gly Asn Me65701le Asn Gly Lys Leu His Ala Glu Pro Gly Lys Tyr Tyr Leu Tyr V857yr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln100<210> SEQ ID NO 20<211> LENGTH: 111<212> TYPE: PRT<213> ORGANISM: C. cerus
35 40 45 Val Leu Asn Glu Asn Arg Ile Gly Met Thr Trp Val Leu Tyr His G 50 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Glu Glu Gly Asn Me 65 70 Ile Asn Gly Lys Leu His Ala Glu Pro Gly Lys Tyr Tyr Leu Tyr V: 85 Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 100 <210> SEQ ID NO 20 <211> LENGTH: 111 <213> ORGANISM: C. cerus
50 55 60 Ser Asp Ser Gln Asn Tyr Ala Ser Phe Gly Gln Glu Glu Gly Asn Me 65 70 75 75 88 Ile Asn Gly Lys Leu His Ala Glu Pro Gly Lys Tyr Tyr Leu Tyr Ve 85 90 90 97 Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 100 105 110 <210> SEQ ID NO 20 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus
65 70 75 84 Ile Asn Gly Lys Leu His Ala Glu Pro Gly Lys Tyr Tyr Leu Tyr V 85 90 95 Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 100 105 110 <210> SEQ ID NO 20 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus
85 90 95 Tyr Lys Phe Glu Asn Glu Asn Gly Thr Tyr Thr Val Gln Val Gln 100 105 110 <210> SEQ ID NO 20 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus
100 105 110 <210> SEQ ID NO 20 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus
<211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: C. cerus
<400> SEQUENCE: 20
Val Thr Glu Asn Glu Pro Asn Asn Glu Pro Arg Gln Ala Asn Lys Va 1 5 10 15
Asn Phe His Thr Pro Val Lys Gly Thr Leu His Asn Ser Asp Arg Va 20 25 30
Asp Val Phe Thr Phe Gln Ile Asp Ser Pro Glu Asn Ile Asn Ile S 35 40 45
Leu Leu Asn Glu Gln Asn Ile Gly Met Thr Trp Val Leu His His G 50 55 60
Ser Asp Leu Asn Asn Tyr Val Ala Tyr Gly Glu Asn Glu Gly Asn V 65 70 75 80
Val Lys Gly Thr Tyr Asn Ala Lys Pro Gly Lys Tyr Tyr Leu Tyr V 85 90 95
Tyr Lys Tyr Glu Asn Lys Asp Gly Ser Tyr Val Leu Asn Ile Lys 100 105 110
<210> SEQ ID NO 21

<210> SEQ ID NO 21 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: B. mycoides

<400> SEQUENCE: 21

<400> SEQUENCE:	21												
Ser Val Glu Lys 1	Glu Pro Asn 5	Asn Ser Pho 10	e Gln Thr Ala	Asn Lys Leu 15									
Gln Leu Asn Gln 20	Leu Leu Arg	Ala Ser Lev 25	ı Gly Asn Gly	Asp Thr Ser 30									
Asp Tyr Phe Glu 35	Ile Asn Val	Glu Thr Ala 40	a Arg Asn Leu 45	Gln Ile Asn									
Val Thr Lys Glu 50	Asn Asn Ile 55	Gly Val As	n Trp Val Leu 60	Tyr Ser Ala									
Ala Asp Leu Asn 65	Asn Tyr Val 70	Thr Tyr Ala	a Gln Thr Gln 75	Gly Asn Lys 80									
Leu Val Gly Ser	Tyr Asn Ala 85	His Pro Gly 90	y Lys Tyr Tyr	Leu His Val 95									
Tyr Gln Tyr Gly 100	Gly Gly Thr	Gly Asn Ty: 105	r Thr Val Glu	Val Lys 110									
<210> SEQ ID NO 22 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: B. weihensteph													
<400> SEQUENCE:	22												
Ala Val Glu Lys 1	Glu Pro Asn 5	Asn Ser Pho 10	e Asp Ala Ala	Asn Pro Leu 15									
Ser Leu Asn Ala 20	Leu Leu Arg	Gly Asn Lev 25	ı Ser Asp Gln	Asp Gln Val 30									
Asp Arg Phe Val 35	Ile Asp Val	Lys Asp Pro 40	o Lys Asp Leu 45	Gln Ile Thr									
Val Thr Asn Glu 50	Gln Asn Leu 55	. Gly Leu Ası	n Trp Val Leu 60	Tyr Ser Glu									
Ser Asp Leu Asn 65	Asn Tyr Val 70	Thr Tyr Ala	a Thr Lys Arg 75	Asp Gly Asn 80									
Lys Leu Leu Gly	Asn Tyr Asn 85	. Ala Lys Pro 90	o Gly Lys Tyr	Tyr Leu Ser 95									
Val Tyr Lys Tyr 100	Gly Gly Gly	Thr Gly As 105	n Phe Thr Val	Glu Val Lys 110									
<210> SEQ ID NO 23 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: B. brevis													
<400> SEQUENCE:	23												
Glu Lys Glu Gln 1	Glu Pro Asn 5	Asn Ser Pho 10	e Ser Glu Ala	Asn Pro Leu 15									
Lys Ser Asn Val 20	Glu Leu Ser	Gly Gln Th: 25	r Ser Lys Gln	Asp Asp Lys 30									
Asp Ile Phe Ala 35	Leu Lys Val	Leu Gly As 40	n Gly Thr Val 45	Lys Ile Asn									
Val Thr Ser Glu 50	His Asp Thr 55	Gly Leu Ası	n Trp Val Val 60	His His Glu									
Asp Asp Leu Asn 65	Asn Tyr Leu 70	. Ala Tyr Pro	o Lys Thr Ser 75	Gly Lys Thr 80									

57

-continued

Leu	Ser	Gly	Glu	Phe 85	Glu	Ala	Thr	Pro	Gly 90	Thr	Tyr	Tyr	Leu	Ser 95	Val
Tyr	Asn	Phe	Asn 100	Gly	Glu	Thr	Ile	Pro 105		Lys	Val	Thr	Ala 110	Glu	
<212	> LI > T	ENGTI YPE :	H: 1 PRT		brev.	is									
<400	> SI	EQUEI	NCE :	24											
Pro 1	Thr	Glu	Val	Glu 5	Pro	Asn	Asn	Ser	Phe 10	Asp	Asp	Ala	Asn	Thr 15	Leu
Gln	Leu	Gly	Lys 20	Glu	Ile	Ser	Gly	Gln 25	Thr	Asp	Arg	Thr	Asp 30	Asp	ГЛа
Asp	Thr	Tyr 35	Met	Ile	Gln	Val	Glu 40	Glu	Glu	Gly	Val	Ile 45	Gln	Val	Thr
Val	Ser 50	Ser	Glu	ГЛа	Aap	Glu 55	Gly	Leu	Asn	Trp	Val 60	Val	Phe	His	Glu
Asp 65	Asp	Leu	Lys	Thr	Tyr 70	Phe	Ala	Tyr	Pro	Lys 75	Thr	Thr	Gly	Lys	ГЛа 80
Leu	Thr	Gly	Glu	Phe 85	Glu	Ala	Lys	Pro	Gly 90	Lys	Tyr	Tyr	Leu	Leu 95	Val
Tyr	Asn	Thr	Asn 100	Asn	Thr	ГÀа	Ile	Pro 105	Tyr	ГÀа	Ala	Ile	Val 110	Asn	
<212 <213	> T > OI	ENGTI IPE : RGANI EQUEI	PRT ISM:	С. ј	perf:	ring	ens								
Ile 1	Lys	Glu	Val	Glu 5	Asn	Asn	Asn	Asp	Phe 10	Asp	ГЛа	Ala	Met	Lys 15	Val
Asp	Ser	Asn	Ser 20	Lys	Ile	Val	Gly	Thr 25	Leu	Ser	Asn	Asp	Asp 30	Leu	Lys
Asp	Ile	Tyr 35	Ser	Ile	Asp	Ile	Lys 40	Asn	Pro	Ser	Asp	Leu 45	Asn	Ile	Val
Val	Glu 50	Asn	Leu	Asp	Asn	Ile 55	Lys	Met	Asn	Trp	Leu 60	Leu	Tyr	Ser	Ala
Asp 65	Asp	Leu	Ser	Asn	Tyr 70	Val	Asp	Tyr	Ala	Asn 75	Ala	Aap	Gly	Asn	Lуя 80
Leu	Ser	Asn	Thr	Cys 85	Lys	Leu	Asn	Pro	Gly 90	Lys	Tyr	Tyr	Leu	Сув 95	Val
Tyr	Gln	Phe	Glu 100	Asn	Ser	Gly	Thr	Gly 105	Asn	Tyr	Thr	Val	Asn 110	Leu	Gln
<211 <212	> LI > T	EQ II ENGTH YPE : RGANI	H: 1 PRT	15	spore	ogene	es								
<400	> SI	EQUEI	NCE :	26											
Ile 1	Ser	Glu	Lys	Glu 5	Asp	Asn	Asp	Ser	Phe 10	Asp	ГЛа	Ala	Asn	Arg 15	Val
Gly	Lys	Asn	Gln 20	Thr	Val	Leu	Ala	Thr 25	Leu	Asp	Thr	ГÀа	Asp 30	Asn	Arg

-continued

Asp	Thr	Tyr 35	Tyr	Phe	Asp	Ala	Leu 40	Ala	Ala	Arg	Thr	Ile 45	Asp	Ile	Val
Met	Glu 50	Asn	Thr	Asp	Asn	Asn 55	Ser	Thr	Ile	Phe	Asn 60	Trp	Leu	Ala	Tyr
Ser 65	Ser	Asp	Asn	Thr	Asn 70	Asn	Tyr	Ile	Gly	Tyr 75	Pro	Thr	Lys	Гла	Glu 80
Gly	Asn	Lys	Leu	Met 85	Gly	Ser	Phe	Lys	Val 90	Pro	Lys	Pro	Gly	Arg 95	Tyr
Tyr	Ile	Leu	Ala 100	Tyr	ГЛа	Asn	Ser	Ser 105	Asn	Lys	Ile	Asn	Tyr 110	Lys	Leu
Thr	Ile	Asn 115													
<211 <212	210> SEQ ID NO 27 211> LENGTH: 115 212> TYPE: PRT 213> ORGANISM: C. botulinum														
<400)> SI	EQUEI	NCE :	27											
Ile 1	Ser	Glu	Lys	Glu 5	Asp	Asn	Asn	Ser	Phe 10	Asp	ГЛа	Ala	Asn	Arg 15	Val
Cys	Lys	Asn	Gln 20	Ser	Val	Ile	Ala	Thr 25	Leu	Asp	Thr	Asn	Asp 30	Pro	Arg
Asp	Thr	Tyr 35	Tyr	Phe	Asp	Ala	Leu 40	Thr	Ala	Gly	Asn	Ile 45	Glu	Val	Thr
Met	Gly 50	Asn	Thr	Aap	Asn	Ser 55	Ser	Asn	Glu	Phe	Asn 60	Trp	Leu	Ala	Tyr
Ser 65	Ser	Asp	Asn	Thr	Asn 70	Asn	Tyr	Ile	Gly	Tyr 75	Ala	Thr	Lys	Arg	Glu 80
Gly	Asn	Lys	Ile	Thr 85	Gly	Asn	Phe	Lys	Val 90	Asp	Lys	Pro	Gly	Arg 95	Tyr
Tyr	Ile	Val	Ala 100	Tyr	ГЛа	Thr	Ser	Ser 105	Asn	Lys	Ile	Asn	Tyr 110	Lys	Leu
Asn	Ile	Lys 115													
		EQ II ENGTI													
<212	2> T	YPE:	PRT		spor	ogen	es								
		equei			- '	5 -									
Val 1	Ser	Glu	Lys	Glu 5	Asp	Asn	Asn	Asp	Phe 10	Thr	Thr	Ala	Asn	Pro 15	Val
Tyr	Tyr	Lys	Asp 20	Leu	Val	Asn	Gly	Ser 25	Val	Ser	Ser	Ser	Asp 30	Asn	Lys
Asp	Thr	Phe 35	Tyr	Phe	Thr	Val	Thr 40	Lys	Pro	Ser	Aap	Ile 45	Thr	Ile	Thr
Val	Glu 50	Lys	Thr	Asn	Asn	Asp 55	Lys	Ser	Glu	Phe	Asn 60	Trp	Leu	Leu	Phe
Ser 65	Asp	Glu	Asp	ГЛа	Ser 70	Asn	Tyr	Met	Ala	Phe 75	Pro	Asn	Lys	Glu	Leu 80
	Asn	Gln	Leu	Ser 85		Thr	Val	Lys	Ile 90		Lys	Pro	Gly	Lys 95	
									20					22	

-continued

Tyr Le	u V	al	Ile 100	Tyr	Lys	Thr	Leu	Gly 105	Glu	Lys	Val	Asp	Tyr 110	Lys	Phe
Ser Il		lu 15													
<210> <211> <212> <213>	LEN TYP	GTH E :	I: 13 PRT	15	botu	linu	n								
<400>	SEQ	UEN	ICE :	29											
Val Se 1	r G	lu	Lys	Glu 5	Asn	Asn	Asn	Asp	Tyr 10	Val	Asn	Ala	Asn	Pro 15	Val
Tyr Se	r L	Уa	Asp 20	Leu	Val	Asn	Gly	Ser 25	Val	Ser	Ser	Ser	Asp 30	Asp	Arg
Asp Il		he 5	Tyr	Phe	Asn	Val	Thr 40	ГЛа	Pro	Ser	Asp	Ile 45	Thr	Ile	Asn
Val Gl 50		уs	Ile	Asn	ГЛа	Asp 55	ГЛа	Ser	Glu	Phe	Ser 60	Trp	Leu	Leu	Phe
Ser Gl 65	u G	lu	Asp	гла	Ser 70	Asn	Tyr	Ile	Thr	Tyr 75	Pro	Asn	Гла	Glu	Leu 80
Glu As	n L	eu	Phe	Tyr 85	Ser	Thr	Val	Гла	Ile 90	Asp	ГЛЗ	Pro	Gly	Lys 95	Tyr
Tyr Le	u V	al	Ile 100	Tyr	Гла	Val	Ser	Gly 105	Glu	ГАЗ	Ser	Asp	Tyr 110	Arg	Phe
Asn Il		lu 15													
<210> <211> <212> <213>	LEN TYP	GTH E :	I: 1: PRT	13	sord	elli	i								
<400>	SEQ	UEN	ICE :	30											
Gly Va 1	1 G	lu	Gln	Glu 5	Asp	Asn	Asn	Ser	Phe 10	Glu	Lys	Ala	Asn	Pro 15	Phe
Ser Il	еA	sn	Gln 20	Leu	Val	Lys	Gly	Glu 25	Leu	Asp	Asn	Asn	Lys 30	Asp	Thr
Ser As	-	yr 5	Phe	Гла	Phe	Glu	Val 40	Lys	Glu	Asp	Ala	Gln 45	Leu	Asn	Ile
Ser Le 50		lu	Lys	Thr	Glu	Gly 55	Asp	Gly	Val	Asn	Trp 60	Leu	Leu	Phe	Lys
Asp Se 65	r A	ap	Leu	Glu	Asn 70	Tyr	Ile	Ala	Ser	Pro 75	Thr	Glu	Ser	Ile	Aap 80
Asn Ly	s L	eu	Asn	Gly 85	Lys	Val	Asp	Leu	Lys 90	Val	Gly	Thr	Tyr	Tyr 95	Leu
Glu Va	1 T	yr	Gly 100	Tyr	Gly	Ser	Ser	Pro 105	Val	Lys	Tyr	Asn	Phe 110	Lys	Val
Thr															

<210> SEQ ID NO 31 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Clostridium histolyticum

-400> SEQUENCE: 31 The Lyo Glu Met Glu Pro Ann Ang Ang Lib ya Glu Ala Ang Gly Pro 1a Val Glu Qly Val Thr Val Lyo Gly Ang Leu Ang Gly Ang Val Thr 11e 20 20 Ala Ang Thr Pho Tyr Pho Ang Val Lyo Glu Ala Gly Ang Val Thr 11e 61u Leu Pro Tyr Ser Gly Ser Ser Ang Pho Thr Trp Leu Val Tyr Lyo So Val Ang Tyr Ser Gly Ang Ang Glu Ang His 11e Ala Ser Gly 11e Ang Lyo Ang Ang Ang Glu Ang His 11e Ala Ser Gly Thr Ser Leu Ang 11e 61u Tyr Lyo His Ang Ser Ala Ser Ang Pho Thr 1yo Gly Ang His Tyr Val Pho 265 (2010 NO 32) 2210> SEQ ID NO 32 2211> EENGTH: 113 2222> TYPE PRT 2110 Jong Ang Glu Pho Ang Nang Ang Pho Glu Lyo Ala Ang Glu Ang Tyr 20 1a Tyr Lyo His Ang Ser Thr Lyo Gly Ang His Tyr Val Pho 265 (2010 NO 32) 2210> SEQ ID NO 32 2210> SEQ UENCE: 32 1a Lyo Seq Jup Tyr Tyr Pho Ang Ang Pho 10 Thr Leu Ser Glu Glu Ang Tyr 20 1a Lyo Seq Jup Tyr Tyr Pho Ang Yan Ang Pho 10 Lyo Ala Ang Glu Glu Ang Tyr 20 1a Lyo Seq Jup Tyr Tyr Pho Ang Ang Chy For 10 Thr Leu Tyr Lyo 10 Ang Tyr 100 1b Law Ang Ang Leu Ang Ser Val Gly Thr Leu Glu Ang Tyr 1yr Leu 56 1b Lyo Seq UENCE: 32 1b Lyo Seq UENCE: 32 1b Leu Lyo Gly Glu Lyo Thr Leu Glu Ang Tyr Tyr Leu 50 1b Lyo Seq UENCE: 33 1b Leu Lyo Gly Glu Lyo Thr Leu Glu Ang Tyr Tyr 20 1b Lyo														
1 5 10 15 11e Val Gu Gly Val Thr Val Lye Gly Aep Leu Aen Gly Ser Aep Aep 20 Aep Aep 20 Ala Aep Thr Phe Tyr Phe Aep Val Lye Glu Aep Gly Aep Val Thr Ile 35 Glu Leu Pro Tyr Ser Gly Ser Ser Aen Phe Thr Trp Leu Val Tyr Lye 60 Glu Gly Aep Aep Gln Aen His Ile Ala Ser Gly Ile Arp Lye Aen Aen 80 Ser Lye Val Gly Thr Phe Lye Ser Thr Lye Gly Arg His Tyr Val Phe 95 Glu Gly Aep Aep Gln Aen His Ile Ala Ser Gly Ile Arp Lye Aen Aen 80 Ser Lye Val Gly Thr Phe Lye Ser Thr Lye Gly Arg His Tyr Val Phe 95 Gle Tyr Lye His Aep Ser Ala Ser Aen Ile Ser Tyr Ser Leu Aen Ile 100 100 Lye Collor No 32 Callo SEQUENCE: 32 11 He Aen Glu Ser Glu Pro Aen Aen Aep Phe Glu Lye Ala Aen Gln Ile 1 Ala Lye Ser Aen Het Leu Val Lye Gly Thr Leu Ser Glu Glu Aep Tyr 1/20 Ser Aep Lye Tyr Tyr Phe Aep Val Ala Lye Uye Gly Aen Val Lye 10/25 Thr Leu Aen Aen Leu Aen Ser Val Gly Ile Thr Trp Thr Leu Tyr Lye 50 Glu Gly Aep Leu Aen Aen Tyr Val Leu Tyr Ala Thr Gly Aen Glu Cly Thr Val Leu Lye Gly Glu Lye Thr Leu Glu Pro Gly Arg Tyr Tyr Leu 85 Ser Val Tyr Thr Tyr Aep Aen Gln Ser Gly Ala Tyr Thr Val Aen Val 100 100 105 100 105 101 100 102 101 103 101	<400> SEQUENCE:	31												
20253030Ala Aop Thr Phe Tyr Phe Aop Val Lys Glu Aop Gly Aop Val Thr Ile 353045Glu Leu Pro Tyr Ser Gly Ser Ser Ann Phe Thr Trp Leu Val Tyr Lys 503030Glu Gly Aop Aop Gln Aon His Ile Ala Ser Gly Ile Aop Lys Aon Aon 753530Ser Lys Val Gly Thr Phe Lys Ser Thr Lys Gly Arg His Tyr Val Phe 8595Ile Tyr Lys His Asp Ser Ala Ser Aon Ile Ser Tyr Ser Leu Aon Ile 100100Lys10032<211> EENOTH: 113 (212) SEQ UENCE: 3232Ile Aon Glu Ser Glu Pro Aon Aon Aop Phe Glu Lys Ala Aon Gln Ile 1115Ala Lys Ser Aon Met Leu Val Lys Gly Thr Leu Ser Glu Glu Aop Tyr 2530Ser Aop Lys Tyr Tyr Phe Aop Val Ala Lys Lys Gly Aon Val Lys Ile 40Glu Gly Asp Aon Aon Tyr Val Leu Tyr Ala Thr Gly Aon Glu Gly 80Glu Gly Asp Leu Aon Aon Tyr Val Leu Tyr Ala Thr Gly Aon Glu Gly 105LysSer Val Tyr Thr Tyr Asp Aon Gln Ser Gly Ala Tyr Tyr Leu 90Ser Val Tyr Thr Tyr Asp Aon Gln Ser Gly Ala Tyr Tyr Val Aon Val 100Lys<211> EENOTH: 113 (212)<212> TPE: PRT (213)<213> CRGANISM: C. cordellii<400> SEQUENCE: 33Ser Gln Glu Val Gly Aon Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 15Ser Ile Kaon In Ser Gly Ala Ser Gly App Leu Ser Asp Thr Aop Aon 10<213> CRGANISM: C. cordellii<400> SEQUENCE: 33Ser Gln Glu Val Gly Ann Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 15Ser Val Tyr Thr Tyr Tyr Phe Asn Tyr Ser Gly App Leu Ser Asp Thr App Aon 10<213> CRGANISM: C. cordellii<400>	-		sn Asp Asp	-	-	Pro								
35 40 45 Glu Leu Pro Tyr Ser Gly Ser Ser Aen Phe Thr Trp Leu Val Tyr Lyg 50 60 Glu Gly Aep Aep Gln Aen His Ile Ala Ser Gly Ile Aep Lys Aen Aen 75 70 Ser Lys Val Gly Thr Phe Lye Ser Thr Lys Gly Arg His Tyr Val Phe 95 95 Ser Lys Val Gly Thr Phe Lye Ser Thr Lys Gly Arg His Tyr Val Phe 100 95 Ile Tyr Lys His Aep Ser Ala Ser Ann Ile Ser Tyr Ser Leu Aen Ile 10 110 Lys 2210> SEQ ID NO 32 2211> LENGTH: 113 2212> TYPE: PRT 2213> ORGANISM: C. perfringens 40 <400> SEQUENCE: 32 11 10 Ile Aen Glu Ser Glu Pro Aen Aen Aep Phe Glu Lys Ala Aen Gln Ile 15 15 Ala Lys Ser Aen Met Leu Val Lys Gly Thr Leu Ser Glu Glu Aep Tyr 20 20 Ser Aep Lye Tyr Tyr Phe Aep Val Ala Lye Lys Gly Aen Val Lys Ile 45 45 Thr Leu Aan Aen Leu Aen Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys 60 80 Glu Gly Aep Leu Aen Aen Tyr Val Leu Tyr Ala Thr Gly Aen Glu Gly 80 95 Ser Val Tyr Thr Tyr Aep Aen Gln Ser Gly Ala Tyr Thr Val Aen Val 100 100 Lys 100 10 100 Ser Gln Glu Val Gly Aen Aep Aen Thr Phe Glu Thr Ala Aen Gly Pro 11 100 Lys 110 12 Ser Gln Glu Val Gly Aen Aep Aep	-	Val Thr V		Asp Leu Asn		Asp								
50 55 60 Glu Gly Asp Asp Gln Asm His Ile Ala Ser Gly Ile Asp Lys Asm Asm 80 50 Ser Lys Val Gly Thr Phe Lys Ser Thr Lys Gly Arg His Tyr Val Phe 95 95 Ile Tyr Lys His Asp Ser Ala Ser Asn Ile Ser Tyr Ser Leu Asm Ile 100 100 Lys 2210> SEQ ID NO 32 <211> SEQ ID NO 32 2213 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. perfringens <400> SEQUENCE: 32 Ile Asm Glu Ser Glu Pro Asm Asm Asp Phe Glu Lys Ala Asm Gln Ile 15 Ala Lys Ser Asm Met Leu Val Lys Gly Thr Leu Ser Glu Glu Asp Tyr 20 Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Asm Val Lys Ile 45 Thr Leu Asm Asm Leu Asm Ser Val Gly Ile Thr Tyr Dr Leu Tyr Lys 60 Glu Gly Asp Leu Asm Asm Tyr Val Leu Tyr Ala Thr Gly Asm Glu Gly 85 Ser Val Tyr Thr Tyr Asp Asm Gln Ser Gly Ala Tyr Thr Val Asm Val 100 Lys Ys Ser Val Tyr Thr Tyr Asp Asm Gln Ser Gly Ala Tyr Thr Val Asm Val 100 Lys Ser Gln Glu Va Gly Asm Asp Thr Phe Glu Thr Ala Asm Gly Pro 10 Lys Ser Gln Glu Val Gly Asm Asp Asp Thr Phe Glu Thr Ala Asm Gly Pro 15 Ser Gln Glu Val Gly Asm Asp Asp Thr Phe Glu Thr Ala Asm Gly Pro 15 Ile Lys Ile Asm Thr Asm Tyr Ser Gly Asp Leu Ser Asp Thr Asp A	Ala Asp Thr Phe		sp Val Lys		-	Ile								
65 70 75 80 Ser Lys Val Gly Thr Phe Lys Ser Thr Lys Gly Arg His Tyr Val Phe $\frac{95}{90}$ 95 Ile Tyr Lys His Asp Ser Ala Ser Asn Ile Ser Tyr Ser Leu Asn Ile $\frac{100}{105}$ 95 Vertice Total Sec Thr 100 105 95 Ile Tyr Lys His Asp Ser Ala Ser Asn Ile Ser Tyr Ser Leu Asn Ile $\frac{100}{105}$ 95 Vertice Total Sec Thr 100 105 100 Lys 110 100 Callo SEQ ID NO 32 211> LENGTH: 113 Callo SEQUENCE: 32 11 11 11 5 10 15 Ala Lys Ser Asn Met Leu Val Lys Gly Thr Leu Ser Glu Glu Asp Tyr 20 30 10 Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Ann Val Lys Ile 45 10 11 11 50 10 10 10 120 125 70 12 10 12 11 80 11 11 12 120 13 10 12 11 11 120 13 10 12 12 12 120 13 10 12 12 12	-	Ser Gly S		Phe Thr Trp	_	Lys								
859095Ile Tyr Lys His Asp Ser Ala Ser Asn Ile Ser Tyr Ser Leu Asn Ile 100105110Lys<210> SEQ ID NO 32 <2111> LENGTH: 113 <2123> VERGANISM: C. perfringens<400> SEQUENCE: 32Ile Asn Glu Ser Glu Pro Asn Asn Asp Phe Glu Lys Ala Asn Gln Ile 101Ala Lys Ser Asm Met Leu Val Lys Gly Thr Leu Ser Glu Glu Asp Tyr 20Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Asm Val Lys Ile 45Thr Leu Asn Asn Leu Asn Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys 60Glu Gly Asp Leu Asn Asn Tyr Val Leu Tyr Ala Thr Gly Asn Glu Gly 85Ser Val Tyr Thr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100Lys<210> SEQ ID NO 33 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii<210> SEQ ID NO 33 <211> Leu Tyr Thr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100Lys<210> SEQ ID NO 33 <211> Leu Tyr Er PRT <213> ORGANISM: C. sordellii<400> SEQUENCE: 33Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 10Lys Asp Tyr Tyr Tyr Phe Asp Cly Asp Asn Pro Ser Asn Ile 20Lys Asp Tyr Tyr Tyr Phe Asp Leu Asp Asn Pro Ser Asn Ile Asn Ile 20Lys Asp Tyr Tyr Tyr Phe Asp Asp Lys Gly Ile Ser Trp Gln Leu Phe His 50Glu Stev Asp Leu Asn Asp Asp Thry Phe Glu Thr Asp Asn 120Lys Asp Tyr Tyr Tyr Phe Asp Asp Leu Ser Asp Pro Ser Asn Ile 45Ile Lys Ile Asn Thr Asp Asm 125Glu Asn Leu Asp Asm Lys Gly Ile Ser Trp Gln Leu Phe His 50Glu Ser Asp Leu Asn Asp Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala			is Ile Ala		Asp Lys Asn									
100 105 110 Lys <211> LENGTH: 113 <212> TTPE: PRT <213> ORGANISM: C. perfringens <400> SEQUENCE: 32 Ile Aan Glu Ser Glu Pro Aan Aan Aap Phe Glu Lys Ala Aan Gln Ile 1 5 Ala Lys Ser Aan Met Leu Val Lys Gly Thr Leu Ser Glu Glu Aap Tyr 20 55 Ser Aap Lys Tyr Tyr Phe Aap Val Ala Lys Lys Gly Aan Val Lys Ile 45 45 Thr Leu Aan Aan Leu Aan Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys 60 60 Glu Gly Asp Leu Aan Aan Ser Val Gly Ile Thr Gly Aan Glu Gly 70 75 Ser Val Tyr Thr Tyr Aap Aan Gln Ser Gly Ala Tyr Thr Val Aan Val 85 90 90 95 Ser Val Tyr Thr Tyr Aap Aan Gln Ser Gly Ala Tyr Thr Val Aan Val 100 105 Lys 85 Ser Val Tyr Thr Tyr Aap Aan Gln Ser Gly Ala Tyr Thr Val Aan Val 100 105 Lys 85 Ser Gln Glu Val Gly Aan Aap App Thr Phe Glu Thr Ala Aan Gly Pro 110 11 Lys 85 Ser Gln Glu Val Gly Aan Aap App Thr Phe Glu Thr Ala Aan Gly Pro	Ser Lys Val Gly				His Tyr Val									
<pre><pre><pre><pre><pre><pre><pre><pre></pre></pre></pre></pre></pre></pre></pre></pre>	Ile Tyr Lys His		la Ser Asn		Ser Leu Asn									
<pre>-211> LENGTH: 113 -212> TYPE: PRT -213> ORCANISM: C. perfringens -4400> SEQUENCE: 32 Ile Asn Glu Ser Glu Pro Asn Asn Asp Phe Glu Lys Ala Asn Gln Ile 1 5 10 15 Ala Lys Ser Asn Met Leu Val Lys Gly Thr Leu Ser Glu Glu Asp Tyr 20 Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Asn Val Lys Ile 45 Thr Leu Asn Asn Leu Asn Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys 60 Glu Gly Asp Leu Asn Asn Tyr Val Leu Tyr Ala Thr Gly Asn Glu Gly 75 Ser Val Tyr Thr Tyr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100 Lys -210> SEQ ID NO 33 -211> LENGTH: 113 -212> TYPE: PRT -213> ORGANISM: C. sordellii Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 1 Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 20 Lys Asp Tyr Tyr Thr Asp Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 35 Thr Leu Glu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala </pre>	Lys													
Ile Asn Glu Ser Glu Pro Asn Asn Asn Asn Phe Glu Lys Ala Asn Gln Ile11 <t< td=""><td colspan="14"><210> SEQ ID NO 32 <211> LENGTH: 113 <212> TYPE: PRT</td></t<>	<210> SEQ ID NO 32 <211> LENGTH: 113 <212> TYPE: PRT													
151015Ala Lys Ser Asn Met Leu Val Lys Gly Thr Leu Ser Glu Glu Asp Tyr 20Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Asn Val Lys Ile 40Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Asn Val Lys Ile 45Thr Leu Asn Asn Leu Asn Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys 50Glu Gly Asp Leu Asn Asn Tyr Val Leu Tyr Ala Thr Gly Asn Glu Gly 80Glu Gly Asp Leu Asn Asn Tyr Val Leu Glu Pro Gly Arg Tyr Tyr Leu 95Ser Val Tyr Thr Tyr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 	<400> SEQUENCE:	32												
20 25 30 Ser Asp Lys Tyr Tyr Phe Asp Val Ala Lys Lys Gly Asn Val Lys Ile 35 Val Gly Asn Asn Leu Asn Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys 50 Glu Gly Asp Leu Asn Asn Tyr Val Leu Tyr Ala Thr Gly Asn Glu Gly 65 70 70 75 rd Gly Arg Tyr Tyr Leu 90 Pro Gly Arg Tyr Tyr Leu 90 Pro Gly Arg Tyr Tyr Leu 95 Ser Val Tyr Thr Tyr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100 105 105 100 110 100 Lys <210> SEQ ID NO 33 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii $<400> SEQUENCE: 33Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro1 control 10 contr$			sn Asn Asp	-		Ile								
$\frac{35}{50} = \frac{40}{50} = \frac{45}{60}$ Thr Leu Asn Asn Leu Asn Ser Val Gly Ile Thr Trp Thr Leu Tyr Lys $\frac{60}{50} = \frac{55}{50} = \frac{55}{70} =$	-	. Met Leu V		Thr Leu Ser	-	Tyr								
50 55 60 Glu Gly Asp Leu Asn Asn Tyr Val Leu Tyr Ala Thr Gly Asn Glu Gly 65 70 70 70 71 Val Leu Tyr Ala Thr Gly Asn Glu Gly 75 80 Thr Val Leu Lys Gly Glu Lys Thr Leu Glu Pro Gly Arg Tyr Tyr Leu 85 90 Ser Val Tyr Thr Tyr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100 10 10 105 105 100 110 Lys <210> SEQ ID NO 33 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii $<400> SEQUENCE: 33Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro1 5 11e Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn20 25 20 20 20 20 20 20 20 20 20 20 20 20 20 $		Tyr Phe A	-	Lys Lys Gly	-	Ile								
65 70 75 80 Thr Val Leu Lys Gly Glu Lys Thr Leu Glu Pro Gly Arg Tyr Tyr Leu 85 90 Ser Val Tyr Thr Tyr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100 105 105 110 Lys <210> SEQ ID NO 33 $<211> LENGTH: 113<212> TYPE: PRT<213> ORGANISM: C. sordellii <400> SEQUENCE: 33Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro1 5 10 10 15Ile Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn20 20 20 20 20 20 20 20 20 20Lys Asp Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile40$ 35 20 20 20 20 20 20 20 20 20 20 20 20 20			_	-	Thr Leu Tyr	Гла								
859095Ser Val Tyr Thr Tyr Asp Asn Gln Ser Gly Ala Tyr Thr Val Asn Val 100105Lys<210> SEQ ID NO 33 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii<400> SEQUENCE: 33Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 1011e Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn 20Lys Asp Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 40So Clu Ser Asp Leu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 60Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala			yr Val Leu		Gly Asn Glu									
100105110Lys<210> SEQ ID NO 33 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii<400> SEQUENCE: 33Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 1Ser Gln Glu Val Gly Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn 20Ile Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn 25Lys Asp Tyr Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 40Thr Leu Glu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala	Thr Val Leu Lys		ys Thr Leu	-		Leu								
<pre>< 210> SEQ ID NO 33 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii <400> SEQUENCE: 33 Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 1 5 10 15 Ile Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn 20 25 25 20 20 20 20 20 20 Lys Asp Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 35 20 20 25 20 20 20 20 20 Lys Asp Tyr Tyr Tyr Phe Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala</pre>				Gly Ala Tyr		Val								
<pre><211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: C. sordellii <400> SEQUENCE: 33 Ser Gln Glu Val Gly Asn Asp Asp Thr Phe Glu Thr Ala Asn Gly Pro 1 5 10 15 Ile Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn 20 25 20 25 30 Lys Asp Tyr Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 35 Thr Leu Glu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala</pre>	Lys													
SerGluGluValGlyAsnAspAspThrPheGluThrAlaAsnGlyPro11LysIleAsnThrAsnTyrSerGlyAspLeuSerAspThrAspAspAsp11eLysIleAsnTyrAsnTyrSerGlyAspLeuSerAspThrAspAsnAspLysAspTyrTyrTyrPheAsnLeuAspAspProSerAsnIleAsnIleLysAspTyrTyrTyrPheAsnLeuAspAspAspNoSerAsnIleAsnIleThrLeuGluAsnLeuAspLysGlyIleSerTrpGlnLeuPheHisGluSerAspLeuAsnTyrValAlaTyrProThrThrSerGlyAla	<211> LENGTH: 113 <212> TYPE: PRT													
1 5 10 15 Ile Lys Ile Asn Thr Asn Tyr Ser Gly Asp Leu Ser Asp Thr Asp Asn 20 20 20 20 Lys Asp Tyr Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 35 20 20 20 Thr Leu Glu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50 55 20 20 20 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala 20 20 20 20	<400> SEQUENCE:	33												
20 25 30 Lys Asp Tyr Tyr Tyr Tyr Phe Asn Leu Asp Asn Pro Ser Asn Ile Asn Ile 35 Thr Leu Glu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala		-	sp Asp Thr		-	Pro								
35 40 45 Thr Leu Glu Asn Leu Asp Asn Lys Gly Ile Ser Trp Gln Leu Phe His 50 50 55 60 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala	-	Thr Asn T		Asp Leu Ser		Asn								
50 55 60 Glu Ser Asp Leu Asn Asn Tyr Val Ala Tyr Pro Thr Thr Ser Gly Ala		Tyr Phe A	-	Asn Pro Ser		Ile								
					Gln Leu Phe	His								
	-		yr Val Ala	-	Thr Ser Gly									

65

-continued

Ile Leu Asn Gly Asp Tyr Asn Ala Thr Lys Pro Gly Lys Tyr Tyr Ile 85 90 Leu Val Tyr Asn His Asp Lys Ser Ile Ala Asn Tyr Asn Leu Lys Val 100 105 110 Asn <210> SEQ ID NO 34 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: Clostridium histolyticum <400> SEQUENCE: 34 Gly Thr Glu Lys Glu Pro Asn Asn Ser Lys Glu Thr Ala Ser Gly Pro 1 5 10 15 Ile Val Pro Gly Ile Pro Val Ser Gly Thr Ile Glu Asn Thr Ser Asp 20 25 30 Gln Asp Tyr Phe Tyr Phe Asp Val Ile Thr Pro Gly Glu Val Lys Ile 35 40 45 Asp Ile Asn Lys Leu Gly Tyr Gly Gly Ala Thr Trp Val Val Tyr Asp 50 55 60 Glu Asn Asn Asn Ala Val Ser Tyr Ala Thr Asp Asp Gly Gln Asn Leu 65 70 75 80 Ser Gly Lys Phe Lys Ala Asp Lys Pro Gly Arg Tyr Tyr Ile His Leu 85 90 95 Tyr Met Phe As
n Gly Ser Tyr Met Pro $\ensuremath{\mathsf{Tyr}}$ Arg Ile As
n Ile Glu 100 105 110 <210> SEQ ID NO 35 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(30) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 35 Pro Xaa Gly Pro 1 5 10 15 Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 20 25 30 <210> SEQ ID NO 36 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(30) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 36 Pro Xaa Gly Pro 1 5 10 15 Xaa Gly Pro Xaa Ala Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 20 25 30

<210> SEQ ID NO 37 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(30) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 37 Pro Xaa Gly Pro 1 5 10 15 Xaa Ala Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 20 25 <210> SEQ ID NO 38 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(30) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEOUENCE: 38 Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Ala Pro 1 5 10 15 Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 20 25 30 <210> SEQ ID NO 39 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(30) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 39 Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Ala Pro Xaa Gly Pro 1 5 10 15 Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 20 25 30 <210> SEQ ID NO 40 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(24) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 40 Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Cys Gly Pro Xaa Gly Pro 1 5 10 15 Xaa Gly Pro Xaa Gly Pro Xaa Gly 20

-continued

<210> SEQ ID NO 41 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(31) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 41 Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Ala Pro 1 5 10 15 Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Cys 25 20 30 <210> SEQ ID NO 42 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(22) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEOUENCE: 42 Gly Pro Xaa Gly 10 1 5 15 Pro Xaa Gly Pro Xaa Gly 20 <210> SEQ ID NO 43 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(31) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 43 Gly Pro Xaa Gly 5 10 15 1 Pro Xaa Gly Pro Xaa Gly Pro Arg Gly Pro Arg Gly Pro Arg Gly 20 25 30 <210> SEQ ID NO 44 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(9) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 44 Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 5 1

-continued

<210> SEQ ID NO 45 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(9) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 45 Pro Xaa Gly Pro Xaa Gly Pro Xaa Ala 5 1 <210> SEQ ID NO 46 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(26) <223> OTHER INFORMATION: Any Xaa is hydroxyproline <400> SEQUENCE: 46 Gly Pro Arg Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly 1 5 10 Pro Xaa Gly Pro Xaa Gly Pro Xaa Gly Cys 2.0 25 <210> SEO ID NO 47 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide: GST Tag <400> SEQUENCE: 47 Gly Ser Pro Gly Ile Pro Gly 5

We claim:

1. A method of treating a subject having alopecia that is $_{45}$ not chemotherapy-induced comprising administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to the subject to increase hair growth in the subject in need thereof for treatment of alopecia that is not chemotherapy-induced, 50 wherein the bacterial collagen-binding polypeptide segment comprises a collagen-binding polypeptide derived from an M9 peptidase from Clostridium, Bacillus and Vibrio selected from the group consisting of one of SEQ ID NOs: 13-34 or a fragment of at least 8 consecutive amino acids of SEQ ID 55 NOs: 13-34, residues 34-158 of SEQ ID NO: 1, a fragment of at least 8 consecutive amino acids from residues 34-158 of SEQ ID NO: 1, or a peptide that is at least 90% identical to residues 34-158 of SEQ ID NO: 1 or SEQ ID NOs: 13-34 and wherein the PTH/PTHrP receptor agonist comprises 60 residues 1-33 of SEQ ID NO: 1, PTH (SEQ ID NO: 7), residues 1-14 of SEQ ID NO: 1, residues 1-34 of SEQ ID NO: 7 or a fragment of at least 8 consecutive amino acids from residues 1-34 of SEQ ID NO: 7.

2. The method of claim **1**, wherein the alopecia is alopecia 65 areata or is related to male pattern baldness or polycystic ovarian syndrome.

3. The method of claim 1, wherein the composition is administered locally.

4. The method of claim 3, wherein the composition is administered topically.

5. The method of claim **1**, wherein the PTH/PTHrP receptor agonist is a polypeptide and the N-terminus of the collagen-binding polypeptide segment is linked directly or through a linker polypeptide segment to the C-terminus of the PTH/PTHrP receptor agonist polypeptide or wherein the collagen-binding polypeptide segment and the therapeutic agent are chemically cross-linked to each other or are polypeptide portions of a fusion protein.

6. The method of claim 1, wherein the subject is a human.

7. The method of claim 1, wherein the subject is a manual. administered in aqueous solution at pH below about 5.0 or above about 6.0.

8. The method of claim **1**, wherein the bacterial collagenbinding polypeptide segment comprises one of SEQ ID NOs: 13-34, residues 34-158 of SEQ ID NO: 1, or a peptide that is at least 90% identical to residues 34-158 of SEQ ID NO: 1 or SEQ ID NOs: 13-34.

9. The method of claim **1**, wherein the PTH/PTHrP receptor agonist comprises residues 1-33 of SEQ ID NO: 1, PTH (SEQ ID NO: 7), residues 1-14 of SEQ ID NO: 1, residues 1-34 of SEQ ID NO: 7.

10. The method of claim 1, wherein the bacterial collagenbinding polypeptide segment linked to the PTH/PTHrP receptor agonist is a fusion protein comprising SEQ ID NO: 1.

11. The method of claim 1, wherein the bacterial collagen-5 binding polypeptide segment linked to the PTH/PTHrP receptor agonist is a fusion protein comprising SEQ ID NO: 2.

12. The method of claim **1**, wherein the collagen-binding polypeptide segment further comprises residues 807-900 of 10 SEQ ID NO: 6.

* * * * *